US 20210071186A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2021/0071186 A1**

Petersen et al. (43) **Pub. Date: Mar. 11, 2021**

(54) **METHODS OF GENE EDITING AND TRANSFORMING CANNABIS**

(71) Applicant: **Wisconsin Alumni Research Foundation**, Madison, WI (US)

(72) Inventors: **Michael W. Petersen**, Merrimac, WI (US); **Edward James Williams**, Madison, WI (US); **Robert Harnish**, Middleton, WI (US); **Heidi Flewelling Kaeppler**, Oregon, WI (US); **Brian Martinell**, Mt. Horeb, WI (US); **Ray Collier**, Middleton, WI (US); **Frank McFarland**, Madison, WI (US); **Shawn Michael Kaeppler**, Oregon, WI (US)

(73) Assignee: **Wisconsin Alumni Research Foundation**, Madison, WI (US)

(21) Appl. No.: **16/930,936**

(22) Filed: **Jul. 16, 2020**

Related U.S. Application Data

(60) Provisional application No. 62/982,522, filed on Feb. 27, 2020, provisional application No. 62/906,210, filed on Sep. 26, 2019, provisional application No. 62/875,311, filed on Jul. 17, 2019.

Publication Classification

(51) **Int. Cl.**

C12N 15/82 (2006.01)

C07K 14/415 (2006.01)

(52) **U.S. Cl.**

CPC ***C12N 15/8201*** (2013.01); ***C07K 14/415*** (2013.01)

(57) **ABSTRACT**

Disclosed herein are methods for the production of *Cannabis* meristem explants from dry seeds. Also described are methods of transforming and gene editing using the *Cannabis* meristem explants disclosed herein.

Specification includes a Sequence Listing.

FIG. 1


Inoculated with Ar18r12v / Dicot Binary 19
Non-inoculated
Brightfield
RFP

FIG. 2



FIG. 3


May 9, 2019 Cannabis meristem transformation
0 mg/L meta-topolin in co-culture
1 mg/L meta-topolin in co-culture
Honey Gold 3WS
Fiber Hemp

FIG. 4


RCGG1190 DICOT BINARY 22 (RC3162)
15,116 bp
BamHI (12)
PvuII (576)
MauBI (2169)
BspEI (3166)
KasI (3179)
NarI (3180)
SfoI (3181)
PluTI (3183)
MfeI (3874)
SpeI (4157)
BstZ17I (6449)
MluI (6929)
PstI (8800)
BmtI (9477)
NheI (9473)
AclI (10,423)
NotI - SacII (11,114)
PmeI (10,879)
PasI (11,667)
SfiI (14,885)
AsrI (14,330)
BstAPI (14,919)
LB
CaMV35S ter
35S enhancer
NOS terminator
RC1721
MluI scar
BpiI scar
BsaI scar
RCAT1 intron
TMV Omega translational enhancer
AATG Overhang
ER signal peptide
EU 3' UTR
TobRB7 Ter
RB
AMPr pro
BsmBI scar
2000
4000
6000
8000
10,000
12,000
14,000

FIG. 5


Female plant 1 day post-treatment
Flower Not treated
Flower Dipped with 5% sucrose and 0.05% Silwet L-77
Flower Dipped with 18r12v / Dicot Binary 22 in 5% sucrose and 0.05% Silwet L-77

FIG. 6


leaves (cleared)
leaves
Nodes
Internodes
Petioles
Nodes (cleared)
Internodes (cleared)
Petioles (cleared)

FIG. 7



FIG. 8



FIG. 9

Cannabis meristem explants on B5 medium; post 4 day co-culture after inoculation with Ar18r12v / Dicot Binary 19



FIG. 9 CONTINUED



FIG. 10

Transient GUS expression in *Cannabis* meristem explants transformed with Ar18r12v / Dicot Binary 19

FIG. 11

Transient GUS expression in *Cannabis* meristem explants transformed with Ar18r12v / Dicot Binary 19 (explants de-stained in 70% EtOH)



FIG. 12

Non-inoculated *Cannabis* seed sanitized in 20% Clorox on B5 media (left)
Non-inoculated meristem explants on B5 media (right)
* POC of viability of *Cannabis* seeds, meristem explants for transformation

FIG. 13

Spectinomycin sensitive (bleaching) phenotype visible in inoculated *Cannabis* meristem explants on 150 mg/L spectinomycin B5

- POC of use of aadA / spectinomycin resistance as a selectable marker in *Cannabis*
- Imaged 12April2019





FIG. 14



FIG. 15



FIG. 16



FIG. 17

FIG. 18

FIG. 19


RCGG139 WC1C SOYTEST2 (RC2477)
13,926 bp
CaMV35S ter
Chlor transit peptide
GmSUBI3pro
MluI (1561)
MauBI (2207)
BspEI (3264)
KasI (3277)
NarI (3278)
SfoI (3279)
PluTI (3281)
SpeI (4256)
BstEII (5463)
AgeI (5709)
PstI (5433)
KDEL - ER retention motif
ER signal peptide
Acceptor site
Donor site
BsaI scar
BbsI scar
MluI scar
BsmBI scar
Acceptor
Donor
TMV Omega translational enhancer
RuBisCO terminator
NcoI (725)
PvuII (676)
BamHI (12)
BstAPI (13,729)
BsmI (13,273)
SfiI (12,899)
NotI - SacII (9924)
PmeI (9869)
BstZ17I (8656)
SmaI (7948)
TspMI - XmaI (7947)

FIG. 20


Non-inoculated Cannabis variety 3WS
Cannabis variety 3WS inoculated with Ar18r12v / Dicot Binary19 (Hemp 5/30-3)
Cannabis variety 3WS inoculated with Ar18r12v / Soy Test 2 (Hemp 6/6-1)
Brightfield
RFP

FIG. 21

FIG. 22


RCGG557 DICOTBOMB13 (RC2780)
6752 bp
1000
2000
3000
4000
5000
6000
AATG Overhang
CaMV35Spro
35S enhancer
GCAA Overhang
CGCT Overhang
GCTT Overhang
TGCC Overhang
CGCT Overhang
Overhang A (TGCC)
CaMV35Sminpro
GGAG Overhang
NOS terminator
Chlor transit peptide
TMV Omega translational enhancer
Candidate probe (ts)
CaMV35S ter
M13F
CAT pro
Bpil scar
PCR32
RC1721
PCR31
BsaI scar
BsmBI scar
rt653
RcCAT1 Intron
GUSplus (5)
ColE1
L2E
Overhang H (GGGA)
GGGA Overhang (Level 2 end)
GGGA Overhang
ACTA Overhang
GGAG Overhang


Non-blasted
650 psi
900 psi
1100 psi
1350 psi
1550 psi
Honey Gold 3WS
Fiber Hemp

FIG. 23

FIG. 24


#6 T0
#6, 3 hours 30 minutes
#7 T0
#6 - 22 hours, 15 minutes
#7 - 22 hours, 15 minutes

FIG. 25


#1 ~ 25% glycerol PGM, -20C
#4 ~ -20C
#6 ~ 25% glycerol PGM, -80C
#8 ~ -80C
75um
T0
T1
T2



FIG. 26


Wild-type Cannabis tissue culture plant
WP421-1 leaf A
WP421-1 leaf B
WP421-1 leaf C
Brightfield
RFP
GUS

FIG. 27

FIG. 28



FIG. 29



FIG. 30

FIG. 31

FIG. 32


Negative control leaf
WP421-1 leaf 1
WP421-1 leaf 2
WP421-1 leaf 3
WP421-1 leaf 4
WP421-1 leaf 5
WP421-1 leaf 6
WP421-1 leaf 7
WP421-1 leaf 8
WP421-1 leaf 9
WP421-1 leaf 10

FIG. 33


RCGG1187 DICOT BINARY 19 (RC3159)
15,134 bp
R211 F56
5379-5398 5243-5262
CaMV35S enhancer
TMV Omega translational enhancer
CaMV35Smpro
GGAG Overhang
GCTT Overhang
BsaI scar
MluI scar
BamHI scar
RCA1721
R235 F102
Candidate probe (ts)
Candidate probe (ts)
35S enhancer
GCTT Overhang
CaMV35S ter
GCTT Overhang
1000
2000
3000

FIG. 34



Ln 1 = Low molecular weight ladder
Ln 2 = blank
Ln 3 = 50:50 reagent negative control
Ln 4 = Cannabis 3WS negative control
Ln 5 = blank
Ln 6 = T0 Cannabis WP421-1 leaf 1
Ln 7 = T0 Cannabis WP421-1 leaf 2
Ln 8 = T0 Cannabis WP421-1 leaf 3
Ln 9 = T0 Cannabis WP421-1 leaf 4
Ln 10 = T0 Cannabis WP421-1 leaf 5
Ln 11 = T0 Cannabis WP421-1 leaf 6
Ln 12 = T0 Cannabis WP421-1 leaf 7
Ln 13 = T0 Cannabis WP421-1 leaf 8
Ln 14 = T0 Cannabis WP421-1 leaf 9
Ln 15 = T0 Cannabis WP421-1 leaf 10
Ln 16 = blank
Ln 17 = 2 ng plasmid DNA
Ln 18 = Low molecular weight ladder



FIG. 35



FIG. 36

FIG. 37

FIG. 38

FIG. 39





FIG. 40

FIG. 41


T1 WPM21-1@1 null segregant (left)
T1 WPM21-1@2 positive segregant (center)
Wild-type 3WS (right)
GUS
Ln 1 = Low molecular weight ladder
Ln 2 = blank
Ln 3 = 50:50 reagent negative control
Ln 4 = blank
Ln 5 = T0 Cannabis WPM21-1
Ln 6 = T1 Cannabis WPM21-1@1
Ln 7 = T1 Cannabis WPM21-1@2
Ln 8 = blank
Ln 9 = 3WS negative control
Ln 10 = blank
Ln 11 = 2 ng plasmid DNA
Ln 12 = Low molecular weight ladder
1 2 3 4 5 6 7 8 9 10 11 12
750 bp
500 bp
350 bp
300 bp
250 bp
200 bp
150 bp
100 bp
75 bp
50 bp
25 bp

FIG. 42

FIG. 43

FIG. 44



FIG. 45



FIG. 46



FIG. 47


WP421-1@3
WP421-1@4
WP421-1@5
.....
WP421-1@44
WP421-1@45
WP421-1@46
Negative control



FIG. 48

FIG. 49



FIG. 50





FIG. 51

FIG. 52



FIG. 53

FIG. 54



Ln 1 = Low molecular weight ladder
Ln 2 = blank
Ln 3 = 50:50 reagent negative control
Ln 4 = Cannabis leaf negative control
Ln 5 = blank
Ln 6 = T0 Cannabis WP001181-1 leaf 1
Ln 7 = T0 Cannabis WP001181-1 leaf 2
Ln 8 = T0 Cannabis WP001181-1 leaf 3
Ln 9 = T0 Cannabis WP001181-1 leaf 4
Ln 10 = T0 Cannabis WP001181-1 leaf 5
Ln 11 = T0 Cannabis WP001181-1 leaf 6
Ln 12 = T0 Cannabis WP001181-1 leaf 7
Ln 13 = T0 Cannabis WP001181-1 leaf 8
Ln 14 = T0 Cannabis WP001181-1 leaf 9
Ln 15 = T0 Cannabis WP001181-1 leaf 10
Ln 16 = blank
Ln 17 = 2 ng plasmid DNA
Ln 18 = blank
Ln 19 = Low molecular weight ladder

FIG. 55


WP001181-1a leaf 5
WP001181-1a leaf 10
WP001181-1a leaf 4
WP001181-1a leaf 9
WP001181-1a leaf 3
WP001181-1a leaf 8
WP001181-1a leaf 2
WP001181-1a leaf 7
WP001181-1a leaf 1
WP001181-1a leaf 6
Negative control leaf

FIG. 56



FIG. 57



FIG. 58

FIG. 59





FIG. 60

FIG. 61





FIG. 62

FIG. 63


Farnesyl diphosphate (FPP)
β-Caryophyllene
Farnesyl diphosphate synthase
α-Humulene
Isopentenyl diphosphate
Dimethylallyl diphosphate
SESQUITERPENES
Olivetolic acid
Geranyl diphosphate synthase
Geranyl diphosphate (GPP)
Cannabigerolic acid synthase
β-Myrcene
(+)-α-Pinene
(-)-Limonene
MONOTERPENES
Cannabigerolic acid (CBG)
Tetrahydro-cannabinolic acid synthase
Cannabidiolic acid synthase
Tetrahydrocannabinolic acid (THCA)
Cannabidiolic acid (CBDA)
Non-Enzymatic
CO2
CO2
CANNABINOIDS
Non-Enzymatic
Cannabinol (CBN)
Tetrahydrocannabinol (THC)
Cannabidiol (CBD)

FIG. 64


THCA synthase (active)
THCA synthase (Genbank KT876047.1)
THCA synthase (ccbr Purple Kush)
THCA synthase (Genbank MG996415.1)
THCA synthase (inactive)
Consensus

FIG. 64 CONTINUED



FIG. 65



FIG. 65 CONTINUED



FIG. 66

BraLTP2 Original sequence: Type IIS recognition sequences: BsaI, BpiI, BsmBI

ATGGCGACAGGTTCTCGTGTTCTGATCGGTCTAGCAATGATCCTCATAATCTCAGGAGAACTGCTAGTTCCAGGGCAAGGA
ACGTGCCAAGGAGACATAGAGGGTCTGATGAGAGAATGTGCGGTCTACGTCCAGCGTCCAGGCCCAAAGGTAAACCCATC
CGCAGCGTGTTGCAAAGTCGTCAAGAGATCAGACATCCCCTGCGCATGTGGCCGTATCACACCCTCGGTTCAAAAAATGAT
AGACATGAATAAGGTTGTTCTTGTCACTTCCTTTTGTGGGAGGCCTCTCGCTCATGGTACCAAGTGTGGAAGCTACATTGTG
CCATGA

BraLTP2 CDS1 STOP Part for synthesis: Type IIS recognition sequences: **BsaI**, BpiI, BsmBI; START; **STOP**; XXXX = motif liberated by BsaI digestion during Golden Gate Level 1 assembly of Transcriptional Unit.

GGTCTCAAATGGCGACAGGTTCTCGTGTTCTGATCGGTCTAGCAATGATCCTCATAATCTCAGGAGAACTGCTAGTTCCAGG
GCAAGGAACGTGCCAAGGAGACATAGAGGGTCTGATGAGAGAATGTGCGGTCTACGTCCAGCGTCCAGGCCCAAAGGTA
AACCCATCCGCAGCGTGTTGCAAAGTCGTCAAGAGATCAGACATCCCCTGCGCATGTGGCCGTATCACACCCTCGGTTCAAA
AAATGATAGACATGAATAAGGTTGTTCTTGTCACTTCCTTTTGTGGGAGGCCTCTCGCTCATGGTACCAAGTGTGGAAGCTA
CATTGTGCCATGAGCTTAGAGACC

BraLTP2 CDS1 ns Part for synthesis: Type IIS recognition sequences: **BsaI**, BpiI, BsmBI; START; **STOP**; XXXX = motif liberated by BsaI digestion during Golden Gate Level 1 assembly of Transcriptional Unit; ; NS replaces STOP (and produces a Serine-Serine linker)

GGTCTCAAATGGCGACAGGTTCTCGTGTTCTGATCGGTCTAGCAATGATCCTCATAATCTCAGGAGAACTGCTAGTTCCAGG
GCAAGGAACGTGCCAAGGAGACATAGAGGGTCTGATGAGAGAATGTGCGGTCTACGTCCAGCGTCCAGGCCCAAAGGTA
AACCCATCCGCAGCGTGTTGCAAAGTCGTCAAGAGATCAGACATCCCCTGCGCATGTGGCCGTATCACACCCTCGGTTCAAA
AAATGATAGACATGAATAAGGTTGTTCTTGTCACTTCCTTTTGTGGGAGGCCTCTCGCTCATGGTACCAAGTGTGGAAGCTA
CATTGTGCCANSTTCGAGAGACC

FIG. 67

CsPT1 Original sequence; ; Type IIS recognition sequences: BsaI, BbsI, BtgZI

ATGGGACTCTCATCAGTTTGTACCTTTTCATTTCAAACTAATTACCATACTTTATTAAATCCTCACAATAATAATCCCAAAACCTCATTATTA
TGTTATCGACACCCCAAAACACCAATTAAATACTCTTACAATAATTTTCCCTCTAAACATTGCTCCACCAAGAGTTTTCATCTACAAAACAA
ATGCTCAGAATCATTATCAATCGCAAAAAATTCCATTAGGGCAGCTACTACAAATCAAACTGAGCCTCCAGAATCTGATAATCATTCAGTA
GCAACTAAAATTTTAAACTTTGGGAAGGCATGTTGGAAACTTCAAAGACCATATACAATCATAGCATTTACTTCATGCGCTTGTGGATTGT
TTGGGAAAGAGTTGTTGCATAACACAAATTTAATAAGTTGGTCTCTGATGTTCAAGGCATTCTTTTTTTTGGTGGCTGTATTATGCATTGCT
TCTTTTACAACTACCATCAATCAGATTTACGATCTTCACATTGACAGAATAAACAAGCCTGATCTACCACTAGCTTCAGGGGAAATATCAG
TAAACACAGCTTGGATTATGAGCATAATTGTGGCACTGTTTGGATTGATAATAACTATAAAAATGAAGGGTGGACCACTCTATATATTTG
GCTACTGTTTTGGTATTTTTGGTGGGATTGTCTATTCTGTTCCACCATTTAGATGGAAGCAAAATCCTTCCACTGCATTTCTTCTCAATTTCC
TGGCCCATATTATTACAAATTTCACATTTTATTATGCCAGCAGAGCAGCTCTTGGCCTACCATTTGAGTTGAGGCCTTCTTTTACTTTCCTGC
TAGCATTTATGAAATCAATGGGTTCAGCTTTGGCTTTAATCAAAGATGCTTCAGACGTTGAAGGCGACACTAAATTTGGCATATCAACCTT
GGCAAGTAAATATGGTTCCAGAAACTTGACATTATTTTGTTCTGGAATTGTTCTCCTATCCTATGTGGCTGCTATACTTGCTGGGATTATCT
GGCCCCAGGCTTTCAACAGTAACGTAATGTTACTTTCTCATGCAATCTTAGCATTTTGGTTAATCCTCCAGACTCGAGATTTTGCGTTAACA
AATTACGACCCGGAAGCAGGCAGAAGATTTTACGAGTTCATGTGGAAGCTTTATTATGCTGAATATTTAGTATATGTTTTCATATAA

CsPT1 CDS1 STOP Part for synthesis: Type IIS recognition sequences: BsaI, BbsI, BtgZI, START, STOP; XXXX = motif liberated by BsaI digestion during Golden Gate Level 1 assembly of Transcriptional Unit.

GGTCTCAAATGGACTCTCATCAGTTTGTACCTTTTCATTTCAAACTAATTACCATACTTTATTAAATCCTCACAATAATAATCCCAAAACCT
CATTATTATGTTATCGACACCCCAAAACACCAATTAAATACTCTTACAATAATTTTCCCTCTAAACATTGCTCCACCAAGAGTTTTCATCTAC
AAAACAAATGCTCAGAATCATTATCAATCGCAAAAAATTCCATTAGGGCAGCTACTACAAATCAAACTGAGCCTCCAGAATCTGATAATC
ATTCAGTAGCAACTAAAATTTTAAACTTTGGGAAGGCATGTTGGAAACTTCAAAGACCATATACAATCATAGCATTTACTTCATGCGCTTG
TGGATTGTTTGGGAAAGAGTTGTTGCATAACACAAATTTAATAAGTTGGTCTCTGATGTTCAAGGCATTCTTTTTTTTGGTGGCTGTATTA
TGCATTGCTTCTTTTACAACTACCATCAATCAGATTTACGATCTTCACATTGACAGAATAAACAAGCCTGATCTACCACTAGCTTCAGGGG
AAATATCAGTAAACACAGCTTGGATTATGAGCATAATTGTGGCACTGTTTGGATTGATAATAACTATAAAAATGAAGGGTGGACCACTCT
ATATATTTGGCTACTGTTTTGGTATTTTTGGTGGGATTGTCTATTCTGTTCCACCATTTAGATGGAAGCAAAATCCTTCCACTGCATTTCTTC
TCAATTTCCTGGCCCATATTATTACAAATTTCACATTTTATTATGCCAGCAGAGCAGCTCTTGGCCTACCATTTGAGTTGAGGCCTTCTTTTA
CTTTCCTGCTAGCATTTATGAAATCAATGGGTTCAGCTTTGGCTTTAATCAAAGATGCTTCAGACGTTGAAGGCGACACTAAATTTGGCAT
ATCAACCTTGGCAAGTAAATATGGTTCCAGAAACTTGACATTATTTTGTTCTGGAATTGTTCTCCTATCCTATGTGGCTGCTATACTTGCTG
GGATTATCTGGCCCCAGGCTTTCAACAGTAACGTAATGTTACTTTCTCATGCAATCTTAGCATTTTGGTTAATCCTCCAGACTCGAGATTTT
GCGTTAACAAATTACGACCCGGAAGCAGGCAGAAGATTTTACGAGTTCATGTGGAAGCTTTATTATGCTGAATATTTAGTATATGTTTTCA
TAATGCTTAGAGACC

CsPT1 CDS1 ns Part for synthesis: Type IIS recognition sequences: BsaI, BbsI, BtgZI, START, STOP; XXXX = motif liberated by BsaI digestion during Golden Gate Level 1 assembly of Transcriptional Unit; ; TC replaces STOP (and produces a Serine-Serine linker)

GGTCTCAAATGGACTCTCATCAGTTTGTACCTTTTCATTTCAAACTAATTACCATACTTTATTAAATCCTCACAATAATAATCCCAAAACCT
CATTATTATGTTATCGACACCCCAAAACACCAATTAAATACTCTTACAATAATTTTCCCTCTAAACATTGCTCCACCAAGAGTTTTCATCTAC
AAAACAAATGCTCAGAATCATTATCAATCGCAAAAAATTCCATTAGGGCAGCTACTACAAATCAAACTGAGCCTCCAGAATCTGATAATC
ATTCAGTAGCAACTAAAATTTTAAACTTTGGGAAGGCATGTTGGAAACTTCAAAGACCATATACAATCATAGCATTTACTTCATGCGCTTG
TGGATTGTTTGGGAAAGAGTTGTTGCATAACACAAATTTAATAAGTTGGTCTCTGATGTTCAAGGCATTCTTTTTTTTGGTGGCTGTATTA
TGCATTGCTTCTTTTACAACTACCATCAATCAGATTTACGATCTTCACATTGACAGAATAAACAAGCCTGATCTACCACTAGCTTCAGGGG
AAATATCAGTAAACACAGCTTGGATTATGAGCATAATTGTGGCACTGTTTGGATTGATAATAACTATAAAAATGAAGGGTGGACCACTCT
ATATATTTGGCTACTGTTTTGGTATTTTTGGTGGGATTGTCTATTCTGTTCCACCATTTAGATGGAAGCAAAATCCTTCCACTGCATTTCTTC
TCAATTTCCTGGCCCATATTATTACAAATTTCACATTTTATTATGCCAGCAGAGCAGCTCTTGGCCTACCATTTGAGTTGAGGCCTTCTTTTA
CTTTCCTGCTAGCATTTATGAAATCAATGGGTTCAGCTTTGGCTTTAATCAAAGATGCTTCAGACGTTGAAGGCGACACTAAATTTGGCAT
ATCAACCTTGGCAAGTAAATATGGTTCCAGAAACTTGACATTATTTTGTTCTGGAATTGTTCTCCTATCCTATGTGGCTGCTATACTTGCTG
GGATTATCTGGCCCCAGGCTTTCAACAGTAACGTAATGTTACTTTCTCATGCAATCTTAGCATTTTGGTTAATCCTCCAGACTCGAGATTTT
GCGTTAACAAATTACGACCCGGAAGCAGGCAGAAGATTTTACGAGTTCATGTGGAAGCTTTATTATGCTGAATATTTAGTATATGTTTTCA
TATCTTCGAGACC

FIG. 68

CsOMT1 CDS Original sequence: Type IIS recognition sequences: BsaI, BbsI, SapIII

ATGGGTTCAACAGGAATAGAGACCCAAATGACCCCAACCCAAATATCCGACGAAGAAGCCAACCTCTTCGCCATGCAATTAGCCAGTGC
CTCAGTCTTACCCATGGTTCTCAAAGCAGCTTTAGAGCTCGACCTCTTGGAGATCATAGCCAAGGCCGGTCCAGGCGCGTTTCTCTCACCT
TCCGACATAGCTCAACAGCTTCCGACTCAGAACCCAGACGCCCCGGTGATGCTGGACCGGATGCTGAGACTGTTGGCTAGCTACAACGT
GGTGACGTACTCGCTGCGTGAGCGTCTTCTGCGGAAGAGGAAGGGAAGGTGGAGAGGCTTTATGGGTTGGCTCCGGTGAGTAAATA
TCTGACGAAGAATGAAGATGGAGTCTCCATTGCTCCTCTTTGTCTCATGAACCAGGATAAGGTTCTTATGGAGAGTTGGTATCACTTAAA
AGATGCAGTACTTGATGGAGGAATACCTTTCAACAAGGCATATGGAATGACAGCATTTGAATATCATGGAACCGATCAAAGGTTCAATA
AAATCTTTAATAGAGGAATGTCCGACCACTCGACTATTACCATGAAAAAAATCCTCGAAACTTACAAGGGTTTCGAGGGTCTTAACTCGA
TTGTTGATGTTGGTGGTGGTACTGGAGCTGTTGTTAACATGATCTTAAGTACCCTACTATTAAGGGTATTAACTTCGATTTGCCTCA
TGTCATCGAAGATGCACCTCCATTGACCGGTGTAGAGCATGTTGGAGGAGACATGTTTGTAAGTGTACCAAAAGGAGATGCAATTTTCAT
GAAGTGGATTTGCCATGATTGGAGCGATGAACACTGCTTGAAATTCTTGAAGAACTGCCACGCTGCACTGCCCGAACACGGAAAAGTGA
TCGTGGCGGAGTGCATTCTTCCGGTGGCACCGGACTCGAGCCTTGCCACAAAGAGTACGGTCCACATTGATGTGATCATGTTGGCCCATA
ACCCTGGTGGCAAAGAGAGAACAGAGAAAGAGTTTGAGGCATTGGCTAAGGGAGCTGGCTTTAAAGGCTTCAAAGTCCATTGCAATGC
TTTCAATACCCATATCATGGAATTTCTCAAGACCATTTAA

CsOMT21 CDS1 STOP Part for synthesis: Type IIS recognition sequences: BsaI, BbsI, SapIII, START, STOP; XXXX = motif liberated by BsaI digestion during Golden Gate Level 1 assembly of Transcriptional Unit; ; § = mutations to eliminate internal Type IIS restriction endonuclease recognition motifs.

GGTCTCAATTGGGTTCAACAGGAATAGAGACCCAAATGACCCCAACCCAAATATCCGACGAAGAAGCCAACCTCTTCGCCATGCAATTAG
CCAGTGCCTCAGTCTTACCCATGGTTCTCAAAGCAGCTTTAGAGCTCGACCTCTTGGAGATCATAGCCAAGGCCGGTCCAGGCGCGTTTC
TCTCACCTTCCGACATAGCTCAACAGCTTCCGACTCAGAACCCAGACGCCCCGGTGATGCTGGACCGGATGCTGAGACTGTTGGCTAGCT
ACAACGTGGTGACGTACTCGCTGCGTGAGCGTCTTCTGCGGAAGAGGAAGGGAAGGTGGAGAGGCTTTATGGGTTGGCTCCGGTGA
GTAAATATCTGACGAAGAATGAAGATGGAGTCTCCATTGCTCCTCTTTGTCTCATGAACCAGGATAAGGTTCTTATGGAGAGTTGGTATC
ACTTAAAAGATGCAGTACTTGATGGAGGAATACCTTTCAACAAGGCATATGGAATGACAGCATTTGAATATCATGGAACCGATCAAAGG
TTCAATAAAATCTTTAATAGAGGAATGTCCGACCACTCGACTATTACCATGAAAAAAATCCTCGAAACTTACAAGGGTTTCGAGGGTCTTA
ACTCGATTGTTGATGTTGGTGGTGGTACTGGAGCTGTTGTTAACATGATCTTAAGTACCCTACTATTAAGGGTATTAACTTCGATTT
GCCTCATGTCATCGAAGATGCACCTCCATTGACCGGTGTAGAGCATGTTGGAGGAGACATGTTTGTAAGTGTACCAAAAGGAGATGCAA
TTTTCATGAAGTGGATTTGCCATGATTGGAGCGATGAACACTGCTTGAAATTCTTGAAGAACTGCCACGCTGCACTGCCCGAACACGGAA
AAGTGATCGTGGCGGAGTGCATTCTTCCGGTGGCACCGGACTCGAGCCTTGCCACAAAGAGTACGGTCCACATTGATGTGATCATGTTG
GCCCATAACCCTGGTGGCAAAGAGAGAACAGAGAAAGAGTTTGAGGCATTGGCTAAGGGAGCTGGCTTTAAAGGCTTCAAAGTCCATT
GCAATGCTTTCAATACCCATATCATGGAATTTCTCAAGACCATTTAAGCTTAGAGACC

CsOMT1 CDS1 ns Part for synthesis: Type IIS recognition sequences: BsaI, BbsI, SapIII, START, STOP; XXXX = motif liberated by BsaI digestion during Golden Gate Level 1 assembly of Transcriptional Unit; § = mutations to eliminate internal Type IIS restriction endonuclease recognition motifs; ns replaces STOP (and produces a Serine-Serine linker)

GGTCTCAATTGGGTTCAACAGGAATAGAGACCCAAATGACCCCAACCCAAATATCCGACGAAGAAGCCAACCTCTTCGCCATGCAATTAG
CCAGTGCCTCAGTCTTACCCATGGTTCTCAAAGCAGCTTTAGAGCTCGACCTCTTGGAGATCATAGCCAAGGCCGGTCCAGGCGCGTTTC
TCTCACCTTCCGACATAGCTCAACAGCTTCCGACTCAGAACCCAGACGCCCCGGTGATGCTGGACCGGATGCTGAGACTGTTGGCTAGCT
ACAACGTGGTGACGTACTCGCTGCGTGAGCGTCTTCTGCGGAAGAGGAAGGGAAGGTGGAGAGGCTTTATGGGTTGGCTCCGGTGA
GTAAATATCTGACGAAGAATGAAGATGGAGTCTCCATTGCTCCTCTTTGTCTCATGAACCAGGATAAGGTTCTTATGGAGAGTTGGTATC
ACTTAAAAGATGCAGTACTTGATGGAGGAATACCTTTCAACAAGGCATATGGAATGACAGCATTTGAATATCATGGAACCGATCAAAGG
TTCAATAAAATCTTTAATAGAGGAATGTCCGACCACTCGACTATTACCATGAAAAAAATCCTCGAAACTTACAAGGGTTTCGAGGGTCTTA
ACTCGATTGTTGATGTTGGTGGTGGTACTGGAGCTGTTGTTAACATGATCTTAAGTACCCTACTATTAAGGGTATTAACTTCGATTT
GCCTCATGTCATCGAAGATGCACCTCCATTGACCGGTGTAGAGCATGTTGGAGGAGACATGTTTGTAAGTGTACCAAAAGGAGATGCAA
TTTTCATGAAGTGGATTTGCCATGATTGGAGCGATGAACACTGCTTGAAATTCTTGAAGAACTGCCACGCTGCACTGCCCGAACACGGAA
AAGTGATCGTGGCGGAGTGCATTCTTCCGGTGGCACCGGACTCGAGCCTTGCCACAAAGAGTACGGTCCACATTGATGTGATCATGTTG
GCCCATAACCCTGGTGGCAAAGAGAGAACAGAGAAAGAGTTTGAGGCATTGGCTAAGGGAGCTGGCTTTAAAGGCTTCAAAGTCCATT
GCAATGCTTTCAATACCCATATCATGGAATTTCTCAAGACCATTTTCGAGAGACC

FIG. 69

CsPT3 CDS Original sequence: Type IIS recognition sequences: BsaI, BbsI, SapIII.

ATGGTGTTCTCATCAGTTTGTAGTTTTCCATCCTCCCTTGGAACTAATTTTAAATTAGTTCCTCGTAGTAATTTTAAGGCATCATCTTCTCAT
TATCATGAAATAAATAATTTTATTAATAATAAACCAATTAAATTCTCATATTTTTCTTCAAGACTATATTGCTCTGCCAAACCAATTGTACAC
AGAGAAAACAAATTCACAAAATCATTTTCACTCAGCCACCTCCAAAGGAAAAGCTCCATAAAGGCACATGGTGAAATTGAAGCTGATGG
GAGTAATGGCACATCTGAATTTAATGTAATGAAAAGTGGAAACGCAATTTGGAGATTTGTAAGGCCATATGCAGCCAAGGGAGTATTGT
TTAACTCTGCTGCTATGTTTGCAAAAGAGTTGGTGGGGAACCTAAATCTATTTAGTTGGCCTTTGATGTTTAAGATACTCTCTTTTACATTG
GTTATTTTATGCATTTTTGTAAGTACAAGTGGCATCAATCAAATTTATGATCTCGACATCGACAGGTTAAACAAACCTAATTTGCCAGTAG
CATCAGGAGAAATTTCAGTTGAATTGGCATGGTTGTTGACTATAGTTTGTACAATAAGTGGCCTCACATTAACAATTATAACGAACTCAG
GGCCATTCTTCCCTTTTCTCTACTCTGCTAGTATCTTTTTTGGCTTTCTCTATTCTGCTCCTCCATTCAGATGGAAGAAGAATCCTTTTACAGC
ATGTTTCTGTAATGTTATGTTGTATGTTGGCACAAGCGTTGGTGTCTATTATGCTTGTAAGGCTAGTCTCGGGCTTCCAGCCAACTGGAGC
CCTGCTTTTTGTTTGCTCTTTTGGTTTATTTCATTGTTGAGTATACCCATCTCCATTGCAAAAGATCTTTCAGACATAGAAGGTGACCGCAA
GTTTGGAATCATAACCTTCTCAACTAAATTTGGAGCAAAACCCATAGCATATATTTGTCATGGACTCATGCTTCTGAATTACGTGAGTGTT
ATGGCTGCAGCTATTATTTGGCCACAGTTTTTCAACAGTAGCGTAATATTGCTTTCTCATGCATTCATGGCAATTTGGGTATTATATCAGGC
TTGGATATTGGAGAAATCAAATTACGCCACG[GAAACG]TGCCAAAAATACTATATATTCCTTTGGATAATTTTTTCTCTTGAACATGCCTTCT
ATTTGTTCATGTAG

CsPT3 CDS1 STOP Part for synthesis: Type IIS recognition sequences: BsaI, BbsI, SapIII, START, STOP. XXXX = motif liberated by BsaI digestion during Golden Gate Level 1 assembly of Transcriptional Unit; § = mutations to eliminate internal Type IIS restriction endonuclease recognition motifs.

GGTCTCAAATGGTGTTCTCATCAGTTTGTAGTTTTCCATCCTCCCTTGGAACTAATTTTAAATTAGTTCCTCGTAGTAATTTTAAGGCATCAT
CTTCTCATTATCATGAAATAAATAATTTTATTAATAATAAACCAATTAAATTCTCATATTTTTCTTCAAGACTATATTGCTCTGCCAAACCAA
TTGTACACAGAGAAAACAAATTCACAAAATCATTTTCACTCAGCCACCTCCAAAGGAAAAGCTCCATAAAGGCACATGGTGAAATTGAAG
CTGATGGGAGTAATGGCACATCTGAATTTAATGTAATGAAAAGTGGAAACGCAATTTGGAGATTTGTAAGGCCATATGCAGCCAAGGGA
GTATTGTTTAACTCTGCTGCTATGTTTGCAAAAGAGTTGGTGGGGAACCTAAATCTATTTAGTTGGCCTTTGATGTTTAAGATACTCTCTTT
TACATTGGTTATTTTATGCATTTTTGTAAGTACAAGTGGCATCAATCAAATTTATGATCTCGACATCGACAGGTTAAACAAACCTAATTTGC
CAGTAGCATCAGGAGAAATTTCAGTTGAATTGGCATGGTTGTTGACTATAGTTTGTACAATAAGTGGCCTCACATTAACAATTATAACGA
ACTCAGGGCCATTCTTCCCTTTTCTCTACTCTGCTAGTATCTTTTTTGGCTTTCTCTATTCTGCTCCTCCATTCAGATGGAAGAAGAATCCTTT
TACAGCATGTTTCTGTAATGTTATGTTGTATGTTGGCACAAGCGTTGGTGTCTATTATGCTTGTAAGGCTAGTCTCGGGCTTCCAGCCAAC
TGGAGCCCTGCTTTTTGTTTGCTCTTTTGGTTTATTTCATTGTTGAGTATACCCATCTCCATTGCAAAAGATCTTTCAGACATAGAAGGTGA
CCGCAAGTTTGGAATCATAACCTTCTCAACTAAATTTGGAGCAAAACCCATAGCATATATTTGTCATGGACTCATGCTTCTGAATTACGTG
AGTGTTATGGCTGCAGCTATTATTTGGCCACAGTTTTTCAACAGTAGCGTAATATTGCTTTCTCATGCATTCATGGCAATTTGGGTATTATA
TCAGGCTTGGATATTGGAGAAATCAAATTACGCCACG[GAAACG]TGCCAAAAATACTATATATTCCTTTGGATAATTTTTTCTCTTGAACAT
GCCTTCTATTTGTTCATG[TAG]GCTTAGAGACC

CsPT3 CDS1 ns Part for synthesis: Type IIS recognition sequences: BsaI, BbsI, SapIII, START, STOP. XXXX = motif liberated by BsaI digestion during Golden Gate Level 1 assembly of Transcriptional Unit; § = mutations to eliminate internal Type IIS restriction endonuclease recognition motifs; [ ] replaces STOP (and produces a Serine-Serine linker)

GGTCTCAAATGGTGTTCTCATCAGTTTGTAGTTTTCCATCCTCCCTTGGAACTAATTTTAAATTAGTTCCTCGTAGTAATTTTAAGGCATCAT
CTTCTCATTATCATGAAATAAATAATTTTATTAATAATAAACCAATTAAATTCTCATATTTTTCTTCAAGACTATATTGCTCTGCCAAACCAA
TTGTACACAGAGAAAACAAATTCACAAAATCATTTTCACTCAGCCACCTCCAAAGGAAAAGCTCCATAAAGGCACATGGTGAAATTGAAG
CTGATGGGAGTAATGGCACATCTGAATTTAATGTAATGAAAAGTGGAAACGCAATTTGGAGATTTGTAAGGCCATATGCAGCCAAGGGA
GTATTGTTTAACTCTGCTGCTATGTTTGCAAAAGAGTTGGTGGGGAACCTAAATCTATTTAGTTGGCCTTTGATGTTTAAGATACTCTCTTT
TACATTGGTTATTTTATGCATTTTTGTAAGTACAAGTGGCATCAATCAAATTTATGATCTCGACATCGACAGGTTAAACAAACCTAATTTGC
CAGTAGCATCAGGAGAAATTTCAGTTGAATTGGCATGGTTGTTGACTATAGTTTGTACAATAAGTGGCCTCACATTAACAATTATAACGA
ACTCAGGGCCATTCTTCCCTTTTCTCTACTCTGCTAGTATCTTTTTTGGCTTTCTCTATTCTGCTCCTCCATTCAGATGGAAGAAGAATCCTTT
TACAGCATGTTTCTGTAATGTTATGTTGTATGTTGGCACAAGCGTTGGTGTCTATTATGCTTGTAAGGCTAGTCTCGGGCTTCCAGCCAAC
TGGAGCCCTGCTTTTTGTTTGCTCTTTTGGTTTATTTCATTGTTGAGTATACCCATCTCCATTGCAAAAGATCTTTCAGACATAGAAGGTGA
CCGCAAGTTTGGAATCATAACCTTCTCAACTAAATTTGGAGCAAAACCCATAGCATATATTTGTCATGGACTCATGCTTCTGAATTACGTG
AGTGTTATGGCTGCAGCTATTATTTGGCCACAGTTTTTCAACAGTAGCGTAATATTGCTTTCTCATGCATTCATGGCAATTTGGGTATTATA
TCAGGCTTGGATATTGGAGAAATCAAATTACGCCACGGAAACGTGCCAAAAATACTATATATTCCTTTGGATAATTTTTTCTCTTGAACAT
GCCTTCTATTTGTTCATG[ ]TTCGAGAGACC

FIG. 70

Reference CsEPSPS sequence:

LOC115705599: TTGACGAAGTTCAACTTTTCCTTGGAAATGCTGGAACAGCAATGCGTCCACTCACAGCTGC **(SEQ ID NO:55)**

LOC115705595: TTGACGAAGTTCAACTTTTCCTTGGAAATGCTGGAACAGCAATGCGTCCACTCACAGCTGC **(SEQ ID NO:55)**

nick

TTGACGAAGTTCAACTTTTCCTTGGAAA GCTGGAACAGCAATGCGTCCACTCACAGCTGC **(SEQ ID NO:55)**

XXX= spacer; XXX= PAM; X= editing position +1

* double-nucleotide mutation: CsEPSPS_9CtoT and 20CtoT (mutation from C to T at position 9 and from C to T at position 20)

pegRNA: CAACTTTTCCTTGGAAA GC -scaffold- TGAGTGAACGCATTGCTATTCCAGCATTTCCAAGGA **(SEQ ID NO:56)**

RT + PBS

CsEPSPS-gRNA1 as oligos:

T**GAAGAC**TTTGCACAACTTTTCCTTGGAAA GCGTTTAA**GTCTTC**T (Forward) **(SEQ ID NO:41)**

A**GAAGAC**TTAAACGCATTTCCAAGGAAAAGTTGTGCAAA**GTCTTC**A (Reverse) **(SEQ ID NO:42)**

CsEPSPS-Ext1 Part for synthesis: (PBS+RT flanked by BspMI sites):

ACCTGCTATAGTGCTGAGTGAACGCATTGCTATTCCAGCATTTCCAAGGAAACATATA**GCAGGT** **(SEQ ID NO:43)**

FIG. 71

Reference CsEPSPS sequence:

LOC115705599: CTTGGAGCAACAGTTGAGGAAGGACCCGATTACTGCGTGATCACTCCACCAGAGAA **(SEQ ID NO:57)**
LOC115705595: CTTGGAGCAACAGTTGAGGAAGGACCCGATTACTGCGTGATCACTCCACCAGAGAA **(SEQ ID NO:57)**

nick
↓
CTTGGAGCAACAGTTGAXXXGAAGGACCCGATTACTGCGTGATCACTCCACCAGAGAA **(SEQ ID NO:57)**
XXX= spacer; XXX= PAM; X= editing position +1

* double-nucleotide mutation: CsEPSPS_9-10CCtoTT (mutation from CC to TT at position 9-10)
pegRNA: CTTGGAGCAACAGTTGAXXXGA-scaffold- CACGCAGTAATCAAGTCCTTCCTCAACTGTTG **(SEQ ID NO:58)**
RT + PBS

CsEPSPS-gRNA2 as oligos:
T**GAAGAC**TTTGCACTTGGAGCAACAGTTGAGGAGTTTAA**GTCTTC**T (Forward) **(SEQ ID NO:44)**

A**GAAGAC**TTAAACTCCTCAACTGTTGCTCCAAGTGCAAA**GTCTTC**A (Reverse) **(SEQ ID NO:45)**

CsEPSPS-Ext2 Part for synthesis: (PBS+RT flanked by BspMI sites):
ACCTGCTATAGTGCCACGCAGTAATCAAGTCCTTCCTCAACTGTTGAACATATA**GCAGGT** **(SEQ ID NO:46)**

FIG. 72

FIG. 73



Ln 1 = Low molecular weight ladder
Ln 2 = blank
Ln 3 = 50:50 reagent negative control
Ln 4 = Cannabis leaf negative control
Ln 5 = blank
Ln 6 = T0 Cannabis WP001181-1b leaf 1
Ln 7 = T0 Cannabis WP001181-1b leaf 2
Ln 8 = T0 Cannabis WP001181-1b leaf 3
Ln 9 = T0 Cannabis WP001181-1b leaf 4
Ln 10 = T0 Cannabis WP001181-1b leaf 5
Ln 11 = T0 Cannabis WP001181-1b leaf 6
Ln 12 = T0 Cannabis WP001181-1b leaf 7
Ln 13 = T0 Cannabis WP001181-1b leaf 8
Ln 14 = T0 Cannabis WP001181-1b leaf 9
Ln 15 = T0 Cannabis WP001181-1b leaf 10
Ln 16 = blank
Ln 17 = 2 ng plasmid DNA
Ln 18 = blank
Ln 19 = Low molecular weight ladder

FIG. 74


WP001181-1b leaf 1
WP001181-1b leaf 2
WP001181-1b leaf 3
WP001181-1b leaf 4
WP001181-1b leaf 5
WP001181-1b leaf 6
WP001181-1b leaf 7
WP001181-1b leaf 8
WP001181-1b leaf 9
WP001181-1b leaf 10
Negative control leaf

FIG. 75



FIG. 76


3d semisolid co-culture
3d 2 ml liquid co-culture
3d 2.25 ml liquid co-culture
23C imbibition
37C imbibition

FIG. 77


3d semisolid co-culture
3d 2 ml liquid co-culture
3d 2.25 ml liquid co-culture
23C imbibition
37C imbibition

FIG. 78


Badger on 50 ppm spectinomycin
3WS non-RFP control
Brightfield
RFP

FIG. 79



FIG. 80



METHODS OF GENE EDITING AND TRANSFORMING CANNABIS

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No. 62/875,311, filed Jul. 17, 2019, U.S. Provisional Application No. 62/906,210, filed Sep. 26, 2019, and U.S. Provisional Application No. 62/982,522, filed Feb. 27, 2020, each of which is incorporated herein by reference in their entirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

[0002] Not Applicable.

SEQUENCE LISTING

[0003] A Sequence Listing accompanies this application and is submitted as an ASCII text file of the sequence listing named "960296_04047_ST25.txt" which is 95.4 KB in size and was created on Nov. 23, 2020. The sequence listing is electronically submitted via EFS-Web on Nov. 23, 2020 and is incorporated herein by reference in its entirety.

BACKGROUND

[0004] A key hurdle in the transformation of plants is the responsiveness of cells in tissue culture to produce embryogenic cells that go on to form clonal, intact and fertile plants. Many species and varieties of plants are recalcitrant to this type of regeneration, including *Cannabis sativa* and *Cannabis indica*. Therefore, a need in the art exists for improved *Cannabis* transformation and gene editing methods.

SUMMARY OF THE INVENTION

[0005] In a first aspect, provided herein is a method of preparing an explant, the method comprising the steps of, rehydrating a dry *Cannabis* seed in a hydration medium, and excising meristematic tissue from the rehydrated *Cannabis* seed to form an explant. In some embodiments, the hydration medium comprises one or more priming agents. In some embodiments, the seed is a *Cannabis sativa* seed.

[0006] In some embodiments, the explant preparation method additionally comprises the step of surface sterilizing the *Cannabis* seed prior to rehydration. In some embodiments, the seed is surface sterilized using bleach.

[0007] In some embodiments, the explant preparation method additionally comprises the step of drying the explant. In some embodiments, the dried explant is capable of being stored for at least 10 days. In some embodiments, the explant is dried in the presence of one or more transformation supplements. In some embodiments, the transformation supplement is selected from the group consisting of a small molecule, a nucleic acid, a polypeptide, a protein, an antibody, a transcription factor, a biological macromolecule, a nanoparticle, and a liposome.

[0008] In some embodiments, the explant preparation method additionally comprise the step of transforming the explant with a heterologous nucleic acid of interest. In some embodiments, the explant is transformed using *Agrobacterium* mediated transformation or particle bombardment.

[0009] In a second aspect, provided herein is a *Cannabis* explant generated by the explant preparation methods described herein.

[0010] In a third aspect, provided herein is a dried *Cannabis* explant generated by the methods described herein.

[0011] In a forth aspect, provided herein is a method of transforming *Cannabis* with a heterologous nucleic acid, the method comprising the steps of rehydrating a dry *Cannabis* seed in a hydration medium, excising meristematic tissue from the rehydrated *Cannabis* seed to form a *Cannabis* explant, incubating the *Cannabis* explant in a pretreatment medium, inoculating the *Cannabis* explant with *Agrobacterium* spp. comprising the heterologous nucleic acid, co-culturing the *Cannabis* explant in a co-culture medium for between about 1 day and about 6 days, and culturing the *Cannabis* explant on a selection medium to select for transformed *Cannabis* explants.

[0012] In some embodiments, the method of transforming *Cannabis* additionally comprises the step of force treating the *Cannabis* explant prior to or following inoculation. In some embodiments, the force treatment is selected from the group consisting of sonication, vortexing, centrifugation, heat-shock, and addition of chemicals.

[0013] In some embodiments, the *Cannabis* transformation method additionally comprises the step of surface sterilizing the *Cannabis* seed prior to rehydration.

[0014] In some embodiments, the heterologous nucleic acid modulates the expression or activity of an endogenous *Cannabis* gene selected from the group consisting of tetrahydrocannabinolic acid synthase (THCA synthase), cannabidiolic acid synthase (CBDA synthase), O-methyltransferase (CsOMT21), lipid transfer protein 2 (LTP2), prenyltransferase 3 (CsPT3), and prenyltransferase 1 (CsPT1). In some embodiments, the heterologous nucleic acid encodes a polypeptide at least 90% identical to SEQ ID NO:28. In some embodiments, the heterologous nucleic acid encodes a guide RNA that targets *Cannabis sativa* THCA synthase gene, *Cannabis sativa* CBDA synthase gene, or *Cannabis sativa* EPSP synthase gene

[0015] In some embodiments, the *Cannabis* seed is a *Cannabis sativa* seed. In some embodiments, the *Cannabis* seed is a seed from a *Cannabis* plant with less than 0.3 percent THC based on dry weight.

[0016] In a fifth aspect, provided herein is a transformed *Cannabis* explant produced by the methods described herein.

[0017] In a sixth aspect, provided herein is a *Cannabis* plant grown from the *Cannabis* explant generated by the methods described herein.

[0018] In a seventh aspect, provided herein is a method of producing a transformed *Cannabis* seed, the method comprising contacting a female *Cannabis* flower with an *Agrobacterium* spp. culture, wherein the *Agrobacterium* comprises a heterologous nucleic acid and pollinating the contacted female *Cannabis* flower with male pollen from a suitable donor plant, whereby a transformed *Cannabis* seed is produced. In some embodiments, the *Agrobacterium* spp. culture comprises sucrose and a wetting agent. In some embodiments, the *Agrobacterium* comprises a vector comprising the heterologous nucleic acid.

[0019] In an eighth aspect, provided herein is a method of transforming a *Cannabis* plant, the method comprising growing a sanitized and imbibed *Cannabis* seed on a non-selective culture medium suitable for supporting the growth

and survival of the *Cannabis* seed until a *Cannabis* explant is formed, inoculating the *Cannabis* explant with a heterologous nucleic acid, co-culturing the *Cannabis* explant in a co-culture medium for between about 1 day and about 6 days, and culturing the *Cannabis* explant on a selection medium to select for transformed *Cannabis* explants. In some embodiments, the explant is selected from the group consisting of a leaf explant, a node explant, an internode explant, a petiole explant, a hypocotyl explant, and a bud explant. In some embodiments, the *Cannabis* explant is inoculated using particle bombardment, high velocity microprojection, microinjection, electroporation, direct DNA uptake, cell-penetrating peptides, silica carbide fibers, nanoparticles, and bacterially-mediated transformation. In some embodiments, *Agrobacterium* spp. is used to inoculate the *Cannabis* explant.

[0020] In some embodiments, the method additionally comprises the step of force treating the *Cannabis* explant prior to or following inoculation. In some embodiments, the force treatment is selected from the group consisting of sonication, vortexing, centrifugation, heat-shock, and addition of chemicals.

[0021] In some embodiments, the heterologous nucleic acid modulates the expression or activity of an endogenous *Cannabis* gene selected from the group consisting of tetrahydrocannabinolic acid synthase (THCA synthase), cannabidiolic acid synthase (CBDA synthase), O-methyltransferase (CsOMT21), lipid transfer protein 2 (LTP2), prenyltransferase 3 (CsPT3), and prenyltransferase 1 (CsPT1). In some embodiments, the heterologous nucleic acid encodes a polypeptide at least 90% identical to SEQ ID NO:28. In some embodiments, the heterologous nucleic acid encodes a guide RNA that targets *Cannabis sativa* THCA synthase gene, *Cannabis sativa* CBDA synthase gene, or *Cannabis sativa* EPSP synthase gene.

[0022] In some embodiments, the *Cannabis* seed is a *Cannabis sativa* seed.

BRIEF DESCRIPTION OF DRAWINGS

[0023] The patent or patent application file contains at least one drawing in color. Copies of this patent or patent application publication with color drawings will be provided by the Office upon request and payment of the necessary fee.

[0024] FIG. **1** shows stable RFP expression in *Cannabis* plantlet from meristem transformation experiments outlined in Example 1.

[0025] FIG. **2** shows a non-transgenic *Cannabis* plant derived from meristem explant in tissue culture.

[0026] FIG. **3** shows transient GUS expression in *Cannabis* meristem explants varieties Honey Gold 3WS and Fiber Hemp inoculated with Ar18r12v/DICOTBINARY-19.

[0027] FIG. **4** shows the plasmid map of the DICOTBINARY-22 vector.

[0028] FIG. **5** shows flower phenotypes post inoculum application (1 day).

[0029] FIG. **6** shows GUS transient expression in *Cannabis* leaves, petioles, internodes, and nodes inoculated with Ar18r12v/DICOTBINARY-19.

[0030] FIG. **7** shows mature *Cannabis* seed and embryo.

[0031] FIG. **8** shows *Cannabis* seeds and meristem explants.

[0032] FIG. **9** shows *Cannabis* meristem explants on B5 medium and after 4 days in co-culture after inoculation with Ar18r12v/DICOTBINARY-19.

[0033] FIG. **10** shows transient GUS expression in *Cannabis* meristem explants transformed with Ar18r12v/DICOTBINARY-19.

[0034] FIG. **11** shows transient GUS expression in *Cannabis* meristem explants transformed with Ar18r12v/DICOTBINARY-19 and de-stained in 70% EtOH.

[0035] FIG. **12** shows a non-inoculated *Cannabis* seed sanitized in 20% Clorox on B5 medium (left) and a non-inoculated meristem explant on B5 medium (right).

[0036] FIG. **13** shows spectinomycin sensitive (bleaching) phenotype visible in inoculated *Cannabis* meristem explants on 150 mg/L spectinomycin B5.

[0037] FIG. **14** shows sanitized *Cannabis* seeds and axenic plantlets on B5 medium after about 6 weeks.

[0038] FIG. **15** shows greening, regenerating *Cannabis* explants that were dried, stored, and regenerated (right) against freshly excised explants (left) that were plated on Hemp Node medium (Table 7) the day of excision. Explants were imaged approximately 3 weeks after excision.

[0039] FIG. **16** shows stable GUS expression in a plantlet derived from the treatment Hemp 3/22-3B described in Example 1. One of the leaves in a plantlet transferred to non-selective BRM expressed GUS in leaf stably.

[0040] FIG. **17** shows *Cannabis* seeds imbibed at 37° C.

[0041] FIG. **18** shows embryonic parts produced by mechanical excision.

[0042] FIG. **19** shows the plasmid map of control binary construct SOYTEST-2.

[0043] FIG. **20** shows positive GUS transients in *Cannabis* meristem explants (3WS variety) using SOYTEST-2 in both the Ar18r12v (left) and GV3101 (right) strains of *Agrobacterium*, demonstrating transfection of *Cannabis* meristems using disarmed strains of both *Agrobacterium rhizogenes* (Ar18r12v) and *Agrobacterium tumefaciens* (GV3101).

[0044] FIG. **21** additional stable RFP expressing *Cannabis* (Plant WP421-1) from experiments in the Honey Gold 3WS variety. The plantlet in the center is rooting on 50 mg/L streptomycin hemp node media (after being on 50 mg/L spectinomycin hemp node media for approximately 1 month).

[0045] FIG. **22** shows the plasmid map of the DICOTBOMB-13 vector.

[0046] FIG. **23** shows GUS transient expression in *Cannabis* meristem explants bombarded with DICOTBOMB-13.

[0047] FIG. **24** shows pollen germination results.

[0048] FIG. **25** shows pollen germination results. T0=initial germination after 1 hr treatment; T1=germination after 4 hr treatment; T2=germination after overnight treatment (22 h).

[0049] FIG. **26** shows the phenotype of plant WP421-1 on the day of transfer from tissue culture to the greenhouse (right) and after approximately 4 weeks in the greenhouse (left).

[0050] FIG. **27** shows stable RFP and GUS expression in leaves of T0 *Cannabis* plant WP421-1 derived from meristem transformation.

[0051] FIG. **28** shows stable GUS expression of leaves of T0 *Cannabis* plant WP421-1 derived from meristem transformation.

[0052] FIG. **29** shows *Cannabis* VAEs after 5 weeks (left) compared to freshly excised *Cannabis* meristem explants (right).

[0053] FIG. **30** shows machine excised *Cannabis* meristem explants imaged after approximately two weeks on non-selective B5 medium.

[0054] FIG. **31** shows transgenic T0 plant WP421-1 after 7 weeks in the greenhouse.

[0055] FIG. **32** shows GUS expression in leaf samples from WP421-1. Nine out of the ten leaf samples showed positive GUS expression confirming minimal chimerism.

[0056] FIG. **33** shows the PCR amplification scheme for PCR of leaf samples from WP421-1. A 156 bp fragment within the aadA1a expression cassette of DICOTBINARY-19 was amplified using primers designated F56 and R11. The fragments and the resulting amplicon is highlighted in blue.

[0057] FIG. **34** shows the results of PCR amplification of a 156 bp fragment of the aadA1a expression cassette. All 10 leaf samples were positive.

[0058] FIG. **35** shows bleached *Cannabis* meristem explants after 1 month on 100 mg/L spectinomycin node medium. RFP negative *Cannabis* meristem explants that were previously greening on 10-50 mg/L spectinomycin were transferred to hemp node medium containing 100 mg/L spectinomycin.

[0059] FIG. **36** shows GUS expression in vascular tissue (petiole sections) of *Cannabis* T0 event WP421-1 ("Candice").

[0060] FIG. **37** shows pollination of WP421-1 by 3WS wild-type plant.

[0061] FIG. **38** shows flower of WP421-1 pollinated by 3WS wild-type plant.

[0062] FIG. **39** shows cuttings of WP421-1.

[0063] FIG. **40** shows T1 seedlings of WP421-1 and RFP expression in T1 seedling WP421-1@2 "Carly."

[0064] FIG. **41** shows germline confirmation of *Cannabis* meristem transformation through RFP, GUS expression, and aadA1a PCR.

[0065] FIG. **42** shows T1 *Cannabis* plants WP421-1@1 and WP421-1@2 after 2 months in greenhouse.

[0066] FIG. **43** shows T1 seed of WP421-1.

[0067] FIG. **44** shows stable RFP expression (tdTomato) in T1 seedlings of WP421-1 (germinated on germination paper).

[0068] FIG. **45** shows stable RFP expression (tdTomato) in T1 seedlings of WP421-1 (germinated in flats).

[0069] FIG. **46** shows stable RFP expression (tdTomato) in T1 seedlings of WP421-1 (germinated in flats).

[0070] FIG. **47** shows stable GUS expression in T1 seedlings of WP421-1 (germinated in flats).

[0071] FIG. **48** shows GUS expression 7-8 weeks post-inoculation in chimeric *Cannabis* shoots (3WS variety) regenerated on 75 mg/L spectinomycin.

[0072] FIG. **49** shows T0 *Cannabis* plant WP421-2 (Honey Gold 3WS+DICOTBINARY-19).

[0073] FIG. **50** shows *Cannabis* meristem explants targeted on carboxymethylcellulose media for particle bombardment.

[0074] FIG. **51** shows phenotype and stable GUS expression in transgenic 3WS *Cannabis* derived from particle-mediated transformation of meristem explants (imaged approximately 2 months post-blast).

[0075] FIG. **52** shows phenotype and stable GUS expression in T0 transgenic 3WS *Cannabis* plant WP-001181-1a ("Fernanda") derived from particle-mediated transformation of meristem explants.

[0076] FIG. **53** shows phenotype of T0 transgenic 3WS *Cannabis* plant WP-001181-1a "Fernanda" derived from particle-mediated transformation of meristem explants after approximately 3 weeks in greenhouse.

[0077] FIG. **54** shows *Cannabis* WP001181-1a particle gun T0 event aadA1a PCR.

[0078] FIG. **55** shows *Cannabis* WP001181-1a particle gun T0 event GUS expression.

[0079] FIG. **56** shows GUS expression in vascular tissue in petiole sections (and corresponding leaf) of *Cannabis* T0 particle gun event WP001181-1a.

[0080] FIG. **57** shows phenotype and stable GUS expression in T0 transgenic 3WS *Cannabis* plant WP-001181-1b ("Hernanda") derived from particle-mediated transformation of meristem explants.

[0081] FIG. **58** shows GUS transient expression in automated-excised *Cannabis* meristem explants of Fiber Hemp variety post co-culture.

[0082] FIG. **59** shows metal rolling pin with glass plate; optional gap can be set by adding/removing shims (metal shims shown on left, paper on right).

[0083] FIG. **60** shows transient GUS expression in *Cannabis* (Abacus variety) meristem explants mechanically excised by crushing under a rolling pin, then stored for 2 months at −20 C (left image seed crushed wet and crushed material then dried; right image seed dried first then crushed.

[0084] FIG. **61** shows GUS transient expression in *Cannabis* meristem explants of variety 3WS and Abacus post co-culture.

[0085] FIG. **62** shows RFP (tdTomato) segregation in the T2 generation of transformed *Cannabis* (derived from T0 event WP421-1).

[0086] FIG. **63** shows a schematic of the gene networks underlying cannabinoid and terpenoid accumulation in *Cannabis*. Zager et al., Plant Physiology, 2019, 180(4):1877-1897.

[0087] FIG. **64** shows a sequence alignment of various THCA synthase cDNA sequences. From top to bottom, the sequences shown are: SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:5, and SEQ ID NO:59.

[0088] FIG. **65** shows a sequence alignment of various CBDA synthase cDNA sequences. From top to bottom, the sequences shown are: SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:11, SEQ ID NO:17, and SEQ ID NO:11.

[0089] FIG. **66** shows embodiments of a cloning strategy for BraLTP2. From top to bottom, the sequences shown are: SEQ ID NO:29, SEQ ID NO:47, and SEQ ID NO:48.

[0090] FIG. **67** shows embodiments of a cloning strategy for CsPT1. From top to bottom, the sequences shown are: SEQ ID NO:31, SEQ ID NO:49, and SEQ ID NO:50.

[0091] FIG. **68** shows embodiments of a cloning strategy for CsOMT1. From top to bottom, the sequences shown are: SEQ ID NO:33, SEQ ID NO:51, and SEQ ID NO:52.

[0092] FIG. **69** shows embodiments of a cloning strategy for CsPT3. From top to bottom, the sequences shown are: SEQ ID NO:35, SEQ ID NO:53, and SEQ ID NO:54.

[0093] FIG. **70** shows an embodiment of the CsEPSPS prime editing mutation strategy as described herein.

[0094] FIG. **71** shows an embodiment of the CsEPSPS prime editing mutation strategy as described herein.

[0095] FIG. **72** shows the phenotype of T0 transgenic 3WS *Cannabis* plant WP-001181-1b ("Hernanda") derived from particle-mediated transformation of meristem explants after transplant to large pot.

[0096] FIG. **73** shows *Cannabis* WP001181-1b particle gun T0 event aadA1a PCR.

[0097] FIG. **74** shows *Cannabis* WP001181-1b particle gun T0 event GUS expression.

[0098] FIG. **75** shows a *Cannabis* seed (Badger variety) surface sanitized followed by incubation at 37° C. without imbibition (note radical emergence in seed on left).

[0099] FIG. **76** shows the phenotype of *Cannabis* meristem explants of Badger variety after 3-day co-culture.

[0100] FIG. **77** shows transient GUS expression in *Cannabis* meristem explants of Badger variety after 3-day co-culture.

[0101] FIG. **78** shows stable RFP (tdTomato) expression in *Cannabis* meristem explants (variety Badger).

[0102] FIG. **79** shows a process diagram timeline for *Cannabis sativa Agrobacterium*-mediated transformation of embodiments described herein. Stage 1 shows *Cannabis* seeds. Stage 2 shows appearance of *Cannabis* meristem explant (mature embryo) derived from imbibed seed, the explant on left has cotyledonary tissue intact; explant on right has cotyledonary tissue removed. Stage 3 shows transient GUS activity in Honey Gold 3WS *Cannabis* explants after co-culture with *Agrobacterium*. Stage 4 shows appearance of *Cannabis* meristem explants after 4 day co-culture. Stage 5 shows phenotypes of *Cannabis* meristem explants after ~3 weeks on 50 mg/L spectinomycin; note incomplete bleaching. Stage 6 shows *Cannabis* T0 event after second selection on 50 mg/L streptomycin prior to handoff to greenhouse. Finally, Stage 7 shows *Cannabis* T0 event prior to transplant in greenhouse.

[0103] FIG. **80** shows a process diagram timeline for *Cannabis sativa* Particle-mediated transformation. Stage 1 shows *Cannabis* seeds. Stage 2 shows appearance of *Cannabis* meristem explant (mature embryo) derived from imbibed seed, the explant on left has cotyledonary tissue intact; explant on right has cotyledonary tissue removed. Stage 3 shows *Cannabis* embryo target on CMC targeting media. Stage 4 shows PDS-1000 Helium gun. Stage 5 shows transient GUS activity in Honey Gold 3WS *Cannabis* explants 1-day post-bombardment. Stage 6 shows phenotypes of *Cannabis* meristem explants 2 months post-bombardment. Stage 7 shows *Cannabis* T0 event prior to handoff to greenhouse. Finally, Stage 8 shows *Cannabis* T0 event prior to transplant in greenhouse.

INCORPORATION BY REFERENCE

[0104] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, and patent application was specifically and individually indicated to be incorporated by reference.

DETAILED DESCRIPTION OF THE INVENTION

[0105] The present disclosure describes methods for preparation and transformation of meristem explants from *Cannabis*. The meristem explant preparation methods described herein allow for pretreatment of the tissues for higher explant transformation and longer explant storage following excision.

[0106] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. All definitions, as defined and used herein, should be understood to control over dictionary definitions, definitions in documents incorporated by reference, and/or ordinary meanings of the defined terms.

[0107] The indefinite articles "a" and "an," as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to mean "at least one."

[0108] The phrase "and/or," as used herein in the specification and in the claims, should be understood to mean "either or both" of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with "and/or" should be construed in the same fashion, i.e., "one or more" of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the "and/or" clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to "A and/or B", when used in conjunction with open-ended language such as "comprising" can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.

[0109] As used herein in the specification and in the claims, "or" should be understood to have the same meaning as "and/or" as defined above. For example, when separating items in a list, "or" or "and/or" shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as "only one of" or "exactly one of," or, when used in the claims, "consisting of," will refer to the inclusion of exactly one element of a number or list of elements. In general, the term "or" as used herein shall only be interpreted as indicating exclusive alternatives (i.e. "one or the other but not both") when preceded by terms of exclusivity, such as "either," "one of," "only one of," or "exactly one of." "Consisting essentially of," when used in the claims, shall have its ordinary meaning as used in the field of patent law.

[0110] As used herein, the terms "approximately" or "about" in reference to a number are generally taken to include numbers that fall within a range of 5% in either direction (greater than or less than) the number unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value). Where ranges are stated, the endpoints are included within the range unless otherwise stated or otherwise evident from the context.

[0111] Provided herein are methods for preparing an explant suitable for transformation from a *Cannabis* seed. Also provided herein are methods of transforming and gene editing *Cannabis* meristem explant tissue. The explants generated by the methods described herein exhibit higher transformation efficiency with a broader capacity to customize the transformation process via pretreatment of the meri-

stematic tissue used to generate the explants. The methods described herein allow for high scale production of storable explants for more effect transformation methods. As described in further detail below, the protocols described herein allow for targeted pretreatment of the meristematic tissues used in explant preparation at various stages and with various factors to improve explant storage and transformation efficiency.

[0112] As used herein, "embryo" refers to part of a seed, consisting of precursor tissues (meristematic tissues) for the leaves, stem, and root, as well as one or more cotyledons. Once the embryo begins to grow (germinate), it becomes a seedling plant.

[0113] As used herein, "meristem" or "meristematic tissue" refers to the portion of a seed that consists of undifferentiated cells, the meristematic cells, which differentiate to produce multiple plant structures including stem, roots, leaves, germline tissues and seeds. The meristematic cells are the targets for transformation to obtain transgenic plants.

[0114] As used herein, "explant" refers to the target material for transformation.

[0115] As used herein, "germline transformation" refers to the transformation of a gene of interest into cells that give rise to pollen or ovule thus into seed.

[0116] In a first aspect, provided herein is a method for preparing an explant from the meristematic tissue of a seed, where the method generally comprises the steps of drying the seed, surface sterilizing the seed, imbibing the seed until sufficiently hydrated, excising meristematic tissue from the hydrated seed to generate an explant, and optionally drying the excised meristematic tissue to generate the storable explant for transformation. The explants generated by the methods described herein are suitable for use in any transformation method known in the art.

[0117] The methods described herein also include one or more priming steps in which one or more priming agents are added to either the hydration medium during imbibing of the seed or to the explant as it is drying to generate a value added explant. As used herein, the term "value added explant" refers to an explant prepared by the methods described herein when a priming factor has been included in the hydration medium or a transformation supplement is included during drying of the explant.

[0118] The method includes a first step of drying a seed or acquiring a dried seed from which the explant will be generated. Preferably, a dry seed for use in the methods of the present invention will have a moisture content of between 1% and 25%. Ideally seeds are grown and harvested to achieve a viable embryo and are grown and harvested and cleaned to achieve blemish-free identity preserved seeds free of plant diseases and microbes that could interfere with sterile tissue culture. It may be desirable to treat the plants with fungicides and/or natural or synthetic plant regulators to improve embryo viability, embryo storage quality, seed coat intactness, seed vigor, percent germination cell response in tissue culture and transformation.

[0119] Seeds from which explants are to be prepared may be harvested from any *Cannabis* cultivar of interest. In some embodiments, the seed is from *Cannabis sativa*. In some embodiments, the seed is from *Cannabis indica*. In some embodiments, the seed is from a *Cannabis* variety developed from cross breeding of *Cannabis sativa* and *Cannabis indica*. In some embodiments, the seed is from a *Cannabis sativa* L. plant with less than 0.3 percent tetrahydrocannabinol (THC) based on the dry weight. In some embodiments, the *Cannabis sativa* cultivar is selected from the group consisting of Elektra x Chardonnay, Honey Gold 3WS (also referred to in the art at 3W1), Abacus, and Fiber Hemp.

[0120] In some embodiments of the present invention, the dry seed is surface sterilized. Any means known in the art for surface sterilization can be used. Suitable methods for surface sterilization may include, but are not limited to, exposure of the seed surface to radiation, UV light, oxidizing gasses, heat, plasma, disinfecting solvents and agents. In some embodiments, the seed is surface sterilized with a chemical agent such as sodium hypochlorite. In some embodiments, the seed is surface sterilized with an antibacterial or antifungal agent. In some embodiments, the seed is surface sterilized with ethanol (e.g., 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% ethanol). In some embodiments, the seed is surface sterilized with Clorox™ bleach.

[0121] The dry seed, which in some embodiments has undergone surface sterilization, is imbibed under conditions that support hydration of the seed. The dry seed is hydrated in a hydration medium and for a time sufficient for the seed to reach a moisture content of between 30% and 70%. In some embodiments, the seed is hydrated for at least 12 hours. In some embodiments, the seed is hydrated between 2 and 24 hours.

[0122] The hydration medium used for hydration of the seed maybe any suitable sterile hydration medium known in the art that supports survival of the meristematic tissue in the seed. In some embodiments, the hydration medium is a modified sterile water and includes antibiotics or antifungals. In some embodiments, the hydration medium is a tissue culture medium that includes natural or synthetic plant growth regulators, plant tissue culture nutrients, a carbon source or a non-nutritive osmoregulator. In one embodiment, the hydration medium is bean germination medium, which includes the components outlined in Table 1 of Example 1.

[0123] In some embodiments of the invention, the hydration medium may optionally include one or more priming factors for pretreatment of the meristematic tissue. As used herein, "priming factor" or "priming agent" references to any molecule or substance included in the hydration medium which promotes survival and storage of the prepared explant or that promotes or increases the transformation efficiency of the prepared explant. Priming factors for use in the hydration medium of the present invention may include, but are not limited to, small molecules, biological molecules such as nucleic acids, polypeptides, proteins, antibodies, transcription factors, and macromolecules or complexes thereof, nanoparticles, liposomes, and cell-penetrating peptides. In some embodiments, the priming factor is a plant growth factor including, but not limited to, thidiazuron (TDZ), 6-benzylaminopurine (BAP), polyethylene glycol (PEG), 2,4-dichlorophenoxyacetic acid (2,4-D), Paczol™, gibberellic acid (GA3), indole-3-acetic acid (IAA), indole-3-butyric acid (IBA), 1-naphthalaneacetic acid (NAA), forchlorfenuron (CPPU), spectinomycin, streptomycin, glyphosate, glufosinate, bialophos, hygromycin, amikacin, tobramycin, imazapyr, dicamba, polyvinylpyrrolidone (PVP), polyvinylpolypyrrolidone (PVPP), salicylic acid, proline, betaine, ethylene, brassinosteroids, nitrates, and gibberellins.

[0124] Following hydration of the seed, meristematic tissue is excised to form an explant. Excision of the meristematic tissue may be performed by any means known in the art in which the seed coat and cotyledons are removed

from the seed. Suitable methods for the excision of the meristematic tissue may include, but are not limited to manual processing, wet milling using a series of rollers and spray nozzles, adjustable grinding plates, rods, knives, wheels and other mechanical or machine based excision methods. These may be composed of, but are not limited to, ceramics, metals, and synthetic polymers. Induced pressure, injected gasses, vacuum and turbulence are also suitable methods. Hydrated explants may be stored in suitable storage medium for up to 7 days. Suitable storage medium for the hydrated explants may be any medium that supports survival and competence of the explant tissue. In some embodiments, the explants are stored with an excess of liquid to explants by volume. In some embodiments, the storage medium is liquid medium including MS salts.

[0125] In some embodiments, the meristematic tissue is excised from a dry seed to form an explant without first imbibing the seed. A dry seed suitable for dry excision will typically have a moisture content of between 1% and 25%. Excision of the meristematic tissue from the dry seed may be performed by any means known in the art in which the seed coat and cotyledons are removed from the seed. Suitable methods for the excision of the meristematic tissue may include, but are not limited to manual processing, wet milling using a series of rollers and spray nozzles, adjustable grinding plates, rods, knives, wheels and other mechanical or machine based excision methods. These may be composed of, but are not limited to, ceramics, metals, and synthetic polymers. Induced pressure, injected gasses, vacuum and turbulence are also suitable methods.

[0126] Following excision, the explant may be dried. Desiccation of the explant may be performed by any means known in the art such that the moisture content of the dry explant is between 1% and 25%. Suitable methods for desiccating the explant may include, but are not limited to, drying in the presence of air with and without an added dehumidifying agent. In some embodiments, the explants are dried in a laminar flow hood. In some embodiments, the explants are dried on the surface of filter paper in a laminar flow hood for about 26 hours. In some embodiments, the explants are dried in a dehumidifier. In some embodiments, the explants are dried at a temperature between 0° C. and 35° C. for at least 5 hours (e.g., at least 5, 7, 9, 12, 15, 18, 24, 30, 36, 42, 48, 72, 96 or 120 hours) and up to 2 weeks (e.g., up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days). In some embodiments, it may be beneficial to control rates of drying by tightly controlling temperature, humidity, air flow, and time.

[0127] During desiccation of the explant, one or more transformation supplements may be added. As used herein, "transformation supplement" refers to any molecule or substance added to the explant during desiccation, which promotes survival and storage of the prepared explant or that promotes or increases the transformation efficiency of the prepared explant. Transformation supplements for use during desiccation of the explant of the present invention may include small molecules, biological molecules such as nucleic acids, polypeptides, proteins, antibodies, transcription factors, and macromolecules or complexes thereof, nanoparticles, liposomes, *Agrobacterium, Rhizobium*, and cell-penetrating peptides. In some embodiments, the transformation supplement is a plant growth factor, cell protectant agent including, or other agent including, but not limited to, thidiazuron (TDZ), 6-benzylaminopurine (BAP), polyethylene glycol (PEG), alginates and alginate complexes, starches, celluloses, synthetic polymers, gums, waxes, proline, betaine, polyvinylpyrrolidone (PVP), polyvinylpolypyrrolidone (PVPP), salicylic acid, calcium sources, silicone sources, colchicine, 2,4-dichlorophenoxyacetic acid (2,4-D), Paczol™, gibberellic acid (GA3), gibberellin (GA) pathway inhibitors, indole-3-acetic acid (IAA), indole-3-butyric acid (IBA), 1-naphthalaneacetic acid (NAA), forchlorfenuron (CPPU), spectinomycin, streptomycin, glyphosate, glufosinate, bialophos, hygromycin, amikacin, tobramycin, imazapyr, lyophilized agrobacterium, lyophilized rhizobium, and potassium hydroxide (KOH). In some embodiments, the transformation supplement is an agent, which promotes multiplication of the meristematic tissue, such as, but not limited to, TDZ, BAP, zeatin, kinetin, and CPPU. In some embodiments, explants are mechanically wounded prior to drying and storage. This can be achieved with exposure to ultrasound energy (e.g., sonication), liquid nitrogen, centrifugation, pressure, and chemical (ex. KOH, PEG, acids, bases), enzymes, abrasives, water jets, lasers, needles, or blades.

[0128] The dried explants are suitable for storage in a variety of conditions. Dried explants may be stored at temperatures ranging from about −200° C. to 50° C. (i.e., about −190° C. to 40° C., about −170° C. to 30° C., about −150° C. to 20° C., about −130° C. to 10° C., and about −102° C. to 0° C.) for a period of time of at least 7 days (i.e., at least 10 days, at least 30 days, at least 50 days, at least 60 days, at least 75 days, at least 90 days, and at least 120 days). Storable dried explants can also be banked to create libraries of germplasms from a variety of cultivars of agronomic significance. In general, lower temperature storage under dry conditions or controlled humidity will allow for prolonged storage of the dried Cannabis explants.

[0129] Explants generated by the methods described herein can be transformed with a heterologous gene or nucleic acid of interest by any means known in the art. Various methods have been developed for transferring genes or nucleic acids into plant tissue including particle bombardment, high velocity microprojection, microinjection, electroporation, direct DNA uptake, silica carbide fibers, cell-penetrating peptides, nanoparticles, viral vectors, and bacterially-mediated transformation. Bacteria known to mediate plant cell transformation include a number of species of the Rhizobiaceae, including, but not limited to, *Agrobacterium* spp., *Sinorhizobium* spp., *Mesorhizobium* spp., *Rhizobium* spp., *Ochrobacterium* spp., and *Bradyrhizobium* spp. In some embodiments, the explant is transformed using *Agrobacterium* spp. In some embodiments, the explant is transformed using *Agrobacterium* strain Ar18r12v. In some embodiments, the explant is transformed using particle bombardment using gold microcarriers. Suitable viral vectors are known and described in the art and may include, but are not limited to, tomato yellow leaf curl virus (TYLCV), tobacco yellow dwarf virus (TobYDV), tomato golden mosaic virus (TGMV), bean pod mottle virus (BPMV). Suitable methods of plant transformation are described in the art, such as, for example, by McCabe et al. (McCabe, D. E., Swain, W. F., Martinell, B. J., Christou, P. (1988) *Nature Biotechnology* 6(8), 923-926), Chen et al. (Chen, Y., Rivlin, A. Lange, A., Ye, X., Vaghchhipawala, Z., Eisinger, E., Dersch, E., Paris, M., Martinell, B., Wan, Y. (2014) *Plant Cell Reports* 33(1), 153-164), Ye et al. (Ye, X., Williams, E. J., Shen, J., Johnson, S., Lowe, B., Radke, S., Strickland, S.

Esser, J. A., Petersen, M. W., and Gilbertson, L. A. (2011) *Transgenic Research* 20(4), 773-7860), and *Plant Transformation Technologies* (Edited by C. Neal Stewart, Alisher Touraev, Vitaly Citovsky and Tzvi Tzfira ©2011 Blackwell Publishing Ltd. ISBN: 978-0-813-82195-5.)

[0130] Prior to inoculation, dried explants to be transformed may be rehydrated using suitable tissue culture medium. In some embodiments, the rehydration medium is Soy INO medium, VAE rehydration medium, or a solid medium such as Basal MS or Gamborg's B5 medium. In some embodiments, the rehydration step is combined with the pretreatment step described below.

[0131] Embryos may be pretreated prior to inoculation and transformation. In some embodiments, the embryos are pretreated with a polyethylene glycol (PEG) solution. In some embodiments, the PEG solution includes about 20% PEG4000. In some embodiments, the embryos are pretreated in the PEG-ethanol solution for between about 1 minute and about 3 hours (e.g. 1 min., 2 min., 5 min., 15 min., 30 min., 45 min., 1 hr., 1.5 hr., 2 hr., 2.5 hr., or 3 hr.). In some embodiments, salts may be added to the PEG solution. In some embodiments, the PEG solution includes one or more fungicides (e.g., Captan, Bravo, etc.). In some embodiments, the PEG solution includes Murashige and Skoog (MS) salts. In some embodiments, the pretreatment step includes sonication, vortexing, centrifugation, heat-shock, or addition of chemicals (e.g., TDZ, glyphosate, or metolachlor).

[0132] In some embodiments, the explant transformation is supplemented with force treatments. Force treatments may include, but are not limited to, sonication, vortexing, centrifugation, increased pressure, vacuum infiltration, heat-shock, dessication or addition of chemicals (e.g., TDZ, glyphosate, or metolachlor). Force treatments may be applied prior to or during transformation. For example, prior to or concurrently with inoculation with *Agrobacterium* or particle bombardment treatment. In some embodiments, explants are sonicated for about 20 seconds at about 45 kHz. Force treatment transformation methods are described in the art. See, for example, Khanna, et al. ("Centrifugation assisted *Agrobacterium tumefaciens*-mediated transformation (CAAT) of embryogenic cell suspensions of banana (Musa spp. Cavendish AAA and Lady finger AAA)," Molecular Breeding, 2004, 14:239-252), Kapila et al. ("An *Agrobacterium*-mediated transient gene expression system for intact leaves," Plant Science, 1997, 122(1):101-108), Trick et al. ("SAAT: sonication-assisted *Agrobacterium*-mediated transformation," Transgenic Research, 1997, 6(5): 329-336), and Hiei et al. ("Improved frequency of transformation in rice and maize by treatment of immature embryos with centrifugation and heat prior to infection with *Agrobacterium tumefaciens*," Plant Cell, Tissue, and Organ Culture, 2006, 87(3):233-243).

[0133] Following inoculation, the explants are co-cultured for between about 1 day and about 6 days in any suitable co-culture medium that supports the growth and survival of the inoculated explant. In some embodiments, the co-culture medium is WCIC INO medium, which includes the components outlined in Table 2 of Example 1.

[0134] Following transformation, the explants or transformed tissue is regenerated using a suitable regeneration medium that supports the growth and survival of at least the positively transformed explants or transformed tissues. Suitable regeneration medium are known and described in the art. For example, the regeneration medium may be B5 medium, WPM based medium, MS salts based medium, ½×MS salts based medium, or similar medium with or without supplementation. The regeneration medium may additionally comprise nystatin, TBZ, meta-topolin (mT), napthylacetic acid (NAA) and GA3. In some embodiments, the regeneration medium includes a selection agent to select for positive transformants. Examples of suitable selection agents include, but are not limited to, RFP, GUS, aadA1a, spectinomycin, streptomycin, and imazapyr.

[0135] The heterologous gene or nucleic acid of interest may be any gene or nucleic acid that may confer a particular desirable trait or phenotype in the transformed plant. Examples of suitable genes of agronomic interest envisioned by the present invention would include but are not limited to genes for disease, insect, or pest tolerance, herbicide tolerance, genes for quality improvements such as yield, nutritional enhancements, environmental or stress tolerances, or any desirable changes in plant physiology, growth, development, morphology or plant product(s) including starch production, modified oils production, high oil production, modified fatty acid content, high protein production, fruit ripening, enhanced animal and human nutrition, and biopolymers production. Also environmental stress resistance, pharmaceutical peptides and secretable peptides, improved processing traits, industrial enzyme production, improved flavor, nitrogen fixation, hybrid seed production, and fiber production. Any of these or other genetic elements, methods, and transgenes may be used with the invention as will be appreciated by those of skill in the art in view of the instant disclosure. The heterologous gene or nucleic acid of interest may also be a sequence that can affect a phenotype of interest by encoding an RNA molecule that causes the targeted inhibition of expression on an endogenous gene via gene silencing technologies.

[0136] In some embodiments, the heterologous nucleic acid of interest modulates the expression or function of the endogenous *Cannabis* tetrahydrocannabinolic acid synthase (THCA synthase) gene. A heterologous nucleic acid is introduced into the *Cannabis* explant to knockout or silence the THCA synthase gene. *Cannabis* plants grown from the transformed *Cannabis* explant are characterized by a tetrahydrocannabinol (THC) low or THC free phenotype. The sequence and activity of the THCA synthase gene is known and described in the art. See, for example, Laverty et al. (Laverty et al., "A physical and genetic map of *Cannabis sativa* identifies extensive rearrangements at the THC/CBD acid synthase loci," Genome Research, 2018, 29:146-156).

[0137] Provided below are five cDNA sequences (SEQ ID NOs:1-5) of THCA genes from various *Cannabis sativa* strains. Single nucleotide polymorphs (SNPs) between the active THCA synthase of SEQ ID NO:1 and each of SEQ ID NOs:2-5 are indicated in each of the respective sequences and a full sequence alignment is shown in FIG. **64**.

[0138] *Cannabis sativa* cultivar Skunk #1 tetrahydrocannabinolic acid synthase (THCA1) gene cDNA (SEQ ID NO:1), Genbank: KJ469378.1

ATGAATTGCTCAGCATTTTCCTTTTGGTTTGTTTGCAAAATAATATT

TTTCTTTCTCTCATTCCATATCCAAATTTCAATAGCTAATCCTCGAG

AAAACTTCCTTAAATGCTTCTCAAAACATATTCCCAACAATGTAGCA

AATCCAAAACTCGTATACACTCAACACGACCAATTGTATATGTCTAT

-continued

CCTGAATTCGACAATACAAAATCTTAGATTCATCTCTGATACAACCC

CAAAACCACTCGTTATTGTCACTCCTTCAAATAACTCCCATATCCAA

GCAACTATTTTATGCTCTAAGAAAGTTGGCTTGCAGATTCGAACTCG

AAGCGGTGGCCATGATGCTGAGGGTATGTCCTACATATCTCAAGTCC

CATTTGTTGTAGTAGACTTGAGAAACATGCATTCGATCAAAATAGAT

GTTCATAGCCAAACTGCGTGGGTTGAAGCCGGAGCTACCCTTGGAGA

AGTTTATTATTGGATCAATGAGAAGAATGAGAATCTTAGTTTTCCTG

GTGGGTATTGCCCTACTGTTGGCGTAGGTGGACACTTTAGTGGAGGA

GGCTATGGAGCATTGATGCGAAATTATGGCCTTGCGGCTGATAATAT

TATTGATGCACACTTAGTCAATGTTGATGGAAAAGTTCTAGATCGAA

AATCCATGGGAGAAGATCTGTTTTGGGCTATACGTGGTGGTGGAGGA

GAAAACTTTGGAATCATTGCAGCATGGAAAATCAAACTGGTTGATGT

CCCATCAAAGTCTACTATATTCAGTGTTAAAAAGAACATGGAGATAC

ATGGGCTTGTCAAGTTATTTAACAAATGGCAAAATATTGCTTACAAG

TATGACAAAGATTTAGTACTCATGACTCACTTCATAACAAAGAATAT

TACAGATAATCATGGGAAGAATAAGACTACAGTACATGGTTACTTCT

CTTCAATTTTTCATGGTGGAGTGGATAGTCTAGTCGACTTGATGAAC

AAGAGCTTTCCTGAGTTGGGTATTAAAAAAACTGATTGCAAAGAATT

TAGCTGGATTGATACAACCATCTTCTACAGTGGTGTTGTAAATTTTA

ACACTGCTAATTTTAAAAAGGAAATTTTGCTTGATAGATCAGCTGGG

AAGAAGACGGCTTTCTCAATTAAGTTAGACTATGTTAAGAAACCAAT

TCCAGAAACTGCAATGGTCAAAATTTTGGAAAAATTATATGAAGAAG

ATGTAGGAGCTGGGATGTATGTGTTGTACCCTTACGGTGGTATAATG

GAGGAGATTTCAGAATCAGCAATTCCATTCCCTCATCGAGCTGGAAT

AATGTATGAACTTTGGTACACTGCTTCCTGGGAGAAGCAAGAAGATA

ATGAAAAGCATATAAACTGGGTTCGAAGTGTTTATAATTTTACGACT

CCTTATGTGTCCCAAAATCCAAGATTGGCGTATCTCAATTATAGGGA

CCTTGATTTAGGAAAAACTAATCATGCGAGTCCTAATAATTACACAC

AAGCACGTATTTGGGGTGAAAAGTATTTTGGTAAAAATTTTAACAGG

TTAGTTAAGGTGAAAACTAAAGTTGATCCCAATAATTTTTTTAGAAA

CGAACAAAGTATCCCACCTCTTCCACCGCATCATCATTAA

[0139] *Cannabis sativa* isolate 60D2 tetrahydrocannabinolic acid synthase (THCA) gene (SEQ ID NO:2), GenBank: MG996415.1, single nucleotide polymorph (SNP) relative to SEQ ID NO:1 shown in bold underline.

atgaattgctcagcattttccttttggtttgtttgcaaaataatatt

tttctttctctcattccatatccaaatttcaatagctaatcctcgag

aaaacttccttaaatgcttctcaaaacatattcccaacaatgtagca

aatccaaaactcgtatacactcaacacgaccaattgtatatgtctat

-continued

cctgaattcgacaatacaaaatcttagattcatctctgatacaaccc

caaaaccactcgttattgtcactccttcaaataactcccatatccaa

gcaactattttatgctctaagaaagttggcttgcagattcgaactcg

aagcggtggccatgatgctgagggtatgtcctacatatctcaagtcc

catttgttgtagtagacttgagaaacatgcattcgatcaaaatagat

gttcatagccaaactgcgtgggttgaagccggagctacccttggaga

agtttattattggatcaatgagaagaatgagaatcttagttttcctg

gtgggtattgccctactgttggcgtaggtggacactttagtggagga

ggctatggagcattgatgcgaaattatggccttgcggctgataatat

tattgatgcacacttagtcaatgttgatggaaaagttctagatcgaa

aatccatgggagaagatctgttttgggctatacgtggtggtggagga

gaaaactttggaatcattgcagcatggaaaatcaaactggttgctgt

cccatcaaagtctactatattcagtgttaaaaagaacatggagatac

atgggcttgtcaagttatttaacaaatggcaaaatattgcttacaag

tatgacaaagatttagtactcatgactcacttcataacaaagaatat

tacagataatcatgggaagaataagactacagtacatggttacttct

cttcaatttttcatggtggagtggatagtctagtcgacttgatgaac

aagagctttcctgagttgggtattaaaaaaactgattgcaaagaatt

tagctggattgatacaaccatcttctacagtggtgttgtaaatttta

acactgctaatttttaaaaaggaaatttttgcttgatagatcagctggg

aagaagacggctttctcaattaagttagactatgttaagaaaccaat

tccagaaactgcaatggtcaaaatttttggaaaaattatatgaagaag

atgtaggagctgggatgtatgtgttgtacccttacggtggtataatg

gaggagatttcagaatcagcaattccattccctcatcgagctggaat

aatgtatgaactttggtacactgcttcctgggagaagcaagaagata

atgaaaagcatataaactgggttcgaagtgtttataatttttacgact

ccttatgtgtcccaaaatccaagattggcgtatctcaattatagggga

ccttgatttaggaaaaactaatcatgcgagtcctaataattacacac

aagcacgtatttggggtgaaaagtattttggtaaaaatttttaacagg

ttagttaaggtgaaaactaaagttgatcccaatattttttttagaaa

cgaacaaagtatcccacctcttccaccgcatcatcattaa

[0140] *Cannabis sativa* clone ABC67 THCA synthase gene (SEQ ID NO:3), GenBank: KT876047.1, SNPs relative to SEQ ID NO: shown in bold underline.

atgaattgctcagcattttccttttggtttgtttgcaaaataatatt

tttctttctctcattccatatccaaatttcaatagctaatcctcgag

aaaacttccttaaatgcttctcaaaacatattcccaacaatgtagca

aatccaaaactcgtatacactcaacacgaccaattgtatatgtctat

cctgaattcgacaatacaaaatcttagattcatctctgatacaaccc

-continued

caaaaccactcgttattgtcactccttcaaataactcccatatccaa

gcaactattttatgctctaagaaagttggcttgcagattcgaactcg

aagcggtggccatgatgctgagggtatgtcctacatatctcaagtcc

catttgttgtagtagacttgagaaacatgcattcgatcaaaatagat

gttcatagccaaactgcgtgggttgaagccggagctacccttggaga

agtttattattggatcaatgagaagaatgagaatcttagttttcctg

gtgggtattgccctactgttggcgtaggtggacactttagtggagga

ggctatggagcattgatgcgaaattatggccttgcggctgataatat

tattgatgcacacttagtcaatgttgatggaaaagttctagatcgaa

aatccatgggagaagatctgttttgggctatacgtggtggtggagga

gaaaactttggaatcattgcagcatggaaaatcaaactggttgctgt

cccatcaaagtctactatattcagtgttaaaaagaacatggagatac

atgggcttgtcaagttatttaacaaatggcaaaatattgcttacaag

tatgacaaagatttagtactcatgactcacttcataacaaagaatat

tacagataatcatgggaagaataagactacagtacatggttacttct

cttcaatttttcatggtggagtggatagtctagtcgacttgatgaac

aagagctttcctgagttgggtattaaaaaaactgattgcaaagaatt

tagctggattgatacaaccatcttctacagtggtgttgtaaatttta

acactgctaattttaaaaaggaaattttgcttgatagatcagctggg

aagaagacggctttctcaattaagttagactatgttaagaaaccaat

tccagaaactgcaatggtcaaaattttggaaaaattatatgaagaag

atgtaggagctgggatgtatgtgttgtacccttacggtggtataatg

gaggagatttcagaatcagcaattccattccctcatcgagctggaat

aatgtatgaactttggtacactgcttcctgggagaagcaagaagata

atgaaaagcatataaactgggttcgaagtgtttataatttttacgact

ccttatgtgtcccaaaatccaagattggcgtatctcaattataggga

ccttgatttaggaaaaactaatcatgcgagtcctaataattacacac

aagcacgtatttggggtgaaaagtattttggtaaaaattttaacagg

ttagttaaggtgaaaactaaagttgatcccaataatttttttagaaa

cgaacaaagtatcccacctcttccaccgcatcatcat

[0141] THCA synthase *Cannabis sativa* Purple Kush (SEQ ID NO:4), SNPs relative to SEQ ID NO:1 shown in bold underline.

ATGAATTGCTCAGCATTTTCCTTTTGGTTTGTTTGCAAAATAATAT

TTTTCTTTCTCTCATTCCATATCCAAATTTCAATAGCTAATCCTCG

AGAAAACTTCCTTAAATGCTTCTCAAAACATATTCCCAACAATGTA

GCAAATCCAAAACTCGTATACACTCAACACGACCAATTGTATATGT

CTATCCTGAATTCGACAATACAAAATCTTAGATTCATCTCTGATAC

-continued

AACCCCAAAACCACTCGTTATTGTCACTCCTTCAAATAACTCCCAT

ATCCAAGCAACTATTTTATGCTCTAAGAAAGTTGGCTTGCAGATTC

GAACTCGAAGCGGTGGCCATGATGCTGAGGGTATGTCCTACATATC

TCAAGTCCCATTTGTTGTAGTAGACTTGAGAAACATGCATTCGATC

AAAATAGATGTTCATAGCCAAACTGCGTGGGTTGAAGCCGGAGCTA

CCCTTGGAGAAGTTTATTATTGGATCAATGAGAAGAATGAGAATCT

TAGTTTTCCTGGTGGGTATTGCCCTACTGTTGGCGTAGGTGGACAC

TTTAGTGGAGGAGGCTATGGAGCATTGATGCGAAATTATGGCCTTG

CGGCTGATAATATCATTGATGCACACTTAGTCAATGTTGATGGAAA

AGTTCTAGATCGAAAATCCATGGGAGAAGATCTGTTTTGGGCTATA

CGTGGTGGTGGAGGAGAAAACTTTGGAATCATTGCAGCATGGAAAA

TCAAACTGGTTGCTGTCCCATCAAAGTCTACTATATTCAGTGTTAA

AAAGAACATGGAGATACATGGGCTTGTCAAGTTATTTAACAAATGG

CAAAATATTGCTTACAAGTATGACAAAGATTTAGTACTCATGACTC

ACTTCATAACAAAGAATATTACAGATAATCATGGGAAGAATAAGAC

TACAGTACATGGTTACTTCTCTTCAATTTTTCATGGTGGAGTGGAT

AGTCTAGTCGACTTGATGAACAAGAGCTTTCGTGAGTTGGGTATTA

AAAAAACTGATTGCAAAGAATTGAGCTGGATTGATACAACCATCTT

CTACAGTGGTGTTGTAAATTACAACACTGCTAATTTTAAAAAGGAA

ATTTTGCTTGATAGATCAGCTGGGAAGAAGACGGCTTTCTCAATTA

AGTTAGACTATGTTAAGAAACCAATTCCAGAAACTGCAATGGTCAA

AATTTTGGAAAAATTATATGAAGAAGATGTAGGAGCTGGGATGTAT

GTGTTGTACCCTTACGGTGGTATAATGGAGGAGATTTCAGAATCAG

CAATTCCATTCCCTCATCGAGCTGGAATAATGTATGAACTTTGGTA

CACTGCTTCCTGGGAGAAGCAAGAAGATAATGAAAAGCATATAAAC

TGGGTTCGAAGTGTTTATAATTTTACGACTCCTTATGTGTCCCAAA

ATCCAAGATTGGCGTATCTCAATTATAGGGACCTTGATTTAGGAAA

AACTAATCATGCGAGTCCTAATAATTACACACAAGCACGTATTTGG

GGTGAAAAGTATTTTGGTAAAAATTTTAACAGGTTAGTTAAGGTGA

AAACTAAAGTTGATCCCAATAATTTTTTTAGAAACGAACAAAGTAT

CCCACCTCTTCCACCGCATCATCATTAA

[0142] Inactive THCA synthase gene (SEQ ID NO:5), SNPs relative to SEQ ID NO:1 shown in bold underline.

ATGAATTGCTCAGCATT**CT**CCTTTTGGTTTGTTTGCAAAATAATATT

TTTCTTTCTCTCATTC**A**ATATCCAAATTTCAATAGCTAATCCTC**A**AG

AAAACTTCCTTAAATGCTTCTC**GG**AA**T**TATTTCC**T**AACAAT**CC**AGCA

AATCCAAAA**T**TC**A**TATACACTCAACACGACCAATTGTATATGTCT**G**T

CCTGAATTCGACAATACAAAATCTTAGATTCA**C**CTCTGATACAACCC

CAAAACCACTCGTTATTGTCACTCCTTCAAAT**GT**CTCCCATATCCA**G**

-continued

GCCAGTATTCTCTGCTCCAAGAAAGTTGGTTTGCAGATTCGAACTCG

AAGCGGTGGCCATGATGCTGAGGGTTTGTCCTACATATCTCAAGTCC

CATTTGCTATAGTAGACTTGAGAAACATGCATACGGTCAAAGTAGAT

ATTCATAGCCAAACTGCGTGGGTTGAAGCCGGAGCTACCCTTGGAGA

AGTTTATTATTGGATCAATGAGATGAATGAGAATTTTAGTTTTCCTG

GTGGGTATTGCCCTACTGTTGGCGTAGGTGGACACTTTAGTGGAGGA

GGCTATGGAGCATTGATGCGAAATTATGGCCTTGCGGCTGATAATAT

CATTGATGCACACTTAGTCAATGTTGATGGAAAAGTTCTAGATCGAA

AATCCATGGGAGAAGATCTATTTTGGGCTATACGTGGTGGAGGAGGA

GAAAACTTTGGAATCATTGCAGCATGGAAAATCAAACTTGTTGTTGT

CCCATCAAAGGCTACTATATTCAGTGTTAAAAAGAACATGGAGATAC

ATGGGCTTGTCAAGTTATTTAACAAATGGCAAAATATTGCTTACAAG

TATGACAAAGATTTAATGCTCACGACTCACTTCAGAACTAGGAATAT

TACAGATAATCATGGGAAGAATAAGACTACAGTACATGGTTACTTCT

CTTCCATTTTTCTTGGTGGAGTGGATAGTCTAGTTGACTTGATGAAC

AAGAGCTTTCCTGAGTTGGGTATTAAAAAAACTGATTGCAAAGAATT

GAGCTGGATTGATACAACCATCTTCTACAGTGGTGTTGTAAATTACA

ACACTGCTAATTTTAAAAAGGAAATTTTGCTTGATAGATCAGCTGGG

AAGAAGACGGCTTTCTCAATTAAGTTAGACTATGTTAAGAAACTAAT

ACCTGAAACTGCAATGGTCAAAATTTTGGAAAAATTATATGAAGAAG

AGGTAGGAGTTGGGATGTATGTGTTGTACCCTTACGGTGGTATAATG

GATGAGATTTCAGAATCAGCAATTCCATTCCCTCATCGAGCTGGAAT

AATGTATGAACTTTGGTACACTGCTACCTGGGAGAAGCAAGAAGATA

ACGAAAAGCATATAAACTGGGTTCGAAGTGTTTATAATTTCACAACT

CCTTATGTGTCCCAAAATCCAAGATTGGCGTATCTCAATTATAGGGA

CCTTGATTTAGGAAAAACTAATCCTGAGAGTCCTAATAATTACACAC

AAGCACGTATTTGGGGTGAAAAGTATTTTGGTAAAAATTTTAACAGG

TTAGTTAAGGTGAAAACCAAAGCTGATCCCAATAATTTTTTTAGAAA

CGAACAAAGTATCCCACCTCTTCCACCGCGTCATCATTAA

[0143] THCA synthase polypeptide sequence (SEQ ID NO:6)

MNCSAFSFWFVCKIIFFFLSHITQISIANPRENFLKCFSKHIPNNVA

NPKLVYTQHDQLYMSILNSTIQNLRFISDTTPKPLVIVTPSNNSHIQ

ATILCSKKVGLQIRTRSGGHDAEGMSYISQVPFVVVDLRNMHSIKID

VHSQTAWVEAGATLGEVYYYVINEKNENLSFPGGYCPTVGVGGHFSG

GGYGALMRNYGLAADNIIDAHLVNVDGKVLDRKSMGEDLFWAIRGGG

GENFGIIAAWKIKLVDVPSKSTIFSVKKNMEIHGLVKLFNKWQNIAY

KYDKDLVLMTHFITKNITDNHGKNKTTVHGYFSSIFHGGVDSLVDLM

-continued

NKSFPELGIKKTDCKEFSWIDTTIFYSGVVNFNTANFKKEILLDRSA

GKKTAFSIKLDYVKKPIPETAMVKILEKLYEEDVGAGMYVLYPYGGI

MEEISESAIPFPHRAGIMYELWYTASWEKQEDNEKHINVVVRSVYNF

TTPYVSQNPRLAYLNYRDLDLGKTNHASPNNYTQARIWGEKYFGKNF

NRLVKVKTKVDPNNFFRNEQSIPPLPPHHH

[0144] In some embodiments, the THCA synthase gene may be knocked out using Clustered Randomly Interspersed Short Palindromic Repeats (CRISPR)/Cas mediated gene editing. To knockout the THCA synthase gene using CRISPR/Cas mediated gene editing, one or more guide RNAs are designed that target the THCA synthase gene or a region adjacent there to and proximal to a Protospacer Adjacent Motif (PAM) site. Upon introduction to a *Cannabis* cell, the guide RNAs target a nuclease to induce a double strand break at the designated cut site. The cell will then undergo non-homologous end joining (NHEJ) to repair the cut site. Due to the nature of NHEJ, one or more insertions or deletions (indels) are introduced at the cut site, thereby silencing the target THCA synthase gene. In some embodiments, a homology directed repair (HDR) template oligonucleotide may be used to direct the repair at the cut site to introduce a mutation of interest. The mutation of interest may be an insertion of a stop codon, a frameshift mutation, or a nonsense mutation that disrupts expression of the THCA synthase gene. In some embodiments, the HDR oligonucleotide encodes a sequence comprising one or more of the THCA synthase gene SNPs recited herein. In some embodiments, the guide RNAs direct cleavage of the THCA gene such that all or a portion of the THCA gene is removed.

[0145] In some embodiments, the nuclease is a Cas nuclease. Suitable Cas nucleases are known and described in the art including, but not limited to, a Cas9 nuclease.

[0146] In some embodiments, the guide RNA targeting the THCA gene is selected from SEQ ID NO:7 (TGCAGCATGGAAAATCAAAC, forward gRNA gRF743), SEQ ID NO:8 (CCCTTACGGTGGTATAATGG, forward gRNA gRF1271), SEQ ID NO:9 (TAGCTATTGAAATTTGGATA, reverse gRNA gRR63), SEQ ID NO:10 (TAGAGCATAAAATAGTTGCT, reverse gRNA gRR279), or combinations thereof. As used herein, the guide RNA (gRNA) nomenclature (e.g., gRF743) refers to the template direction of the gRNA, either forward (F) or reverse (R), and nucleotide position at which the 20 base pair (bp) gRNA ends. For example, gRF743 is a forward gRNA that aligns with the THCA synthase gene and ends at nucleotide 743. Other nomenclature schemes and identification methods will be known to a skilled artisan. In some embodiments, the guide RNA sequences are cloned into a vector for introduction to the cell. In some embodiments, the vector also encodes a Cas nuclease (e.g., Cas9 nuclease). In some embodiments, one or more vectors encoding the guide RNA and the Cas nuclease are introduced into the cell in the presence of an HDR oligonucleotide. Cells positive for transformation and the desired CRISPR/Cas mediated editing results may be screened and selected for using standard molecular biology and sequencing techniques known in the art.

[0147] In some embodiments, the heterologous nucleic acid of interest modulates the expression or function of the endogenous *Cannabis* cannabidiolic-acid synthase (CBDA synthase) gene. A heterologous nucleic acid is introduced

into the *Cannabis* explant to knockout or silence the CBDA synthase gene. *Cannabis* plants grown from the transformed *Cannabis* explant are characterized by a tetrahydrocannabinol (THC) low or THC free phenotype. The sequence and activity of the CBDA synthase gene is known and described in the art. See, for example, Laverty et al. (Laverty et al., "A physical and genetic map of *Cannabis sativa* identifies extensive rearrangements at the THC/CBD acid synthase loci," Genome Research, 2018, 29:146-156).

[0148] Provided below are four cDNA or reverse complement sequences (SEQ ID NOs:11, 13, 15, and 17) of CBDA genes from various *Cannabis sativa* strains. Single nucleotide polymorphs (SNPs) between the active CBDA synthase of SEQ ID NO:11 and each of SEQ ID NOs:13 and 15 are indicated in each of the respective sequences and a full sequence alignment is shown in FIG. **65**. Additionally, mutations in the CBDA synthase sequences of SEQ ID NOs:14 and 16 are shown relative to SEQ ID NO:12.

[0149] *Cannabis sativa* cultivar Carmen cannabidiolic acid synthase (CBDA1) gene (SEQ ID NO:11), GenBank: KJ469374.1

atgaagtgctcaacattctccttttggtttgtttgcaagataatatt

tttctttttctcattcaatatccaaacttccattgctaatcctcgag

aaaacttccttaaatgcttctcgcaatatattcccaataatgcaaca

aatctaaaactcgtatacactcaaaacaacccattgtatatgtctgt

cctaaattcgacaatacacaatcttagattcagctctgacacaaccc

caaaaccacttgttatcgtcactccttcacatgtctctcatatccaa

ggcactattctatgctccaagaaagttggcttgcagattcgaactcg

aagtggtggtcatgattctgagggcatgtcctacatatctcaagtcc

catttgttatagtagacttgagaaacatgcgttcaatcaaaatagat

gttcatagccaaactgcatgggttgaagccggagctacccttggaga

agtttattattgggttaatgagaaaaatgagagtcttagtttggctg

ctgggtattgccctactgtttgcgcaggtggacactttggtggagga

ggctatggaccattgatgagaagctatggcctcgcggctgataatat

cattgatgcacacttagtcaacgttcatggaaaagtgctagatcgaa

aatctatgggggaagatctcttttgggctttacgtggtggtggagca

gaaagcttcggaatcattgtagcatggaaaattagactggttgctgt

cccaaagtctactatgtttagtgttaaaaagatcatggagatacatg

agcttgtcaagttagttaacaaatggcaaaatattgcttacaagtat

gacaaagatttattactcatgactcacttcataactaggaacattac

agataatcaagggaagaataagacagcaatacacacttacttctctt

cagttttccttggtggagtggatagtctagtcgacttgatgaacaag

agttttcctgagttgggtattaaaaaaacggattgcagacaattgag

ctggattgatactatcatcttctatagtggtgttgtaaattacgaca

ctgataatttttaacaaggaaatttttgcttgatagatccgctgggcag

aacggtgctttcaagattaagttagactacgttaagaaaccaattcc

-continued

agaatctgtatttgtccaaattttggaaaaattatatgaagaagata

taggagctgggatgtatgcgttgtacccttacggtggtataatggat

gagatttctgaatcagcaattccattccctcatcgagctggaatctt

gtatgagttatggtacatatgtagctgggagaagcaagaagataacg

aaaagcatctaaactggattagaaatatttataacttcatgactcct

tatgtgtcccaaaatccaagattggcatatctcaattatagagacct

tgatataggaataaatgatcccaagaatccaaataattacacacaag

cacgtatttggggtgagaagtattttggtaaaaattttgacaggcta

gtaaaagtgaaaaccctggttgatcccaataatttttttagaaacga

acaaagcatcccacctcttccacggcatcgtcattaa

[0150] *Cannabis sativa* CBDA synthase (SEQ ID NO:12)

MKCSTFSFWFVCKIIFFFFSFNIQTSIANPRENFLKCFSQYIPNNAT

NLKLVYTQNNPLYMSVLNSTIHNLRFSSDTTPKPLVIVTPSHVSHIQ

GTILCSKKVGLQIRTRSGGHDSEGMSYISQVPFVIVDLRNMRSIKID

VHSQTAWVEAGATLGEVYYWVNEKNESLSLAAGYCPTVCAGGHFGGG

GYGPLMRSYGLAADNIIDAHLVNVHGKVLDRKSMGEDLFWALRGGGA

ESFGIIVAWKIRLVAVPKSTMFSVKKIMEIHELVKLVNKWQNIAYKY

DKDLLLMTHFITRNITDNQGKNKTAIHTYFSSVFLGGVDSLVDLMNK

SFPELGIKKTDCRQLSWIDTIIFYSGVVNYDTDNFNKEILLDRSAGQ

NGAFKIKLDYVKKPIPESVFVQILEKLYEEDIGAGMYALYPYGGIMD

EISESAIPFPHRAGILYELWYICSWEKQEDNEKHLNVVIRNIYNFMT

PYVSQNPRLAYLNYRDLDIGINDPKNPNNYTQARIWGEKYFGKNFDR

LVKVKTLVDPNNFFRNEQSIPPLPREIRH

[0151] *Cannabis sativa* cannabidiolic acid synthase (LOC115697762) (SEQ ID NO:13), GenBank: XM_030624886.1, SNPs relative to SEQ ID NO:11 shown in bold underline.

ATGAAGTGCTCAACATTCTCCTTTTGGTTTGTTTGCAAGATAATATT

TTTCTTTTTCTCATTCAATATCCAAACTTCCATTGCTAATCCTCGAG

AAAACTTCCTTAAATGCTTCTCGCAATATATTCCCAATAATGCAACA

AATCTAAAACTCGTATACACTCAAAACAACCCATTGTATATGTCTGT

CCTAAATTCGACAATACACAATCTTAGATTCA**C**CTCTGACACAACCC

CAAAACCACTTGTTATCGTCACTCCTTCACATGTCTCTCATATCCAA

GGCACTATTCTATGCTCCAAGAAAGTTGGCTTGCAGATTCGAACTCG

AAGTGGTGGTCATGATTCTGAGGGCATGTCCTACATATCTCAAGTCC

CATTTGTTATAGTAGACTTGAGAAACATGCGTTCAATCAAAATAGAT

GTTCATAGCCAAACTGCATGGGTTGAAGCCGGAGCTACCCTTGGAGA

AGTTTATTATTGGGTTAATGAGAAAAATGAGA**A**TCTTAGTTTGGC**G**G

CTGGGTATTGCCCTACTGTTTGCGCAGGTGGACACTTTGGTGGAGGA

-continued

GGCTATGGACCATTGATGAGAA**A**CTATGGCCTCGCGGCTGATAATAT

CATTGATGCACACTTAGTCAACGTTCATGGAAAAGTGCTAGATCGAA

AATCTATGGGGGAAGATCTCTTTTGGGCTTTACGTGGTGGTGGAGCA

GAAAGCTTCGGAATCATTGTAGCATGGAAAATTAGACTGGTTGCTGT

CCCAAAGTCTACTATGTTTAGTGTTAAAAAGATCATGGAGATACATG

AGCTTGTCAAGTTAGTTAACAAATGGCAAAATATTGCTTACAAGTAT

GACAAAGATTTATTACTCATGACTCACTTCATAACTAGGAACATTAC

AGATAATCAAGGGAAGAATAAGACAGCAATACACACTTACTTCTCTT

CAGTTTTCCTTGGTGGAGTGGATAGTCTAGTCGACTTGATGAACAAG

AGTTTTCCTGAGTTGGGTATTAAAAAAACGGATTGCAGACAATTGAG

CTGGATTGATACTATCATCTTCTATAGTGGTGTTGTAAATTACGACA

CTGATAATTTTAACAAGGAAATTTTGCTTGATAGATCCGCTGGGCAG

AACGGTGCTTTCAAGATTAAGTTAGACTACGTTAAGAAACCAATTCC

AGAATCTGTATTTGTCCAAATTTTGGAAAAATTATATGAAGAAGATA

TAGGAGCTGGGATGTATGCGTTGTACCCTTACGGTGGTATAATGGAT

GAGATTTC**A**GAATCAGCAATTCCATTCCCTCATCGAGCTGGAATCTT

GTATGAGTTATGGTACATATGTAG**T**TGGGAGAAGCAAGAAGATAACG

AAAAGCATCTAAACTGGATTAGAAATATTTATAACTTCATGACTCCT

TATGTGTCC**A**AAAATCCAAGATTGGCATATCTCAATTATAGAGACCT

TGATATAGGAATAAATGATCCCAAGAATCCAAATAATTACACACAAG

CACGTATTTGGGGTGAGAAGTATTTTGGTAAAAATTTTGACAGGCTA

GTAAAAGTGAAAACCCTGGTTGATCCCAATAA**C**TTTTTTAGAAACGA

ACAAAGCATCCCACCTCTTCCACGGCATC**G**TCATTAA

[0152] CBDA synthase protein sequence corresponding to SEQ ID NO:13 (SEQ ID NO:14), mutations relative to SEQ ID NO:12 shown in bold underline.

MKCSTFSFWFVCKIIFFFFSFNIQTSIANPRENFLKCFSQYIPNNATN

LKLVYTQNNPLYMSVLNSTIHNLRFTSDT**T**PKPLVIVTPSHVSHIQGT

ILCSKKVGLQIRTRSGGEIDSEGMSYISQVPFVIVDLRNMRSIKIDVH

SQTAWVEAGATLGEVYYVVVNEKNE**N**LSLAAGYCPTVCAGGEIFGGGG

YGPLMR**N**YGLAADNIIDAHLVNVHGKVLDRKSMGEDLFWALRGGGAES

FGIIVAWKIRLVAVPKSTMFSVKKIMEIHELVKLVNKWQNIAYKYDKD

LLLMTHFITRNITDNQGKNKTAIHTYFSSVFLGGVDSLVDLMNKSFPE

LGIKKTDCRQLSWIDTIIFYSGVVNYDTDNFNKEILLDRSAGQNGAFK

IKLDYVKKPIPESVFVQILEKLYEEDIGAGMYALYPYGGIMDEISESA

IPFPHRAGILYELWYICSWEKQEDNEKHLNVVIRNIYNFMTPYVS**K**NP

RLAYLNYRDLDIGINDPKNPNNYTQARIWGEKYFGKNFDRLVKVKTLV

DPNNFFRNEQSIPPLPREIRH

[0153] *Cannabis sativa* Finola CBDA synthase gene reverse complement (SEQ ID NO:15), SNPs relative to both SEQ ID NOs:11 and 13 shown in bold underline, SNPs relative to SEQ ID NO:13 shown in bold italics.

ATGAAGT**A**CTCAACATTCTCCTTTTGGTTTGTTTGCAAGATAATATT

TTTCTTTTTCTCATTCAATATCCAAACTTCCATTGCTAATCCTCGAG

AAAACTTCCTTAAATGCTTCTCGCAATATATTCCCAATAATGCAACA

AATCTAAAACTCGTATACACTCAAAACAACCCATTGTATATGTCTGT

CCTAAATTCGACAATACACAATCTTAGATTCA***G***CTCTGACACAACC

CCAAAACCACTTGTTATCGTCACTCCTTCACATGTCTCTCATATCCA

AGGCACTATTCTATGCTCCAAGAAAGTTGGCTTGCAGATTCGAACTC

GAAGNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN

NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN

NNNNNNNNNNNNNNNNNNNTGGGTTGAAGCCGGAGCTACCCTTGGAG

AAGTTTATTATTGGGTTAATGAGAAAAATGAGA***G***TCTTAGTTTGGC***T***

GCTGGGTATTGCCCTACTGTTTGCGCAGGTGGACACTTTGGTGGAGG

AGGCTATGGACCATTGATGAGA***G***CTATGGCCTCGCGGCTGATAATA

TCATTGATGCACACTTAGTCAACGTTCATGGAAAAGTGCTAGATCGAA

AATCTATGGGGGAAGATCTCTTTTGGGCTTTACGTGGTGGTGGAGCAG

AAAGCTTCGGAATCATTGTAGCATGGAAAATTAGACTGGTTGCTGTCC

CAAAGTCTACTATGTTTAGTGTTAAAAAGATCATGGAGATACATGAGC

TTGTCAAGTTAGTTAACAAATGGCAAAATATTGCTTACAAGTATGACA

AAGATTTATTACTCATGACTCACTTCATAACTAGGAACATTACAGATA

ATCAAGGGAAGAATAAGACAGCAATACACACTTACTTCTCTTCAGTTT

TCCTTGGTGGAGTGGATAGTCTAGTCGACTTGATGAACAAGAGTTTTC

CTGAGTTGGGTATTAAAAAAACGGATTGCAGACAATTGAGCTGGATTG

ATACTATCATCTTCTATAGTGGTGTTGTAAATTACGACACTGATAATT

TTAACAAGGAAATTTTGCTTGATAGATCCGCTGGGCAGAACGGTGCTT

TCAAGATTAAGTTAGACTACGTTAAGAAACCAATTCCAGAATCTGTAT

TTGTCCAAATTTTGGAAAAATTATATGAAGAAGATATAGGAGCTGGGA

TGTATGCGTTGTACCCTTACGGTGGTATAATGGATGAGATTTC***T***

GAATCAGCAATTCCATTCCCTCATCGAGCTGGAATCTTGTATGAGTTA

TGGTACATATGTAGCTGGGAGAAGCAAGAAGATAACGAAAAGCATCTA

AACTGGATTAGAAATATTTATAACTTCATGACTCCTTATGTGTCCCAA

AATCCAAGATTGGCATATCTCAATTATAGAGACCTTGATATAGGAATA

AATGATCCCAAGAATCCAAATAATTACACACAAGCACGTATTTGGGGT

GAGAAGTATTTTGGTAAAAATTTTGACAGGCTAGTAAAAGTGAAAACC

CTGGTTGATCCCAATAA***T***TTTTTTAGAAACGAACAAAGCATCCCACCT

CTTCCACGGCATC**A**TCATTAA

[0154] CBDA synthase protein sequence corresponding to SEQ ID NO:15 (SEQ ID NO:16), mutations relative to both SEQ ID NOs:12 and 14 shown in bold underline, mutations relative to SEQ ID NO:14 shown in bold italics.

MKYSTFSFWFVCKIIFFFFSFNIQTSIANPRENFLKCFSQYIPNNATN

LKLVYTQNNPLYMSVLNSTIHNLRFSSDTTPKPLVIVTPSHVSHIQGT

ILCSKKVGLQIRTRXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX

XXXWVEAGATLGEVYYVVVNEKNESLSLAAGYCPTVCAGGHFGGGGY

GPLMRSYGLAADNIIDAHLVNVHGKVLDRKSMGEDLFWALRGGGAESF

GIIVAWKIRLVAVPKSTMFSVKKIMEIHELVKLVNKWQNIAYKYDKDL

LLMTHFITRNITDNQGKNKTAIHTYFSSVFLGGVDSLVDLMNKSFPEL

GIKKTDCRQLSWIDTIIFYSGVVNYDTDNFNKEILLDRSAGQNGAFKI

KLDYVKKPIPESVFVQILEKLYEEDIGAGMYALYPYGGIMDEISESAI

PFPHRAGILYELWYICSWEKQEDNEKHLNVVIRNIYNFMTPYVSQNPR

LAYLNYRDLDIGINDPKNPNNYTQARIWGEKYFGKNFDRLVKVKTLVD

PNNFFRNEQSIPPLPRHHH

[0155] Inactive CBDA synthase (SEQ ID NO:17)

ATGAAGTGCTCAACATTCCCCTTTTGGTTTGTTTGCAAGATAATATTT

TTCTTTCTCTCATTCAATATCCAAACTTCAATTGCTAATCCTCGAGAA

AACTTCCTTAAATGCTTCTCGCAATATATTCCCACCAATGTAACAAAT

CTAAAACTTACACCCAAAACAACCAATTGTATATGCCTGTCCAAAATT

CAACAATACACAATCTTAGATTCACCTCTAACACAACCCCAAAACTAC

TTGTTATCGTCACTCCTTCATATGTCTCTCATATCCAAGGCACTATTC

TATGTCCAAGAAAATTGGTTTGCAAATTCGAACTCGAAGCGGTGGTCA

TGATTCTGAAGACATGTCCTACATATCTCAAGTCCCATTTGTTATAGT

AGACTTGAGAAACATGCATTCAATCAACATAGATGTTCATAGCCAAAT

CGCAAGGGTTGAAGCCGGAGCTACCCTTGGAGAAGTTTATTATTGGGT

TAATGAGAAAAATGAGAATCTTAGTTTGGCTGCTGGGTATTGCCCTAC

TGTTAGCGCAGCTGGACACTTTGGTGGAGGAGGATATGGACCATTGAT

GCAAAATTATGGCCTCGCGGCTGATAATATCGTTGATGCACACTTAGT

CAACGTTGATGCAAAAGTGCTAGATCGAAAATCTATGGGGGAAGATCT

CTTTTGGGCTATACGTGGTGGTGGAGGAGAAAGCTTCGGAATCATTGT

AGCATGGAAAATTAGACTGGTTGCTGTCCCAACAAAGTCTACTATGTT

TAGTGTTAAAAAGATCATGGAGATACATGAGCTTGTCAAGTGAGTTAA

CAAATGGCAAAATATTGCTTACAAGTATGACAAAGATTTATTACTCAT

GACTCACTTCATAACTAGGAATATTACAAATAATCATGGGAAGAATAA

GACAACAATACACACTTACTTCTCTTCAGTTTTCCTTGGTGGAGTGGA

TAGTCTAGTCGACTTGATGAATAAGAGTTTTCCTGAGTTGGGTATTAA

AAAAACAGATTGCAAACAATTGAGCTAGATTGATATTATCATCTTTTA

TAGCGGTGTTGTAAATTACGGCACTGATAATTTTAATAAGGAAATTTT

GCTTGATAGATCAGCTGGGCAGAACGGTTCTTTAAAGATTAAGTTAGA

CTACGTTAAGAAACCAATTCCAGAATCTGCGTTTGTCAAAATTTTGGA

-continued

AAAATTATATGAAGAAGATGAAGGAGTTGGGATGTATGCGTTGTACCC

TTACGGTGGTATAATGGATGAGATTTCAGAATCAGCAATTCCATTCCC

TCATTGAGCTGGAATCATGTATGAATTATGGTACATATGTAGCTGGGA

GAAGCACGAAGATAACGAAAAAGCATCTAAACTGGATTCGAAATGTTT

ATAGCTTCATTACTCCTTATGTGTCCTAAAATCCAAGATTGGCATATC

TCAATTATAGAGACCTTGATACTGGAATAAATGATCCCAAGAGTCCAA

ATAATTACACACAAGAAAGTATTTGGGGTGAGAAGTATTTTGGTAAAA

ATTTTGACAGGGTAGTAAAAGTGAAAACCCTGGTTGATCCCAATAATT

TTTTTAGAAATGAACAAAGCATCCCACCTCTTCCACGGCATCGTCATT

AA

[0156] In some embodiments, the CBDA synthase gene may be knocked out using CRISPR/Cas mediated gene editing. To knockout the CBDA synthase gene using CRISPR/Cas mediated gene editing, one or more guide RNAs are designed that target the CBDA synthase gene or a region adjacent there to and proximal to a PAM site. Upon introduction to a *Cannabis* cell, the guide RNAs target a nuclease to induce a double strand break at the designated cut site. The cell will then undergo NHEJ to repair the cut site. Due to the nature of NHEJ, one or more indels are introduced at the cut site, thereby silencing the target CBDA synthase gene. In some embodiments, an HDR template oligonucleotide may be used to direct the repair at the cut site to introduce a mutation of interest. The mutation of interest may be an insertion of a stop codon, a frameshift mutation, or a nonsense mutation that disrupts expression of the CBDA synthase gene. In some embodiments, the HDR oligonucleotide encodes a sequence comprising one or more the CBDA synthase gene SNPs recited herein or encodes a mutation in the CBDA synthase polypeptide sequence as demonstrated herein. In some embodiments, the guide RNAs direct cleavage of the CBDA gene such that all or a portion of the CBDA gene is removed. In some embodiments, the nuclease is a Cas nuclease. Suitable Cas nucleases are known and described in the art including, but not limited to, a Cas9 nuclease.

[0157] In some embodiments, the guide RNA targeting the CBDA gene is selected from SEQ ID NO:18 (GCTAGATCGAAAATCTATGG, forward gRNA gRF668), SEQ ID NO:19 (AAAGCATCCCACCTCTTCCA, forward gRNA gRF1621), SEQ ID NO:20 (TTTAGGACAGACATATACAA, reverse gRNA gRR172), SEQ ID NO:21 (GAAAGCACCGTTCTGCCCAG, reverse gRNA gRR1118), or combinations thereof. In some embodiments, the guide RNA sequences are cloned into a vector for introduction to the cell. In some embodiments, the vector also encodes a Cas nuclease (e.g., Cas9 nuclease). In some embodiments, one or more vectors encoding the guide RNA and the Cas nuclease are introduced into the cell in the presence of an HDR oligonucleotide. Cells positive for transformation and the desired CRISPR/Cas mediated editing results may be screened and selected for using standard molecular biology and sequencing techniques known in the art.

[0158] In some embodiments, both the THCA synthase and CBDA synthase genes are knocked out to produce a THC low or THC free *Cannabis* plant. The polypeptide

sequence of the THCA synthase and CBDA synthase enzymes are approximately 84% identical and both contribute to THC production in *Cannabis*. Plants produced by knocking out both the THCA synthase and CBDA synthase genes have significantly increased production of cannabigerolic acid (CBG), which is the substrate for both THCA synthase and CBDA synthase, relative to a *Cannabis* plant with wild-type expression of THCA synthase and CBDA synthase. In some embodiments, both the THCA synthase and the CBDA synthase genes are knocked-out using CRISPR/Cas mediated gene editing as described herein. In some embodiments, guide RNAs targeting both the THCA synthase gene and the CBDA gene simultaneously are designed and used for CRISPR/Cas9 mediated gene editing. In some embodiments, the guide RNAs targeting both THCA synthase and CBDA synthase are selected from SEQ ID NO:22 (CATTTAAGGAAGTTTTCTCG, reverse gRNA gRR88), SEQ ID NO:23 (AAATGGGACTTGAGATATGT, reverse gRNA gRR259), SEQ ID NO:24 (CCCTTGGAGAAGTTTATTAT, forward gRNA gRF481), SEQ ID NO:25 (GTACCCTTACGGTGGTATAA, forward gRNA gRF1265), SEQ ID NO:26 (ATTCCAGCTCGATGAGGGAA, reverse gRNA gRR1291), SEQ ID NO:27 (TACACACAAGCACGTATTTG, forward gRNA gRF1515), and combinations thereof. In some embodiments, the guide RNA sequences are cloned into a vector for introduction to the cell. In some embodiments, the vector also encodes a Cas nuclease (e.g., Cas9 nuclease). In some embodiments, one or more vectors encoding the guide RNA and the Cas nuclease are introduced into the cell in the presence of an HDR oligonucleotide. Cells positive for transformation and the desired CRISPR/Cas mediated editing results may be screened and selected for using standard molecular biology and sequencing techniques known in the art.

[0159] In some embodiments, the heterologous nucleic acid of interest encodes a SOLO DANCERS (SDS) and BARNASE fusion gene. The SDS gene encodes a meiosis-specific cyclin and is required for homology interaction during meiotic prophase I in Arabidopsis. The BARNASE gene encodes a ribonuclease, is driven by a tapetum-specific promoter, and, when activated is toxic to and eliminates tapetal cells to create male sterile plants. Co-expression of SDS and BARNASE from a heterologous nucleic acid will create a male and female sterile plant. See, for example, Huang et al. ("Creating completely both male and female sterile plants by specifically ablating microspore and megaspore mother cells," Frontiers in Plant Science, 2016, 7(30)).

[0160] SDS gene from *Arabidopsis* (SEQ ID NO:60)

```
ATGAAGGAGATCGCGATGAGGAATTCAAAGCGCAAGCCTGAGCCGACG
CCGTTCGCCGGGAAGAAGCTCCGGTCGACGCGATTACGCCGGAAGAGA
GCACAGATCTCTCCCGTTCTTGTTCAATCACCTCTCTGGAGCAAACAA
ATCGGAGTCTCTGCTGCTTCTGTCGATTCCTGCTCCGATTTGCTAGCT
GATGACAACGTTTCCTGTGGTTCGAGCAGAGTCGAGAAGAGCTCGAAT
CCGAAGAAGACTCTAATTGAAGAGGTAGAAGTTTCTAAACCTGGTTAT
AATGTGAAGGAGACGATTGGTGATTCGAAATTTCGAAGGATTACGAGG
TCTTACTCTAAGCTACACAAGGAGAAGGAGGGAGATGAGATCGAAGTA
AGCGAATCGTCTTGTGTTGATTCGAATTCTGGTGCTGGATTAAGGAGA
```

-continued

```
TTGAATGTGAAGGGAAATAAAATTAACGACAACGATGAGATCTCTTTC
TCACGATCCGATGTGACCTTCGCCGGACATGTCTCCAACAGCCGGAGT
TTGAATTTCGAATCGGAGAATAAGGAGAGCGACGTCGTTTCTGTCATA
TCTGGAGTTGAGTACTGTTCCAAGTTCGGGAGCGTTACCGGAGGAGCT
GATAACGAAGAAATTGAAATCTCCAAGCCGAGCAGCTTCGTGGAAGCT
GATTCCTCTCTTGGATCGGCCAAGGAATTGAAGCCGGAGCTTGAGATA
GTCGGATGCGTCTCTGATCTCGCTTGCTCTGAGAAATTCTCGGAAGAG
GTTTCGGATTCTCTCGATGATGAGTCATCTGAGCAACGTTCAGAGATA
TATTCACAGTATTCCGACTTCGATTACTCGGATTACACTCCGTCCATC
TTCTTCGACTCTGGCAGCGAATTCTCTGAGAAATCTTCCTCTGATTCT
CCTATTTCACATTCTCGCTCTCTGTACCTCCAGTTCAAGGAACAGTTC
TGTAGATCCACGATTCCCAACGATTTTGGATCTTCTTGCGAGGAAGAA
ATTCACTCTGAATTGCTAAGGTTTGATGATGAGGAGGTGGAAGAGAGC
TATCTAAGGCTGAGGGAAAGAGAAAGAAGTCATGCATATATGCGGGAC
TGTGCTAAGGCATACTGCTCCAGGATGGACAATACTGGTCTCATCCCT
CGTCTACGCTCCATCATGGTTCAATGGATTGTAAAGCAATGTTCTGAC
ATGGGGCTTCAGCAAGAGACATTGTTTCTAGGAGTTGGTCTGTTGGAT
CGATTCCTGAGCAAAGGATCATTCAAAAGCGAAAGGACTCTAATACTA
GTCGGGATTGCGAGTCTTACTCTGGCCACCAGAATTGAAGAAAATCAA
CCTTACAACAGCATCCGGAAAAGGAACTTCACCATTCAGAACCTAAGA
TATAGCCGGCATGAAGTGGTGGCAATGGAGTGGCTGGTTCAAGAAGTC
CTCAACTTCAAATGCTTCACACCCACAATCTTCAACTTCTTGTGGTTC
TACTTAAAAGCTGCTCGAGCCAATCCAGAAGTTGAAAGGAAAGCCAAA
TCCTTGGCTGTTACCTCACTATCCGACCAAACTCAACTCTGTTTTTGG
CCCTCAACTGTAGCAGCTGCACTCGTGGTTCTCGCCTGCATCGAACAC
AACAAAATCTCTGCATACCAACGAGTCATAAAGGTCCATGTTAGAACA
ACAGATAACGAGTTGCCTGAATGCGTTAAGAGTCTGGACTGGTTGCTT
GGGCAGTAA
```

[0161] BARNASE gene (SEQ ID NO:61)

```
CTGGAAAACGTCACATTGCTTCCGCATATCGGGTCAGCAACGGCTAA
AATCCGCTTGAATATGTTCACACAAGCCGCTCAAAACATGATTGACG
CCGTATACGGAAGAACGCCGAAAAACCTTACTAAGGAATTTCAATAA
GAAGAAAAATCCCGGTTGGTTCAGCCGGGGTTTATTTTTCGCTAGAT
AAAAAGTACTATTTTTAAATTCTTTCTATTCCTTTCTTTCGTTGCTG
ATACAATGAAAAGGAATCAGCTTCACATGATGAAAATGGGAGGTATT
GCTTTGAAAAAACGATTATCGTGGATTTCCGTTTGTTTACTGGTGCT
TGTCTCCGCGGCGGGGATGCTGTTTTCAACAGCTGCCAAAACGGAAA
CATCTTCTCACAAGGCACACACAGAAGCACAGGTTATCAACACGTTT
```

-continued

GACGGGGTTGCGGATTATCTTCAGACATATCATAAGCTACCTGATAA

TTACATTACAAAATCAGAAGCACAAGCCCTCGGCTGGGTGGCATCAA

AAGGGAACCTTGCAGACGTCGCTCCGGGGAAAAGCATCGGCGGAGAC

ATCTTCTCAAACAGGGAAGGCAAACTCCCGGGCAAAAGCGGACGAAC

ATGGCGTGAAGCGGATATTAACTATACATCAGGCTTCAGAAATTCAG

ACCGGATTCTTTACTCAAGCGACTGGCTGATTTACAAAACAACGGAC

CATTATCAGACCTTTACAAAAATCAGATAACGAAAAAAACGGCTTCC

CTGCGGAGGCCGTTTTTTTCAGCTTTACATAAAGTGTGTAATAAATT

TTTCTTCAAACTCTGATCGGTCAATTTCACTTT

[0162] In some embodiments, provided herein is a *Cannabis* plant with increased trichomes that has increased expression of endogenous Cannabis lipid transfer protein 2 (LTP2) or includes a heterologous nucleic acid encoding *Brassica napus* LTP2 (BraLTP2). In some embodiments, a *Cannabis* cell is transformed with a heterologous polynucleotide encoding a polypeptide at least 80%, 85%, 90%, 95%, 98%, 99%, or 99.9% identical to SEQ ID NO:28. In some embodiments, a *Cannabis* cell is transformed with a heterologous polynucleotide encoding the polypeptide of SEQ ID NO:28. In some embodiments, the heterologous polynucleotide is at least 80%, 85%, 90%, 95%, 98%, 99%, or 99.9% identical to SEQ ID NO:29. The heterologous nucleic acid encoding BraLTP2 may be incorporated into a construct or vector as described herein. One embodiment for cloning BraLTP2 into a vector suitable for transformation using the methods described herein is demonstrated in FIG. **66**. Trichomes in the transformed *Cannabis* plant may be at least 2 fold, 5 fold, 10 fold, or 15 fold higher than trichomes in a *Cannabis* plant that does not include the heterologous polynucleotide. In some embodiments, the modulation of the LTP2 gene in other plants, such as *Brassica napus* is described in the art. See, for example, Tian et al. (Tian et al., "Overexpression of BraLTP2, a lipid transfer protein of *Brassica napus*, results in increased trichome density and altered concentration of secondary metabolites," Int. J. Mol. Sci., 2018, 19:1733).

[0163] BraLTP2 protein sequence (SEQ ID NO:28)

MATGSRVLIGLANilLIISGELLVPGQGTCQGDIEGLMRECAVYVQR

PGPKVNPSAACCKVVKRSDIPCACGRITPSVQKMIDMNKVVLVTSFC

GRPLAHGTKCGSYIVP

[0164] BraLTP2 gene sequence GenBank: KM062522.1 (SEQ ID NO:29)

ATGGCGACAGGTTCTCGTGTTCTGATCGGTCTAGCAATGATCCTCAT

AATCTCAGGAGAACTGCTAGTTCCAGGGCAAGGAACGTGCCAAGGAG

ACATAGAGGGTCTGATGAGAGAATGTGCGGTCTACGTCCAGCGTCCA

GGCCCAAAGGTAAACCCATCCGCAGCGTGTTGCAAAGTCGTCAAGAG

ATCAGACATCCCCTGCGCATGTGGCCGTATCACACCCTCGGTTCAAA

-continued

AAATGATAGACATGAATAAGGTTGTTCTTGTCACTTCCTTTTGTGGG

AGGCCTCTCGCTCATGGTACCAAGTGTGGAAGCTACATTGTGCCATG

A

[0165] In some embodiments, the heterologous nucleic acid of interest modulates the expression or function of the endogenous *Cannabis* LTP2 gene. A heterologous nucleic acid is introduced into the *Cannabis* explant to upregulate, overexpress, or provide multiple copies of the LPT2 gene. *Cannabis* plants grown from the transformed *Cannabis* explant are characterized by a phenotype with an increase in trichomes compared to a wild-type plant as well as increased cannabidiol (CBD) production.

[0166] In some embodiments, the heterologous nucleic acid of interest modulates the expression or function of the endogenous *Cannabis sativa* prenyltransferase 1 (CsPT1) gene. A heterologous nucleic acid is introduced into the *Cannabis* explant to upregulate, overexpress, or provide multiple copies of the CsPT1 gene. In some embodiments, a *Cannabis* cell is transformed with a heterologous nucleic acid encoding a polypeptide at least 80%, 85%, 90%, 95%, 98%, 99%, or 99.9% identical to SEQ ID NO:30. In some embodiments, a *Cannabis* cell is transformed with a heterologous nucleic acid encoding the polypeptide SEQ ID NO:30. In some embodiments, a *Cannabis* cell is transformed with a heterologous nucleic acid comprising SEQ ID NO:31 or a sequence at least 80%, 85%, 90%, 95%, 98%, 99%, or 99.9% identical thereto. The heterologous nucleic acid encoding CsPT1 may be incorporated into a construct or vector as described herein. One embodiment for cloning CsPT1 into a vector suitable for transformation using the methods described herein is demonstrated in FIG. **67**. *Cannabis* plants grown from the transformed *Cannabis* explant are characterized by a phenotype with increased cannabigerol (CBG) production and increased cannabidiol (CBD) production. The sequence and activity of the CsPT1 gene is known and described in the art. See, for example, Luo et al. (Luo et al., "Complete biosynthesis of cannabinoids and their unnatural analogues in yeast," Nature, 2019, 567) and U.S. Pat. No. 8,884,100.

[0167] CsPT1 protein sequence (SEQ ID NO:30)

MGLSSVCTFSFQTNYHTLLNPHNNNPKTSLLCYREIPKTPIKYSYNN

FPSKHCSTKSFEILQNKCSESLSIAKNSIRAATTNQIEPPESDNHSV

ATKILNFGKACWKLQRPYTIIAFTSCACGLFGKELLHNTNLISWSLM

FKAFFFLVAVLCIASFTTTINQIYDLHIDRINKPDLPLASGEISVNT

AWIMSIIVALFGLIITIKMKGGPLYIFGYCFGIFGGIVYSVPPFRWK

QNPSTAFLLNFLAIIIITNFTFYYASRAALGLPFELRPSFTFLLAFM

KSMGSALALIKDASDVEGDTKFGISTLASKYGSRNLTLFCSGIVLLS

YVAAILAGIIWPQAFNSNVMLLSHAILAFWLILQTRDFALTNYDPEA

GRRFYEFMVVKLYYAEYLVYVFI

[0168] CsPT1 cDNA sequence (SEQ ID NO:31)

atgggactctcatcagtttgtacctttttcatttcaaactaattaccata

ctttattaaatcctcacaataataatcccaaaacctcattattatgtta

-continued

tcgacaccccaaaacaccaattaaatactcttacaataattttccctct

aaacattgctccaccaagagttttcatctacaaaacaaatgctcagaat

cattatcaatcgcaaaaaattccattagggcagctactacaaatcaaac

tgagcctccagaatctgataatcattcagtagcaactaaaatttaaac

tttgggaaggcatgttggaaacttcaaagaccatatacaatcatagcat

ttacttcatgcgcttgtggattgtttgggaaagagttgttgcataacac

aaatttaataagttggtctctgatgttcaaggcattctttttttggtg

gctgtattatgcattgcttcttttacaactaccatcaatcagatttacg

atcttcacattgacagaataaacaagcctgatctaccactagcttcagg

ggaaatatcagtaaacacagcttggattatgagcataattgtggcactg

tttggattgataataactataaaaatgaagggtggaccactctatatat

ttggctactgttttggtatttttggtgggattgtctattctgttccacc

atttagatggaagcaaaatccttccactgcatttcttctcaatttcctg

gcccatattattacaaatttcacattttattatgccagcagagcagctc

ttggcctaccatttgagttgaggccttatttactttcctgctagcattt

atgaaatcaatgggttcagctttggctttaatcaaagatgcttcagacg

ttgaaggcgacactaaatttggcatatcaaccttggcaagtaaatatgg

ttccagaaacttgacattattttgttctggaattgttctcctatcctat

gtggctgctatacttgctgggattatctggccccaggctttcaacagta

acgtaatgttactttctcatgcaatcttagcattttggttaatcctcca

gactcgagattttgcgttaacaaattacgacccggaagcaggcagaaga

ttttacgagttcatgtggaagctttattatgctgaatatttagtatatg

ttttcatataa

[0169] In some embodiments, the heterologous nucleic acid of interest modulates the expression or function of the endogenous *Cannabis sativa* O-methyltransferase (CsOMT21) gene. A heterologous nucleic acid is introduced into the *Cannabis* explant to upregulate, overexpress, or provide multiple copies of the CsOMT21 gene. In some embodiments, a *Cannabis* cell is transformed with a heterologous nucleic acid encoding a polypeptide at least 80%, 85%, 90%, 95%, 98%, 99%, or 99.9% identical to SEQ ID NO:32. In some embodiments, a *Cannabis* cell is transformed with a heterologous nucleic acid encoding the polypeptide SEQ ID NO:32. In some embodiments, a *Cannabis* cell is transformed with a heterologous nucleic acid comprising SEQ ID NO:33 or a sequence at least 80%, 85%, 90%, 95%, 98%, 99%, or 99.9% identical thereto. The heterologous nucleic acid encoding CsOMT21 may be incorporated into a construct or vector as described herein. One embodiment for cloning CsOMT21 into a vector suitable for transformation using the methods described herein is demonstrated in FIG. **68**. *Cannabis* plants grown from the transformed *Cannabis* explant are characterized by a phenotype with increased chrysoeriol production and increased cannflavin A and cannflavin B production. The sequence and activity of the CsOMT21 gene is known and described in the art. See, for example, Rea et al. Phytochemistry 2019: "Biosynthesis of cannflavins A and B from *Cannabis sativa* L."

[0170] CsOMT21 (PK24150) (SEQ ID NO:32)

MGSTGIETQMTPTQISDEEANLFAMQLASASVLPMVLKAALELDLLEI

TAKAGPGAFLSPSDIAQQLPTQNPDAPVMLDRMLRLLASYNVVTYSLR

ERETAEEEGKVERLYGLAPVSKYLTKNEDGVSIAPLCLMNQDKVLMES

WYEILKDAVLDGGIPFNKAYGMTAFEYHGTDQRFNKIFNRGMSDHSTI

TMKKILETYKGFEGLNSIVDVGGGTGAVVNMIVSKYPTIKGINFDLPH

VIEDAPPLTGVEHVGGDMFVSVPKGDAIFMKWICHDWSDEHCLKFLKN

CHAALPEHGKVIVAECILPVAPDSSLATKSTVHIDVIMLAHNPGGKER

TEKEFEALAKGAGFKGFKVHCNAFNTHIMEFLKTI

[0171] *Cannabis sativa* PK24150.1_1.CasaPuKu, GenBank: JP459899.1 (SEQ ID NO:33)

ATGGGTTCAACAGGAATAGAGACCCAAATGACCCCAACCCAAATATCC

GACGAAGAAGCCAACCTCTTCGCCATGCAATTAGCCAGTGCCTCAGTC

TTACCCATGGTTCTCAAAGCAGCTTTAGAGCTCGACCTCTTGGAGATC

ATAGCCAAGGCCGGTCCAGGCGCGTTTCTCTCACCTTCCGACATAGCT

CAACAGCTTCCGACTCAGAACCCAGACGCCCCGGTGATGCTGGACCGG

ATGCTGAGACTGTTGGCTAGCTACAACGTGGTGACGTACTCGCTGCGT

GAGCGTGAGACGGCGGAAGAGGAAGGGAAGGTGGAGAGGCTTTATGGG

TTGGCTCCGGTGAGTAAATATCTGACGAAGAATGAAGATGGAGTCTCC

ATTGCTCCTCTTTGTCTCATGAACCAGGATAAGGTTCTTATGGAGAGT

TGGTATCACTTAAAAGATGCAGTACTTGATGGAGGAATACCTTTCAAC

AAGGCATATGGAATGACAGCATTTGAATATCATGGAACCGATCAAAGG

TTCAATAAAATCTTTAATAGAGGAATGTCCGACCACTCGACTATTACC

ATGAAAAAAATCCTCGAAACTTACAAGGGTTTCGAGGGTCTTAACTCG

ATTGTTGATGTTGGTGGTGGTACTGGAGCTGTTGTTAACATGATCGTC

TCTAAGTACCCTACTATTAAGGGTATTAACTTCGATTTGCCTCATGTC

ATCGAAGATGCACCTCCATTGACCGGTGTAGAGCATGTTGGAGGAGAC

ATGTTTGTAAGTGTACCAAAAGGAGATGCAATTTTCATGAAGTGGATT

TGCCATGATTGGAGCGATGAACACTGCTTGAAATTCTTGAAGAACTGC

CACGCTGCACTGCCCGAACACGGAAAAGTGATCGTGGCGGAGTGCATT

CTTCCGGTGGCACCGGACTCGAGCCTTGCCACAAAGAGTACGGTCCAC

ATTGATGTGATCATGTTGGCCCATAACCCTGGTGGCAAAGAGAGAACA

GAGAAAGAGTTTGAGGCATTGGCTAAGGGAGCTGGCTTTAAAGGCTTC

AAAGTCCATTGCAATGCTTTCAATACCCATATCATGGAATTTCTCAAG

ACCATTTAA

[0172] In some embodiments, the heterologous nucleic acid of interest modulates the expression or function of the endogenous *Cannabis sativa* prenyltransferace 3 (CsPT3) gene. A heterologous nucleic acid is introduced into the

Cannabis explant to upregulate, overexpress, or provide multiple copies of the CsPT3 gene. In some embodiments, a *Cannabis* cell is transformed with a heterologous nucleic acid encoding a polypeptide at least 80%, 85%, 90%, 95%, 98%, 99%, or 99.9% identical to SEQ ID NO:34. In some embodiments, a *Cannabis* cell is transformed with a heterologous nucleic acid encoding the polypeptide SEQ ID NO:34. In some embodiments, a *Cannabis* cell is transformed with a heterologous nucleic acid comprising SEQ ID NO:35 or a sequence at least 80%, 85%, 90%, 95%, 98%, 99%, or 99.9% identical thereto. The heterologous nucleic acid encoding CsPT3 may be incorporated into a construct or vector as described herein. One embodiment for cloning CsPT3 into a vector suitable for transformation using the methods described herein is demonstrated in FIG. **69**. *Cannabis* plants grown from the transformed *Cannabis* explant are characterized by a phenotype with increased cannabigerol (CBG) production and increased cannabidiol (CBD) production.

[0173] CsPT3 (PK17697) (SEQ ID NO:34)

MVFSSVCSFPSSLGTNFKLVPRSNFKASSSHYHEINNFINNKPIKFSY

FSSRLYCSAKPIVHRENKFTKSFSLSEILQRKSSIKAHGEIEADGSNG

TSEFNVMKSGNAIWRFVRPYAAKGVLFNSAAMFAKELVGNLNLFSWPL

MFKILSFTLVILCIFVSTSGINQIYDLDIDRLNKPNLPVASGEISVEL

AWLLTIVCTISGLTLTIITNSGPFFPFLYSASIFFGFLYSAPPFRWKK

NPFTACFCNVMLYVGTSVGVYYACKASLGLPANWSPAFCLLFWFISLL

SIPISIAKDLSDIEGDRKFGIITFSTKFGAKPIAYICHGLMLLNYVSV

MAAAIIWPQFFNSSVILLSHAFMAIWVLYQAWILEKSNYATETCQKYY

IFLWIIFSLEHAFYLFM

[0174] *Cannabis sativa* PK17697.1_1.CasaPuKu, GenBank: JP460361.1, (SEQ ID NO:35)

atggtgttctcatcagtttgtagttttccatcctcccttggaactaat

tttaaattagttcctcgtagtaattttaaggcatcatcttctcattat

catgaaataaataattttattaataataaaccaattaaattctcatat

ttttcttcaagactatattgctctgccaaaccaattgtacacagagaa

aacaaattcacaaaatcattttcactcagccacctccaaaggaaaagc

tccataaaggcacatggtgaaattgaagctgatgggagtaatggcaca

tctgaatttaatgtaatgaaaagtggaaacgcaatttggagatttgta

aggccatatgcagccaagggagtattgtttaactctgctgctatgttt

gcaaaagagttggtggggaacctaaatctatttagttggcattgatgt

ttaagatactctcttttacattggttatttttatgcatttttgtaagta

caagtggcatcaatcaaatttatgatctcgacatcgacaggttaaaca

aacctaatttgccagtagcatcaggagaaatttcagttgaattggcat

ggttgttgactatagtttgtacaataagtggcctcacattaacaatta

taacgaactcagggccattcttccctttttctctactctgctagtatct

tttttggctttctctattctgctcctccattcagatggaagaagaatc

-continued

ctttttacagcatgtttctgtaatgttatgttgtatgttggcacaagcg

ttggtgtctattatgcttgtaaggctagtctcgggcttccagccaact

ggagccctgctttttgtttgctcttttggtttatttcattgttgagta

tacccatctccattgcaaaagatctttcagacatagaaggtgaccgca

agtttggaatcataaccttctcaactaaatttggagcaaaacccatag

catatatttgtcatggactcatgcttctgaattacgtgagtgttatgg

ctgcagctattatttggccacagtttttcaacagtagcgtaatattgc

tttctcatgcattcatggcaatttgggtattatatcaggcttggatat

tggagaaatcaaattacgccacggagacgtgccaaaaatactatatat

tcctttggataatttttttctcttgaacatgccttctatttgttcatgt

ag

[0175] In some embodiments, the heterologous nucleic acid of interest produces a glyphosate resistant Cannabis plant following transformation. To create a glyphosate resistant Cannabis plant, a Cannabis cell is transformed as described herein with a heterologous nucleic suitable for mutating the *Cannabis sativa* gene encoding 3-phosphoshikimate 1-carboxyvinyltransferase 2 (EPSP synthase) such that when expressed, the EPSP synthase enzyme is not inhibited by the herbicide glyphosate. Without wishing to be bound by any particular theory or embodiment, glyphosate is a competitive inhibitor of phosphoenolpyruvate (PEP) in EPSP, acting as a transition state analog that binds more tightly to the EPSPS-S3P (shikimate-3-phosphate bound EPSP synthase) complex than PEP. Upon exposure to glyphosate, the EPSP synthase enzyme is non-functional or severely inhibited resulting in plant death. However, it is possible to mutate the EPSP synthase enzyme such at it does not bind glyphosate but still catalyzes the synthesis of 5-enol-pyruvylshikimate-3-phosphate.

[0176] In some embodiments, the *Cannabis sativa* gene encoding EPSP synthase is mutated using prime editing guide RNA (pegRNA) together with a Cas9 nuclease and reverse transcriptase fusion protein. In some embodiments, the Cas9 nuclease is a mutated Cas9 nuclease that only cleaves a single strand of the target DNA. In some embodiments, the mutated Cas9 nuclease is a Cas9 H840A nickase or a Cas9 D10A nickase (Cas9n). pegRNA are designed with the desired genetic mutation and to target the *Cannabis sativa* EPSPS gene loci of interest. A nucleic acid encoding the pegRNA and the Cas9 nuclease/reverse transcriptase fusion protein is introduced into a *Cannabis sativa* cell. Cells positive for transformation and the desired prime editing mutations may be screened and selected for using standard molecular biology and sequencing techniques known in the art.

[0177] In some embodiments, the Cannabis EPSPS gene (SEQ ID NO:40) is mutated at positions 1790, 1801, 3620, and 3621 to encode an EPSP synthase that is glyphosate resistant and includes T181I, P185S, and P460L mutations relative to the wild-type sequence. In some embodiments, the pegRNA for the mutations at positions 1790 and 1801 comprises the gRNA sequences tgaagactt tgcaCAACTTTTCCTTGGAAATGCgtttaagtcttct (forward, SEQ ID NO:41) and AGAAGACTT AAACGCATTTCCAAGGAAAAGTTG

TGCAAAGTCTTCA (reverse, SEQ ID NO:42) and the sequence ACCTGCTATA GTGCTGAGTGAACGCATTGCTATTCCAGCATTTCCA AGGAAACATAT AGCAGGT (SEQ ID NO:43) encoding the two C→T mutations at positions 1790 and 1801. See, FIG. **70**. In some embodiments, the pegRNA for the mutations at positions 3620 and 3621 comprises the gRNA sequences tgaagactttgccaCTTGGAGCAACAGTTGAGGA gtttaagtcttct (forward, SEQ ID NO: 44) and AGAAGACTT AAACTCCTCAACTGTTGCTCCAAG TGCAAAGTCTTCA (reverse, SEQ ID NO:45) and the sequence ACCTGCTATA GTGCCACGCAGTAATCAAGTCCTTCCTCAACTGTTG AACATATAGCA GGT (SEQ ID NO:46) encoding the two C→T mutations at positions 3620 and 3621. See, FIG. **71**.

[0178] Cannabis EPSP synthase (SEQ ID NO:36)

MAQVSKICSNGAQTILTLPNISKSHTPRSLNSVSLRSPFLGSSNSLSL

KIGTEFGGCSTVGKAMAGPVMASAVTAEKPSKVPEIVLQPIKDISGTV

KLPGSKSLSNRILLLAALSEGTTVVDNLLDSDDIHYMLGALETLGLRV

EADKESKRAIVEGCAGQFPAGKESVDEVQLFLGNAGTAMRPLTAAVTV

AGGNASYVLDGVPRMRERPIGDLVTGLKQLGADVDCFHGTDCPPVRVL

GKGGLPGGKVKLSGSISSQYLTALLMAAPLALGDVEIEIIDKLISVPY

VDMTLKLMARFGVTVEHSDSWDRFLVKGGQKYKSPGNAYVEGDASSAS

YFLAGAAVTGGTVTVEGCGTSSLQGDVKFAEVLEKMGAKVSWTENSVT

VTGPPRDSVKSKHLKAIDVNMNKMPDVAMTLAVVALFADGPTAIRDVA

SWRVKETERMIAICIELRKLGATVEEGPDYCVITPPEKLNITAIDTYD

DEIRMAMAFSLAACSDVPVTIKDPGCTRKTFPDYFEVLERFTKH

[0179] Glyphosate resistant Cannabis EPSP synthase (SEQ ID NO:37), mutations relative to SEQ ID NO:36 shown in bold underline including T181I, P185S, P460L

MAQVSKICSNGAQTILTLPNISKSHTPRSLNSVSLRSPFLGSSNSLSL

KIGTEFGGCSTVGKAMAGPVMASAVTAEKPSKVPEIVLQPIKDISGTV

KLPGSKSLSNRILLLAALSEGTTVVDNLLDSDDIHYMLGALETLGLRV

EADKESKRAIVEGCAGQFPAGKESVDEVQLFLGNAG**I**AMRSLTAAVTV

AGGNASYVLDGVPRMRERPIGDLVTGLKQLGADVDCFHGTDCPPVRVL

GKGGLPGGKVKLSGSISSQYLTALLMAAPLALGDVEIEIIDKLISVPY

VDMTLKLMARFGVTVEHSDSWDRFLVKGGQKYKSPGNAYVEGDASSAS

YFLAGAAVTGGTVTVEGCGTSSLQGDVKFAEVLEKMGAKVSWIENSVT

VTGPPRDSVKSKHLKAIDVNMNKMPDVAMTLAVVALFADGPTAIRDVA

SWRVKETERMIAICTELRKLGATVEEG**L**DYCVITPPEKLNITAIDTYD

DEIRMAMAFSLAACSDVPVTIKDPGCTRKTFPDYFEVLERFTKH

[0180] Cannabis EPSP synthase cDNA (SEQ ID NO:38)

ATGGCCCAAGTGAGCAAAATCTGTAGCAATGGAGCTCAAACTATCCTTA

CTCTCCCAAATATATCTAAGTCTCATACACCAAGATCCCTAAATTCAGT

-continued

TTCGTTGAGATCACCGTTTTTGGGTTCATCTAACTCTTTGAGTTTGAAG

ATTGGAACTGAATTTGGGGGTTGTTCTACGGTTGGTAAAGCTATGGCTG

GTCCAGTCATGGCTTCAGCTGTCACAGCGGAGAAGCCTTCAAAGGTACC

GGAGATTGTGTTGCAGCCCATTAAAGATATCTCTGGCACTGTCAAGTTG

CCGGGTTCCAAGTCACTATCGAATCGGATTCTACTCCTGGCTGCTCTTT

CTGAGGGGACAACTGTTGTGGACAACTTGTTAGATAGTGATGACATTCA

CTACATGCTTGGTGCCTTGGAAACCCTTGGTCTTCGTGTTGAAGCAGAC

AAGGAAAGCAAACGAGCAATTGTGGAAGGTTGTGCGGGTCAGTTTCCTG

CAGGTAAAGAATCTGTTGACGAAGTTCAACTTTTCCTTGGAAATGCTGG

AACAGCAATGCGTCCACTCACAGCTGCGGTGACTGTTGCTGGTGGAAAT

GCTAGCTACGTACTTGATGGTGTTCCTCGAATGAGAGAAAGACCAATTG

GAGATTTGGTGACTGGTCTTAAGCAGCTTGGTGCAGATGTTGATTGTTT

TCATGGTACGGATTGTCCCCCTGTTCGTGTGCTTGGAAAAGGAGGCCTT

CCTGGGGGCAAGGTGAAACTTTCTGGATCAATTAGCAGTCAATATTTGA

CAGCCTTGCTTATGGCAGCTCCCTTGGCTCTTGGAGATGTTGAAATCGA

GATAATTGATAAATTGATCTCGGTTCCCTATGTTGATATGACTTTGAAG

TTGATGGCACGTTTTGGGGTTACTGTTGAACACAGTGATAGCTGGGATC

GATTTTTAGTTAAAGGAGGTCAAAAGTACAAATCTCCTGGAAACGCTTA

TGTTGAAGGTGATGCTTCAAGTGCTAGTTACTTCCTAGCTGGTGCTGCA

GTCACTGGTGGTACAGTCACCGTAGAAGGTTGTGGGACTAGTAGTTTAC

AGGGAGACGTAAAATTTGCTGAAGTTCTTGAGAAAATGGGTGCTAAAGT

TAGCTGGACAGAGAACAGTGTCACGGTCACTGGACCACCACGAGATTCT

GTAAAAAGTAAACACTTGAAAGCCATTGATGTCAACATGAACAAAATGC

CTGATGTTGCCATGACTCTTGCTGTAGTTGCTCTTTTTGCTGATGGCCC

CACTGCTATAAGAGATGTGGCAAGTTGGAGAGTCAAGGAGACAGAGAGA

ATGATTGCCATCTGCACTGAACTCAGAAAGCTTGGAGCAACAGTTGAGG

AAGGACCCGATTACTGCGTGATCACTCCACCAGAGAAACTAAATATCAC

AGCAATAGACACATACGACGACCACAGGATGGCTATGGCGTTCTCTCTT

GCAGCTTGTTCAGATGTGCCAGTTACCATTAAGGATCCTGGTTGCACCC

GAAAAACTTTCCCAGATTACTTTGAAGTCCTTGAGAGATTTACAAAGCA

CTGA

[0181] Glyphosate resistant Cannabis EPSP synthase cDNA (SEQ ID NO:39), mutations relative to SEQ ID NO:38 shown in bold underline, including C542T, C553T, C1379T, and C1380T

ATGGCCCAAGTGAGCAAAATCTGTAGCAATGGAGCTCAAACTATCCTTA

CTCTCCCAAATATATCTAAGTCTCATACACCAAGATCCCTAAATTCAGT

TTCGTTGAGATCACCGTTTTTGGGTTCATCTAACTCTTTGAGTTTGAAG

ATTGGAACTGAATTTGGGGGTTGTTCTACGGTTGGTAAAGCTATGGCTG

-continued

GTCCAGTCATGGCTTCAGCTGTCACAGCGGAGAAGCCTTCAAAGGTACC

GGAGATTGTGTTGCAGCCCATTAAAGATATCTCTGGCACTGTCAAGTTG

CCGGGTTCCAAGTCACTATCGAATCGGATTCTACTCCTGGCTGCTCTTT

CTGAGGGGACAACTGTTGTGGACAACTTGTTAGATAGTGATGACATTCA

CTACATGCTTGGTGCCTTGGAAACCCTTGGTCTTCGTGTTGAAGCAGAC

AAGGAAAGCAAACGAGCAATTGTGGAAGGTTGTGCGGGTCAGTTTCCTG

CAGGTAAAGAATCTGTTGACGAAGTTCAACTTTTCCTTGGAAATGCTGG

AA**T**AGCAATGCGT**T**CACTCACAGCTGCGGTGACTGTTGCTGGTGGAAAT

GCTAGCTACGTACTTGATGGTGTTCCTCGAATGAGAGAAAGACCAATTG

GAGATTTGGTGACTGGTCTTAAGCAGCTTGGTGCAGATGTTGATTGTTT

TCATGGTACGGATTGTCCCCCTGTTCGTGTGCTTGGAAAAGGAGGCCTT

CCTGGGGGCAAGGTGAAACTTTCTGGATCAATTAGCAGTCAATATTTGA

CAGCCTTGCTTATGGCAGCTCCCTTGGCTCTTGGAGATGTTGAAATCGA

GATAATTGATAAATTGATCTCGGTTCCCTATGTTGATATGACTTTGAAG

TTGATGGCACGTTTTGGGGTTACTGTTGAACACAGTGATAGCTGGGATC

GATTTTTAGTTAAAGGAGGTCAAAAGTACAAATCTCCTGGAAACGCTTA

-continued

TGTTGAAGGTGATGCTTCAAGTGCTAGTTACTTCCTAGCTGGTGCTGCA

GTCACTGGTGGTACAGTCACCGTAGAAGGTTGTGGGACTAGTAGTTTAC

AGGGAGACGTAAAATTTGCTGAAGTTCTTGAGAAAATGGGTGCTAAAGT

TAGCTGGACAGAGAACAGTGTCACGGTCACTGGACCACCACGAGATTCT

GTAAAAAGTAAACACTTGAAAGCCATTGATGTCAACATGAACAAAATGC

CTGATGTTGCCATGACTCTTGCTGTAGTTGCTCTTTTTGCTGATGGCCC

CACTGCTATAAGAGATGTGGCAAGTTGGAGAGTCAAGGAGACAGAGAGA

ATGATTGCCATCTGCACTGAACTCAGAAAGCTTGGAGCAACAGTTGAGG

AAGGACTTGA**TT**ACTGCGTGATCACTCCACCAGAGAAACTAAATATCAC

AGCAATAGACACATACGACGACCACAGGATGGCTATGGCGTTCTCTCTT

GCAGCTTGTTCAGATGTGCCAGTTACCATTAAGGATCCTGGTTGCACCC

GAAAAACTTTCCCAGATTACTTTGAAGTCCTTGAGAGATTTACAAAGCA

CTGA

[0182] *Cannabis* EPSP synthase gene, *Cannabis sativa* chromosome 2, cs10, whole genome shotgun sequence, *Cannabis sativa* 3-phosphoshikimate 1-carboxyvinyltransferase 2 (LOC115705599), (SEQ ID NO:40), possible glyphosate resistant mutation target loci indicated in bold underline italics including positions 1790, 1801, 3620, and 3621.

GGTTGGTAAGCCCTCCTACCCTCTTTGAAAATTGAAAGAGAGTCAATGTCGACCTACAGCAG

CAGCATCCATTAACGTTACCATTGCCACCAAAAATCCAACCTTTATTTGTATAGAGAGAATC

AGAGAAGGTTTGGGTTTCAGAGAGAGAGAGAAGAAGAACAAAAAAATGGCCCAAGTGAGCAA

AATCTGTAGCAATGGAGCTCAAACTATCCTTACTCTCCCAAATATATCTAAGTCTCATACA

CCAAGATCCCTAAATTCAGTTTCGTTGAGATCACCGTTTTTGGGTTCATCTAACTCTTTGAG

TTTGAAGATTGGAACTGAATTTGGGGGTTGTTCTACGGTTGGTAAAGCTATGGCTGGTCCAG

TCATGGCTTCAGCTGTCACAGCGGAGAAGCCTTCAAAGGTACCGGAGATTGTGTTGCAGCCC

ATTAAAGATATCTCTGGCACTGTCAAGTTGCCGGGTTCCAAGTCACTATCGAATCGGATTCT

ACTCCTGGCTGCTCTTTCTGAGGTATATTTCATTTTTTTTAAAACGTCAAACATGTATTTTT

GTCGAGGAAGTTTTCTGTATATACAAAGATAAGAGAGTAAAAATATGGAACATCAATACCAA

AATGAACCAAAACTAGGCTAAGCTATCAAATCATGTCATGGTATGCCATACTCTACTTTCCT

ATCTCAAGCTCCACAGCTATAAAATACTATATCGTAATTATTTTGTCAACTGCTTTCATATT

CCTTGTAATTTCCCTCATTCCCACTAAAACTAGTTCCAATGGATTGTGTGGCTGGAAACTGT

AGTTAGTTACATTAGCTAGATCTGAACCATGATCAGCATCGACTGCCCAACTGGTAAACCAT

GTAATTGCATGGAATTCTTCCTTTGTTATCCACAAATTTGAAAAGTATTTTTGAGGTATACA

AAGATTGTGCTTTTTATGAGCAATTTTCTTTTAGTTTTATGTTAAGAGTTTGTAGCGATGGG

ATGTTTTTTTTTCTAGAAAATGGACAGTAAAGCTTAGCATTTTTACTTTATTGGTGTAAATGA

ATAGTGTTCATTGAAGCTGAACTCATGCCCTTAATTGGGAGGAAAATTGAGAGAAATGGAGT

AAAGTAATATGATATTTTGGTTAAATTCGTAAGAATATGATGGAAATAAAAAATGCAACTCA

ACTGGGTTACTGAAGTTATATTTCTGGTCTCAGTTGTGCTTTTACAACTTTAGTCTAGAGCT

CCACGCTGCGGAGAGATTCGGAGTCCTTACAGTTTATTTTGATAATGATTTATGAGAATTTC

-continued

ATAACTCTACGCTTTTGTTACATTATATATGAGGTGTTTCGTTGGTGCATTGTCTCACCTGA

ACTCCCTAAATTTTAGAATGTGGGATTTAGAATGAAGTTATACTATTAGTGTTTGAGTCATC

TAGAATTTGTAGCTGCTCATTCTCCATATACTCTTTCTCTATTTCCTCCCCATATTTTGGCG

CTACTACTTATCTTTACAGTTCATGTTATTTTCATGTACTTGAGTTTTTTGCCCTATAAAAT

ATTTTGAGCGGTGGGAAGTAACTGTTTTTTTTGTTATAATTATCCAGGGGACAACTGTTGTG

GACAACTTGTTAGATAGTGATGACATTCACTACATGCTTGGTGCCTTGGAAACCCTTGGTCT

TCGTGTTGAAGCAGACAAGGAAAGCAAACGAGCAATTGTGGAAGGTTGTGCGGGTCAGTTTC

CTGCAGGTAAAGAATCTGTTGACGAAGTTCAACTTTTCCTTGGAAATGCTGGAA<u>C</u>AGCAATG

CGT<u>C</u>CACTCACAGCTGCGGTGACTGTTGCTGGTGGAAATGCTAGGTTTGTCTTCATTGCAAT

TGCTTTTGAATATAAAGTACTTCTAATGCAGTGAATTTATGCTCTTGTTTTTCTTACTGGCC

GAGTAGCTCTTACATTTTAGGTAAAGAAAGTCACTTTTGCTAACAACATCACCATTTATACT

TCCCTCTTTACTTTGATGTGGTTATGCTAGAAATTACATGTTGGAAATGAACTAGCACATAT

CATAAATTATTTTGTATGCTGTTATTACATTTTCTCAGTAACCTCTTAACTTCTATATCTCA

GCTACGTACTTGATGGTGTTCCTCGAATGAGAGAAAGACCAATTGGAGATTTGGTGACTGGT

CTTAAGCAGCTTGGTGCAGATGTTGATTGTTTTCATGGTACGGATTGTCCCCCTGTTCGTGT

GCTTGGAAAAGGAGGCCTTCCTGGGGGCAAGGTGAGGCTTGCATTGCTTCTTCTTATTCTTT

TTGGCCATAAAACATCATTGTAATAGTGGTTTTATGTTATGAAATCCATTGACTGGTTTATT

TTTAGGTTGTTGTTTTGCTTTTAAATAAAAACAATATTGTCAAATGATGCATAAGTAGTGAT

TACATCTACATCATTTAATTTATTATCTTAAATGATGACAAACTTCATCATTTTGACTCAGA

ATTATGTAATATTACCCTTTGCAGGTGAAACTTTCTGGATCAATTAGCAGTCAATATTTGAC

AGCCTTGCTTATGGCAGCTCCCTTGGCTCTTGGAGATGTTGAAATCGAGATAATTGATAAAT

TGATCTCGGTTCCCTATGTTGATATGACTTTGAAGTTGATGGCACGTTTTGGGGTTACTGTT

GAACACAGTGATAGCTGGGATCGATTTTTAGTTAAAGGAGGTCAAAAGTACAAGTAGGTTTC

TTCTGAATATAGTTGATAGTATTGTTACATTACATCTGGTTATGTCAAAGAGTAATAAATTG

AAAAATAAAAATCTGTCAGATCTCCTGGAAACGCTTATGTTGAAGGTGATGCTTCAAGTGCT

AGTTACTTCCTAGCTGGTGCTGCAGTCACTGGTGGTACAGTCACCGTAGAAGGTTGTGGGAC

TAGTAGTTTACAGGTATTTTGCTTAGACCTTGAAATCTCTTATTCTTGTACTTGTGTTTACA

TAGAATCTAAGATTAAGTGTATTTACATACATTAACTGGTGTTTAATAAAGGGAGACGTAAA

ATTTGCTGAAGTTCTTGAGAAAATGGGTGCTAAAGTTAGCTGGACAGAGAACAGTGTCACGG

TCACTGGACCACCACGAGATTCTGTAAAAAGTAAACACTTGAAAGCCATTGATGTCAACATG

AACAAAATGCCTGATGTTGCCATGACTCTTGCTGTAGTTGCTCTTTTTGCTGATGGCCCCAC

TGCTATAAGAGATGGTATGTTTTTCCTTAAATTTGTGAGATGGTAAAATGGGGCAGTCGGTT

TGGGTTGGGGTAGATTATCGGTTCTCGTCTGCCATAATAAAAAATAATCTGCTCATTTGCAA

TAAATTTCACAGACACAAAAATGAAAACCAATAAAATATTATTTTGTTTAGAGGATTAAATA

CTCATTTCTTGCCTTTCCTAATTCCCAGTGGCAAGTTGGAGAGTCAAGGAGACAGAGAGAAT

GATTGCCATCTGCACTGAACTCAGAAAGGTTAGTTTTTATGCTGTTTTATGTACTTGTTATG

TCATGCGCCTTGGAATGTAATGGCTGATAGCTATCTGTTCTTATGGGAACAAACATTTCAGC

TTGGAGCAACAGTTGAGGAAGGAC<u>***CC***</u>GATTACTGCGTGATCACTCCACCAGAGAAACTAAAT

ATCACAGCAATAGACACATACGACGACCACAGGATGGCTATGGCGTTCTCTCTTGCAGCTTG

-continued

TTCAGATGTGCCAGTTACCATTAAGGATCCTGGTTGCACCCGAAAAACTTTCCCAGATTACT

TTGAAGTCCTTGAGAGATTTACAAAGCACTGAATGAGTATTTATTAACTGGATAGAGAACAA

TAGCATCGGCTACTGTCATTACAACTAAAGCAGTTGGGAGGCAGGCAATCCTTTTCAATTAT

CATGTGTTTGATTTTGGTCGACTGTATTGCAAGTTGAGCTTCTCATTATTATTAAGACTGTA

ATCGTAGTTATTTGTTGTAACTTCTGCAAACCCTTCATGTTATTTTTTCACCCTTCTAATAA

GCCAGTGGGGCAAATTCTATATCTGCTATATGAGCTTGAGTGTAGAGAGAACTTTTGTCAAT

GTATAGGTTTCTAGCAGAAGCACCATCCCTAATATGCTTTATTATAAGAGTTGCTGTGATCG

TGTAGTGTTATTTTATTGAAAGTAACCGACGCATCTCATATTA

[0183] As used herein, the terms "polynucleotide," "polynucleotide sequence," "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide (which terms may be used interchangeably), or any fragment thereof. These phrases also refer to DNA or RNA of natural or synthetic origin (which may be single-stranded or double-stranded and may represent the sense or the antisense strand). The polynucleotides may be cDNA or genomic DNA.

[0184] As used herein, the term "construct" refers to recombinant polynucleotides including, without limitation, DNA and RNA, which may be single-stranded or double-stranded and may represent the sense or the antisense strand. Recombinant polynucleotides are polynucleotides formed by laboratory methods that include polynucleotide sequences derived from at least two different natural sources or they may be synthetic. Constructs thus may include new modifications to endogenous genes introduced by, for example, genome-editing technologies. Constructs may also include recombinant polynucleotides created using, for example, recombinant DNA methodologies.

[0185] The constructs provided herein may be prepared by methods available to those of skill in the art. Notably each of the constructs used or claimed are recombinant molecules and as such do not occur in nature. Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, and recombinant DNA techniques that are well known and commonly employed in the art. Standard techniques available to those skilled in the art may be used for cloning, DNA and RNA isolation, amplification and purification. Such techniques are thoroughly explained in the literature.

[0186] The constructs provided herein may include a promoter operably linked to any one of the polynucleotides described herein. The promoter may be a heterologous promoter or an endogenous promoter associated with the heterologous gene, nucleic acid, or polypeptide of interest.

[0187] As used herein, the terms "heterologous promoter," "promoter," "promoter region," or "promoter sequence" refer generally to transcriptional regulatory regions of a gene, which may be found at the 5' or 3' side of the polynucleotides described herein, or within the coding region of the polynucleotides, or within introns in the polynucleotides. Typically, a promoter is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. The typical 5' promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence is a transcription initiation site (conveniently defined by mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase.

[0188] In some embodiments, the heterologous polynucleotides of interest are operably connected to the promoter. As used herein, a polynucleotide is "operably connected" or "operably linked" when it is placed into a functional relationship with a second polynucleotide sequence. For instance, a promoter is operably linked to a polynucleotide if the promoter is connected to the polynucleotide such that it may effect transcription of polynucleotides. In various embodiments, the polynucleotides may be operably linked to at least 1, at least 2, at least 3, at least 4, at least 5, or at least 10 promoters.

[0189] Heterologous promoters useful in the practice of the present invention include, but are not limited to, constitutive, inducible, temporally-regulated, developmentally regulated, chemically regulated, tissue-preferred and tissue-specific promoters. The heterologous promoter may be a plant, animal, bacterial, fungal, or synthetic promoter. Suitable promoters for expression in plants include, without limitation, the 35S promoter of the cauliflower mosaic virus, ubiquitin, tCUP cryptic constitutive promoter, actin, the Rsyn7 promoter, pathogen-inducible promoters, the maize In2-2 promoter, the tobacco PR-1a promoter, glucocorticoid-inducible promoters, estrogen-inducible promoters and tetracycline-inducible and tetracycline-repressible promoters. Other promoters include the T3, T7 and SP6 promoter sequences, which are often used for in vitro transcription of RNA. Those of skill in the art are familiar with a wide variety of additional promoters for use in various cell types. In some embodiments, the heterologous promoter includes a plant promoter, either endogenous to the plant host or heterologous.

[0190] Vectors including any of the constructs or polynucleotides described herein are provided. The term "vector" is intended to refer to a polynucleotide capable of transporting another polynucleotide to which it has been linked. In some embodiments, the vector may be a "plasmid," which refers to a circular double-stranded DNA loop into which additional DNA segments may be ligated. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors can be integrated into the genome of a host cell upon introduction into the host cell,

and thereby are replicated along with the host genome, such as some viral vectors or transposons. Plant mini-chromosomes are also included as vectors. Any suitable vector design known in the art may be used with the explants of the present invention.

[0191] Vectors may carry genetic elements, such as those that confer resistance to certain drugs or chemicals. In some embodiments, the vector will additionally include one or more selectable or screenable markers. The selectable or screenable marker may confer upon the plant tissue resistance to an otherwise toxic compound. A number of screenable or selectable marker are known in the art and can be used in the present invention. The screenable marker may be fluorescent (e.g., RFP) or non-fluorescent (e.g., GUS). More than 20 selectable marker genes have been reported in the transformation of higher plants (Komari T, Takakura Y, Ueki J, Kato N, Ishida Y, Hiei Y (2006) Binary vectors and super-binary vectors. In: KanWang (ed.), and *Methods in Molecular Biology*, vol. 343: *Agrobacterium* Protocols, Vol. 1, Second Edition. Humana Press Inc., Totowa, N.J., pp. 15-41). In some embodiments, the selectable or screenable marker is selected from the group consisting of RFP, GUS, aadA, spectinomycin, streptomycin, and imazapyr. In some embodiments, the vector is a DICOTBINARY-19 plasmid. In some embodiments, the vector is a DICOTBINARY-22 plasmid.

[0192] In some aspects, provided herein are methods for transforming *Cannabis* using floral dip transformation. Female *Cannabis* flowers are exposed to *Agrobacterium* cultures suitable for flower dip transformation. In some embodiments, Cannabis flowers are submerged in an Agrobacterium culture under vacuum to induce transformation. In some embodiments, the *Agrobacterium* culture comprises *Agrobacterium* comprising the heterologous gene or nucleic acid of interest, a wetting agent, and a carrier. In some embodiments, the heterologous gene or nucleic acid of interest is included on a vector such as the DICOTBINARY-22 vector described herein. Other suitable vectors are known in the art. In some embodiments, the *Agrobacterium* strain is Ar18r12v, although other suitable *Agrobacterium* strains are known and used in the art. In some embodiments, the *Agrobacterium* used is a constitutively active variant or virG mutant of *Agrobacterium* (e.g., N45D mutant *Agrobacterium*). In some embodiments, the carrier is a cell culture medium suitable for the survival of the *Agrobacterium*. In some embodiments, the carrier is 5% sucrose. In some embodiments, the wetting agent is 0.05% silwet L-77. In some embodiments, the *Agrobacterium* culture includes Triton X-100, NP-40, Tween, or combinations thereof. In some embodiments, the *Agrobacterium* culture additionally comprises acetosyringone, galacturonic acid, cinnamic acid, coumarin, vanillin, other phenolic compounds, or combinations thereof. Suitable surfactants for plant floral dip transformations are known in the art. Following application of the *Agrobacterium* culture to the female *Cannabis* flower, the flowers are pollinated with male pollen from a suitable donor plant. In some embodiments, female *Cannabis* flowers are exposed to the *Agrobacterium* culture for at least 1, at least 2, at least 5, at least 10, at least 12, at least 15, at least 16, or at least 18 days before pollination. In some embodiments, the female *Cannabis* flowers are pollinated using a paintbrush.

[0193] In some embodiments of the floral dip transformations, DNA is delivered directly to the *Cannabis* ovules. In some embodiments, DNA is complexed with cell penetrating peptides prior to administration to *Cannabis* ovules.

[0194] In some aspects, provided herein are methods for transforming *Cannabis* nodes, internodes, leafs, petioles, hypocotyls, and buds. Sanitized and imbibed seeds are plated on non-selective medium (e.g., B5 medium) and grown for approximately 6 weeks or until explants suitable for transformation are formed. Resulting explants are inoculated with a heterologous gene or nucleic acid of interest. In some embodiments, the explants are inoculated using a force treatment as described herein. In some embodiments, the explants are inoculated by sonication with a vector comprising the heterologous gene or nucleic acid of interest. In some embodiment, the vector additionally comprises a selectable markers.

[0195] Following inoculation, node and bud explants are co-cultured in a culture medium that supports growth and survival of the node or bud for at least about 4 days. In some embodiments, the culture medium that supports the growth and survival of the node or bud is WCIC INO medium. In some embodiments, the medium additionally comprises nystatin, TBZ, and meta-topolin (mT). Following co-culture of at least about 4 days, the nodes and buds are transferred to a second culture medium suitable for the growth and survival of the nodes or buds. In some embodiments, the second culture medium is hemp node medium described herein in Table 7. In some embodiments, the hemp node medium additionally comprises a selection agent. In some embodiments, the hemp node medium additionally comprises activated charcoal.

[0196] Following inoculation, internode, leaf, hypocotyl, and petiole explants are co-cultured in a culture medium that supports growth and survival of the internode, leaf, hypocotyl, or petiole for at least about 4 days. In some embodiments, the culture medium that supports the growth and survival of the internode, leaf, hypocotyl, or petiole is WCIC INO medium. In some embodiments, the medium additionally comprises nystatin, TBZ, meta-topolin (mT), napthylacetic acid (NAA) and GA3. Following co-culture for at least about 4 days, leaf, petiole, hypocotyl, and internode explants are transferred to a second culture medium suitable for the growth and survival of the leaf, petiole, or internode. In some embodiments, the second culture medium is hemp internode medium described herein in Table 12. In some embodiments, the medium additionally includes a selection agent.

[0197] In some aspects, provided herein are methods for transforming *Cannabis* pollen or anther cultures. *Cannabis* pollen is harvested by shaking branches of male plants and collecting the pollen. In some embodiments, after harvest and collection, the pollen may be sized by passing the pollen through a sieve (e.g., a #80 sieve). Pollen may be used immediately for transformation, or may be stored prior to use. Pollen may be stored at a temperature between about 4° C. and about 20° C. The pollen may be stored in the presence of a storage medium. In some embodiments, the storage medium is medium suitable for pollen germination. In some embodiments, the storage medium includes boric acid, calcium chloride, potassium phosphate, and water. In some embodiments, the storage medium additionally includes glycerol.

[0198] Pollen may be transformed using particle bombardment, high velocity microprojection, microinjection, electroporation, direct DNA uptake, cell-penetrating peptides,

silica carbide fibers, nanoparticles, and bacterially-mediated transformation. In some embodiments, pollen is transformed using silica carbide fibers. In some embodiments, pollen is transformed using cell-penetrating peptides. Following transformation, pollen is co-cultured and germinated on medium suitable for the survival of the pollen. The medium may include a suitable selection agent. In some embodiments, transformed pollen is used to pollenate female flowers for rapid generation of transgenic T1 progeny.

[0199] In some aspects, provided herein are methods for transforming Cannabis callus tissue or embryogenic suspension cells. In general, Cannabis leaf tissue is cultured on plant medium containing hormones suitable to induce embryogenic calli formation. Embryogenic calli are then transformed using any of the suitable transformation methods as described herein. Calli are then grown a suitable plant medium containing hormones suitable for induction of shooting in the plant. Suspension cells may similarly be transformed in suspension as single cells then subsequently grown into plants using suitable medium including suitable hormones. Suitable medium and hormones are known and described in the art.

[0200] The present invention has been described in terms of one or more preferred embodiments, and it should be appreciated that many equivalents, alternatives, variations, and modifications, aside from those expressly stated, are possible and within the scope of the invention.

Example 1

[0201] The embodiment described here demonstrates *Cannabis* meristem explant transformation.

[0202] Seeds of variety Elektra x Chardonnay were surface sanitized with 20% Clorox for 5 minutes, rinsed, and sat for ~2 hrs before overnight imbibition with WCIC Bean Germination Media (BGM).

TABLE 1

WCIC Bean Germination Media (BGM)

Ingredients and Notes	Amount to add per liter (grams)
Phytotechnology Laboratories WPM L449	2.41
Sucrose	20
pH to 5.8 with 1N KOH and autoclave	
Add the following prior to use:	
Captan fungicide (50WP)	0.06
Bravo fungicide (Daconil) (82DP)	0.03
Cefotaxime (100 mg/ml)	1.25 ml

[0203] The next day, meristem explants were aseptically excised from seed and incubated for approximately 2 hrs in 20% PEG4000 with 60 mg/L Captan and 30 mg/L Bravo fungicides. Explants were then rinsed and inoculated with Agrobacterium strain Ar18r12v harboring the binary plasmid DICOTBINARY-19. During inoculation, explants were exposed to 20 seconds of sonication at ~45 kHz. Explants were co-cultured in either 1.75 ml or 2.0 ml WCIC INO media with 100 uM acetosyringone, 50 mg/L nystatin, 10 mg/L TBZ, and 95 uM lipoic acid for 4 days at 23 C 16/8 photoperiod. Thidiazuron (TDZ) was added to some co-culture treatments at 1 mg/L.

TABLE 2

WCIC INO media

Ingredients and Notes	Amount to add per liter (grams)
Gamborg B5 Phytotechnology Laboratories G398	1.284
Glucose	30
MES	2.8
pH to 5.4 with 1N KOH and autoclave	

[0204] After 4 days of co-culture, transient GUS expression was evaluated in explants. Explants were then transferred to either 10 mg/L spectinomycin or 150 mg/L spectinomycin WCIC Gamborg B5 medium (Table 3) for selection. Explants on 10 mg/L spectinomycin B5 were transferred to 150 mg/L spectinomycin B5 approximately 1 week later, and then explants from all treatments were transferred to 50 mg/L spectinomycin B5 1 month later. Additional transfers have been made with explants remaining green on spectinomycin. A summary of this experiment is given in Table 4.

TABLE 3

WCIC Gamborg B5 Medium

Ingredients and Notes	Amount to add per liter (grams)
Phytotechnology Laboratories B5 salts G398	2.41
Sucrose	20
Cleary's 3336 (50WP)	0.06
Ca Gluconate	1.29
pH to 5.8 with 1N KOH	
Phytagel	3.50
autoclave	
Add the following fresh before use:	
Timetin (150 mg/ml stock)	Use 1 mL per Liter (150 mg/L)
Cefotaxime (100 mg/ml stock)	Use at 2 ml per Liter (200 mg/L)
Carbenicillin (100 mg/ml stock)	Use at 4 ml per Liter (400 mg/L)
Selective Agent	as needed

TABLE 4

Description and summary of *Cannabis* meristem explant transformation experiments.

Co-Culture conditions	Experiment ID	# embryos to Selection	Selection Media	2nd media	3rd media	Notes	Notes
Filter paper in plantcon with 1.75 ml INO + 50 ppm nystatin + 10 ppm TBZ + lipoic acid; 23 C. 16/8 photoperiod	Hemp 3/22-1A	7	10 ppm spec B5; 28 C. 16/8 photoperiod;	150 ppm spec B5; 28 C. 16/8 photoperiod;	50 ppm spec B5; 28 C. 16/8 photoperiod;	1 greening explant transferred to non-selective BRM	
Filter paper in plantcon with 1.75 ml INO + 50 ppm nystatin + 10 ppm TBZ + lipoic acid; 23 C. 16/8 photoperiod	Hemp 3/22-1B	4	150 ppm spec B5; 28 C. 16/8 photoperiod;	NA	50 ppm spec B5; 28 C. 16/8 photoperiod;	1 greening explant transferred to non-selective BRM	
Filter paper in plantcon with 2 ml INO + 50 ppm nystatin + 10 ppm TBZ + lipoic acid; 23 C. 16/8 photoperiod	Hemp 3/22-2A	9	10 ppm spec B5; 28 C. 16/8 photoperiod;	150 ppm spec B5; 28 C. 16/8 photoperiod;	50 ppm spec B5; 28 C. 16/8 photoperiod;	1 greening explant transferred to 10 ppm spec B5	
Filter paper in plantcon with 2 ml INO + 50 ppm nystatin + 10 ppm TBZ + lipoic acid; 23 C. 16/8 photoperiod	Hemp 3/22-2B	10	150 ppm spec B5; 28 C. 16/8 photoperiod;	NA	50 ppm spec B5; 28 C. 16/8 photoperiod;	1 chimeric RFP+ explant (primary leaves) transferred to B5	1 greening explant transferred to non-selective BRM
Filter paper in plantcon with 1.75 ml INO + 50 ppm nystatin + 10 ppm TBZ + lipoic acid + 1 ppm TDZ; 23 C. 16/8 photoperiod	Hemp 3/22-3A	9	10 ppm spec B5; 28 C. 16/8 photoperiod;	150 ppm spec B5; 28 C. 16/8 photoperiod;	50 ppm spec B5; 28 C. 16/8 photoperiod;		
Filter paper in plantcon with 1.75 ml INO + 50 ppm nystatin + 10 ppm TBZ + lipoic acid + 1 ppm TDZ; 23 C. 16/8 photoperiod	**Hemp 3/22-3B**	**10**	**150 ppm spec B5; 28 C. 16/8 photoperiod;**	**NA**	**50 ppm spec B5; 28 C. 16/8 photoperiod;**	**1 chimeric RFP + explant (primary leaves) transferred to B5**	**4 greening explant transferred to non-selective BRM; GUS positive leaf imaged**
Filter paper in plantcon with 2 ml INO + 50 ppm nystatin + 10 ppm TBZ + lipoic acid + 1 ppm TDZ; 23 C. 16/8 photoperiod	**Hemp 3/22-4A**	**9**	**10 ppm spec B5; 28 C. 16/8 photoperiod;**	**150 ppm spec B5; 28 C. 16/8 photoperiod;**	**50 ppm spec B5; 28 C. 16/8 photoperiod;**	**RFP positive shoot imaged**	
Filter paper in plantcon with 2 ml INO + 50 ppm nystatin + 10 ppm TBZ + lipoic acid + 1 ppm TDZ; 23 C. 16/8 photoperiod	Hemp 3/22-4B	12	150 ppm spec B5; 28 C. 16/8 photoperiod;	NA	50 ppm spec B5; 28 C. 16/8 photoperiod;	5 greening explants transferred to 10 ppm spec B5	

[0205] Stable RFP (tdTomato) was imaged several explants 3 weeks after inoculation, but was confined primarily to primary leaves and cotyledonary remnants. The stable RFP signal in the chimeric plantlet that appeared to be from new growth was from treatment 4A (treatment bolded in Table 4—2 ml co-culture volume with TDZ, and initial transfer to 10 mg/L spectinomycin B5), shown again in FIG. **1**. This plant did not survive tissue culture, which may have been result of its chimerism in response to selection, or possibly non-optimal media conditions.

[0206] We have also observed stable GUS expression in a plantlet derived from this experiment in treatment Hemp 3/22-3B. One of the leaves in a plantlet transferred to non-selective BRM expressed GUS in leaf stably. The leaf shown in FIG. **16** was imaged 2 months after inoculation after clearing with 70% ethanol.

[0207] The non-inoculated control meristem explant was sent to the greenhouse as a proof of concept of tissue culture (TC) regeneration of a plant from a meristem explant (rooted on non-selective B5 media). See FIG. **2**.

[0208] Additional experiments with additional varieties of *Cannabis* inoculated with Ar18r12v/DICOTBINARY-19 and a 4 day co-culture are outlined in Table 5. The co-culture volume was increased as we noted in the prior tests explants were very dry post co-culture. Some of these experiments used meta-topolin in co-culture, which has been demonstrated to encourage propagation in *Cannabis* nodal cultures (H. Lata et al./Journal of Applied Research on Medicinal and Aromatic Plants 3 (2016) 18-26); some used a full-strength formulation of B5 media for selection; and some used an MS-based selection media with meta-topolin (mT) based on Lata 2016 but without activated charcoal.

TABLE 5

Description and summary of follow-up experiments with *Cannabis* meristem explants.

Cannabis sativa Genotype/ Line	Comments	Experiment ID	Strain	Binary	# embryos to Selection	Notes
Honey Gold 3WS	Hand excised from seed surface sanitized in 20% Clorox 5 min; rinsed; imbibed for ~20 h in BGM; explants placed in 20% PEG4000 with Captan/Bravo for 1.5-2.5 h, rinsed, inoculated and sonicated 20 s 45 kHz; incubated 30 min, inoculum removed; explants co-cultured on filter paper in plantcon with 2.5 ml INO + 60 ppm Cleary's + 50 ppm nystatin + 10 ppm TBZ; 23 C. 16/8 photoperiod	Hemp 5/9-1	Ar18r12v	DICOT-BINARY-19	35	10 ppm spec 100% B5; 28 C. 16/8 photoperiod;
Honey Gold 3WS	Hand excised from seed surface sanitized in 20% Clorox 5 min; rinsed; imbibed for ~20 h in BGM; explants placed in 20% PEG4000 with Captan/Bravo for 1.5-2.5 h, rinsed, inoculated and sonicated 20 s 45 kHz; incubated 30 min, inoculum removed; explants co-cultured on filter paper in plantcon with 2.5 ml INO + 60 ppm Cleary's + 50 ppm nystatin + 10 ppm TBZ + 1 ppm meta-topolin (mT); 23 C. 16/8 photoperiod	Hemp 5/9-2	Ar18r12v	DICOT-BINARY-19	25	10 ppm spec 100% B5; 28 C. 16/8 photoperiod;
Fiber Hemp	Hand excised from seed surface sanitized in 20% Clorox 5 min; rinsed; imbibed for ~20 h in BGM; explants placed in 20% PEG4000 with Captan/Bravo for 1.5-2.5 h, rinsed, inoculated and sonicated 20 s 45 kHz; incubated 30 min, inoculum removed; explants co-cultured on filter paper in plantcon with 2.5 ml INO + 60 ppm Cleary's + 50 ppm nystatin + 10 ppm TBZ; 23 C. 16/8 photoperiod	Hemp 5/9-3	Ar18r12v	DICOT-BINARY-19	21	10 ppm spec 100% B5; 28 C. 16/8 photoperiod;
Fiber Hemp	Hand excised from seed surface sanitized in 20% Clorox 5 min; rinsed; imbibed for ~20 h in BGM; explants placed in 20% PEG4000 with Captan/Bravo for 1.5-2.5 h, rinsed, inoculated and sonicated 20 s 45 kHz; incubated 30 min, inoculum removed; explants co-cultured on filter paper in plantcon with 2.5 ml INO + 60 ppm Cleary's + 50 ppm nystatin + 10 ppm TBZ + 1 ppm meta-topolin (mT); 23 C. 16/8 photoperiod	Hemp 5/9-4	Ar18r12v	DICOT-BINARY-19	12	10 ppm spec 100% B5; 28 C. 16/8 photoperiod;
Honey Gold 3WS	Hand excised from seed surface sanitized in 20% Clorox 5 min; rinsed; imbibed for ~20 h in BGM; explants placed in 20% PEG4000 with Captan/Bravo for 1.5-2.5 h, rinsed, inoculated and sonicated 20 s 45 kHz; incubated 30 min, inoculum removed; explants co-cultured on filter paper in plantcon with 2.5 ml INO + 60 ppm Cleary's + 50 ppm nystatin + 10 ppm TBZ 1 ppm TDZ; 23 C. 16/8 photoperiod	Hemp 5/16-1	Ar18r12v	DICOT-BINARY-19	59	10 ppm spec 100% B5; 28 C. 16/8 photoperiod;
Honey Gold 3WS	Hand excised from seed surface sanitized in 20% Clorox 5 min; rinsed; imbibed for ~20 h in BGM; explants placed in 20% PEG4000 with Captan/Bravo for 1.5-2.5 h, rinsed, inoculated and sonicated 20 s 45 kHz; incubated 30 min, inoculum removed; explants co-cultured on filter paper on top of semisolid INO (8 g/L agarose I) + 60 ppm Cleary's + 1 ppm TDZ; 23 C. 16/8 photoperiod	Hemp 5/16-2	Ar18r12v	DICOT-BINARY-19	19	10 ppm spec 100% B5; 28 C. 16/8 photoperiod;
Honey Gold 3WS	Hand excised from seed surface sanitized in 20% Clorox 5 min; rinsed; imbibed for ~20 h in BGM; explants placed in 20% PEG4000 with Captan/Bravo for 1.5-2.5 h, rinsed, inoculated and sonicated 20 s 45 kHz; incubated 30 min, inoculum removed; explants co-cultured on filter paper in plantcon with 2.5 ml INO + 60 ppm Cleary's + 50 ppm nystatin + 10 ppm TBZ 1 ppm TDZ; 23 C. 16/8 photoperiod	Hemp 5/30-1	Ar18r12v	DICOT-BINARY-19	5	non-selective hemp node media (minus activated charcoal)
Honey Gold 3WS	Hand excised from seed surface sanitized in 20% Clorox 5 min; rinsed; imbibed for ~20 h in BGM; explants placed in 20% PEG4000 with Captan/Bravo for 1.5-2.5 h, rinsed, inoculated and sonicated 20 s 45 kHz; incubated 30 min, inoculum removed; explants co-cultured on filter paper in plantcon with 2.5 ml INO + 60 ppm Cleary's + 50 ppm nystatin + 10 ppm TBZ 1 ppm TDZ; 23 C. 16/8 photoperiod	Hemp 5/30-2	Ar18r12v	DICOT-BINARY-19	36	10 ppm sec hemp node media (minus activated charcoal)
Honey Gold 3WS	Hand excised from seed surface sanitized in 20% Clorox 5 min; rinsed; imbibed for ~20 h in BGM; explants placed in 20% PEG4000 with Captan/Bravo for 1.5-2.5 h, rinsed, inoculated and sonicated 20 s 45 kHz; incubated 30 min, inoculum removed; explants co-cultured on filter paper in plantcon with 2.5 ml INO + 60 ppm Cleary's + 50 ppm nystatin + 10 ppm TBZ + 1 ppm TDZ; 23 C. 16/8 photoperiod	Hemp 5/30-3	Ar18r12v	DICOT-BINARY-19	43	50 ppm sec hemp node media (minus activated charcoal)
Honey Gold 3WS	Hand excised from seed surface sanitized in 20% Clorox 5 min; rinsed; imbibed for ~20 h in BGM at 37 C.; explants placed in 20% PEG4000 with Captan/Bravo for 1.5-2.5 h, rinsed, inoculated and sonicated 20 s 45 kHz; incubated 30 min, inoculum removed; explants co-cultured on filter paper in plantcon with 2.5 ml INO + 60 ppm Cleary's + 50 ppm nystatin + 10 ppm TBZ + 1 ppm TDZ; 23 C. 16/8 photoperiod	Hemp 6/6-1	Ar18r12v	SOYTEST-2	36	50 ppm sec hemp node media (minus activated charcoal)

TABLE 5-continued

Description and summary of follow-up experiments with *Cannabis* meristem explants.

Cannabis sativa Genotype/ Line	Comments	Experiment ID	Strain	Binary	# embryos to Selection	Notes
Honey Gold 3WS	Hand excised from seed surface sanitized in 20% Clorox 5 min; rinsed; imbibed for ~20 h in BGM at 37 C.; explants placed in 20% PEG4000 with Captan/Bravo for 1.5-2.5 h, rinsed, inoculated and sonicated 2 min 45 kHz; incubated 30 min, inoculum removed; explants co-cultured on filter paper in plantcon with 2.5 ml INO + 60 ppm Cleary's + 50 ppm nystatin + 10 ppm TBZ + 1 ppm TDZ; 23 C. 16/8 photoperiod	Hemp 6/6-2	Ar18r12v	SOYTEST-2	36	50 ppm sec hemp node media (minus activated charcoal)
Honey Gold 3WS	Hand excised from seed surface sanitized in 20% Clorox 5 min; rinsed; imbibed for ~20 h in BGM at 37 C.; explants placed in 20% PEG4000 with Captan/Bravo for 1.5-2.5 h, rinsed, inoculated and sonicated 20 s 45 kHz; incubated 30 min, inoculum removed; explants co-cultured on filter paper in plantcon with 2.5 ml INO + 50 ppm nystatin + 10 ppm TBZ + 1 ppm TDZ; 23 C. 16/8 photoperiod	Hemp 6/13-1	Ar18r12v	SOYTEST-2	44	50 ppm sec hemp node media (minus activated charcoal)
Honey Gold 3WS	Hand excised from seed surface sanitized in 20% Clorox 5 min; rinsed; imbibed for ~20 h in BGM at 37 C.; explants placed in 20% PEG4000 with Captan/Bravo for 1.5-2.5 h, rinsed, inoculated and sonicated 2 min 45 kHz; incubated 30 min, inoculum removed; explants co-cultured on filter paper in plantcon with 2.5 ml INO + 50 ppm nystatin + 10 ppm TBZ + 1 ppm TDZ; 23 C. 16/8 photoperiod	Hemp 6/13-2	Ar18r12v	SOYTEST-2	45	50 ppm sec hemp node media (minus activated charcoal)
Honey Gold 3WS	Hand excised from seed surface sanitized in 20% Clorox 5 min; rinsed; imbibed for ~20 h in BGM at 37 C.; explants placed in 20% PEG4000 with Captan/Bravo for 1.5-2.5 h, rinsed, inoculated and sonicated 20 s 45 kHz; incubated 30 min, inoculum removed; explants co-cultured on filter paper in plantcon with 2.5 ml INO + 60 ppm Cleary's + 50 ppm nystatin + 10 ppm TBZ; 23 C. 16/8 photoperiod	Hemp 6/20-1A	Ar18r12v	SOYTEST-2	20	10 ppm sec B5; 28 C. 16/8 photocopied;
Honey Gold 3WS	Hand excised from seed surface sanitized in 20% Clorox 5 min; rinsed; imbibed for ~20 h in BGM at 37 C.; explants placed in 20% PEG4000 with Captan/Bravo for 1.5-2.5 h, rinsed, inoculated and sonicated 20 s 45 kHz; incubated 30 min, inoculum removed; explants co-cultured on filter paper in plantcon with 2.5 ml INO + 60 ppm Cleary's + 50 ppm nystatin + 10 ppm TBZ; 23 C. 16/8 photoperiod	Hemp 6/20-1B	Ar18r12v	SOYTEST-2	10	10 ppm sec node-AC; 28 C. 16/8 photocopied;
Honey Gold 3WS	Hand excised from seed surface sanitized in 20% Clorox 5 min; rinsed; imbibed for ~20 h in BGM at 37 C.; explants placed in 20% PEG4000 with Captan/Bravo for 1.5-2.5 h, rinsed, inoculated and sonicated 20 s 45 kHz; incubated 30 min, inoculum removed; explants co-cultured on filter paper in plantcon with 2.5 ml INO + 60 ppm Cleary's + 50 ppm nystatin + 10 ppm TBZ; 23 C. 16/8 photoperiod	Hemp 6/20-1C	Ar18r12v	SOYTEST-2	10	50 ppm sec B5; 28 C. 16/8 photocopied;
Honey Gold 3WS	Hand excised from seed surface sanitized in 20% Clorox 5 min; rinsed; imbibed for ~20 h in BGM at 37 C.; explants placed in 20% PEG4000 with Captan/Bravo for 1.5-2.5 h, rinsed, inoculated and sonicated 20 s 45 kHz; incubated 30 min, inoculum removed; explants co-cultured on filter paper in plantcon with 2.5 ml INO + 60 ppm Cleary's + 50 ppm nystatin + 10 ppm TBZ; 23 C. 16/8 photoperiod	Hemp 6/20-1D	Ar18r12v	SOYTEST-2	10	50 ppm strep node-AC; 28 C. 16/8 photoperiod;
Honey Gold 3WS	Hand excised from seed surface sanitized in 20% Clorox 5 min; rinsed; imbibed for ~20 h in BGM at 37 C.; explants placed in 20% PEG4000 with Captan/Bravo for 1.5-2.5 h, rinsed, inoculated and sonicated 20 s 45 kHz; incubated 30 min, inoculum removed; explants co-cultured on filter paper in plantcon with 2.5 ml INO + 1 ppm TDZ, 60 ppm Cleary's + 50 ppm nystatin + 10 ppm TBZ; 23 C. 16/8 photoperiod	Hemp 6/20-2A	Ar18r12v	SOYTEST-2	10	10 ppm spec B5; 28 C. 16/8 photoperiod;
Honey Gold 3WS	Hand excised from seed surface sanitized in 20% Clorox 5 min; rinsed; imbibed for ~20 h in BGM at 37 C.; explants placed in 20% PEG4000 with Captan/Bravo for 1.5-2.5 h, rinsed, inoculated and sonicated 20 s 45 kHz; incubated 30 min, inoculum removed; explants co-cultured on filter paper in plantcon with 2.5 ml INO + 1 ppm TDZ, 60 ppm Cleary's + 50 ppm nystatin + 10 ppm TBZ; 23 C. 16/8 photoperiod	Hemp 6/20-2B	Ar18r12v	SOYTEST-2	10	10 ppm spec node-AC; 28 C. 16/8 photoperiod;
Honey Gold 3WS	Hand excised from seed surface sanitized in 20% Clorox 5 min; rinsed; imbibed for ~20 h in BGM at 37 C.; explants placed in 20% PEG4000 with Captan/Bravo for 1.5-2.5 h, rinsed, inoculated and sonicated 20 s 45 kHz; incubated 30 min, inoculum removed; explants co-cultured on filter paper in plantcon with 2.5 ml INO + 1 ppm TDZ, 60 ppm Cleary's + 50 ppm nystatin + 10 ppm TBZ; 23 C. 16/8 photoperiod	Hemp 6/20-2C	Ar18r12v	SOYTEST-2	10	50 ppm spec B5; 28 C. 16/8 photoperiod;

TABLE 5-continued

Description and summary of follow-up experiments with *Cannabis* meristem explants.

Cannabis sativa Genotype/ Line	Comments	Experiment ID	Strain	Binary	# embryos to Selection	Notes
Honey Gold 3WS	Hand excised from seed surface sanitized in 20% Clorox 5 min; rinsed; imbibed for ~20 h in BGM at 37 C.; explants placed in 20% PEG4000 with Captan/Bravo for 1.5-2.5 h, rinsed, inoculated and sonicated 20 s 45 kHz; incubated 30 min, inoculum removed; explants co-cultured on filter paper in plantcon with 2.5 ml INO + 1 ppm TDZ, 60 ppm Cleary's + 50 ppm nystatin + 10 ppm TBZ; 23 C. 16/8 photoperiod	Hemp 6/20-2D	Ar18r12v	SOYTEST-2	10	50 ppm strep node-AC; 28 C. 16/8 photoperiod;
Honey Gold 3WS	Hand excised from seed surface sanitized in 20% Clorox 5 min; rinsed; imbibed for ~20 h in BGM at 37 C.; explants placed in 20% PEG4000 with Captan/Bravo for 1.5-2.5 h, rinsed, inoculated and sonicated 20 s 45 kHz; incubated 30 min, inoculum removed; explants co-cultured on filter paper in plantcon with 2.25 ml INO + 60 ppm Cleary's + 50 ppm nystatin + 10 ppm TBZ + 1 ppm TDZ; 23 C. 16/8 photoperiod	Hemp 6/27-1	GV3101	SOYTEST-2	48	50 ppm spec meristem regeneration; 28 C. 16/8 photoperiod;
Honey Gold 3WS	Hand excised from seed surface sanitized in 20% Clorox 5 min; rinsed; imbibed for ~20 h in BGM at 37 C.; explants placed in 20% PEG4000 with Captan/Bravo for 1.5-2.5 h, rinsed, inoculated and sonicated 20 s 45 kHz; incubated 30 min, inoculum removed; explants co-cultured on filter paper in plantcon with 2.25 ml INO + 60 ppm Cleary's + 50 ppm nystatin + 10 ppm TBZ + 1 ppm TDZ; 23 C. 16/8 photoperiod	Hemp 6/27-2	GV3101	SOYTEST-2	36	50 ppm spec meristem regeneration with 0.5 ppm MT; 28 C. 16/8 photoperiod;
Honey Gold 3WS	Hand excised from seed surface sanitized in 20% Clorox 5 min; rinsed; imbibed for ~20 h in BGM at 37 C.; explants placed in 20% PEG4000 with Captan/Bravo for 1.5-2.5 h, rinsed, inoculated and sonicated 20 s 45 kHz; incubated 30 min, inoculum removed; explants co-cultured on filter paper in plantcon with 2.25 ml INO + 60 ppm Cleary's + 1 ppm TDZ; 23 C. 16/8 photoperiod	Hemp 7/3-1	Ar18r12v	SOYTEST-2	83	10 ppm spec meristem regeneration; 28 C. 16/8 photoperiod;
Honey Gold 3WS	Hand excised from seed surface sanitized in 20% Clorox 5 min; rinsed; imbibed for ~20 h in BGM at 37 C.; explants placed in 20% PEG4000 with Captan/Bravo for 1.5-2.5 h, rinsed, inoculated and sonicated 20 s 45 kHz; incubated 30 min, inoculum removed; explants co-cultured on filter paper on semisolid INO (8 g/L agarose I) + 60 ppm Cleary's 1 ppm TDZ; 23 C. 16/8 photoperiod	Hemp 7/8-1	Ar18r12v	SOYTEST-2	48	50 ppm spec meristem regeneration with 0.5 ppm mT; 28 C. 16/8 photoperiod;

TABLE 6

WCIC TRUE Gamborg B5 Media

Ingredients and Notes	Amount to add per liter (grams)
Phytotechnology Laboratories B5 salts G398	3.21
Sucrose	20
Cleary's 3336 (50WP)	0.06
Ca Gluconate	1.29
pH to 5.8 with 1 N KOH	
Phytagel	3.50
autoclave	
Add the following fresh before use:	
Timetin (150 mg/ml stock)	Use 1 mL per Liter (150 mg/L)
Cefotaxime (100 mg/ml stock)	Use at 2 ml per Liter (200 mg/L)
Carbenicillin (100 mg/ml stock)	Use at 4 ml per Liter (400 mg/L)
Selective Agent	as needed

TABLE 7

WCIC Hemp Node Media (modified from Lata 2016)

Ingredients and Notes	Amount to add per liter (grams)
MS Salts complete with vitamins (PhytoTech M519)	4.43
Sucrose	30
Cleary's 3336	0.06
pH to 5.7 with 1 N KOH	
Agar (Sigma A7921)	8
autoclave	
Meta-topolin (mT) (1 mg/ml)	0.5 ml
Carbenicillin (200 mg/ml)	1.25 ml
Cefotaxime (100 mg/ml)	2 ml
Selection	as needed

TABLE 7-continued

WCIC Hemp Node Media (modified from Lata 2016)

Ingredients and Notes	Amount to add per liter (grams)

[0209] We did obtain strong GUS transients using both *Cannabis* varieties Honey Gold 3WS and the Fiber Hemp (in addition to the transients shown for Elektra x Chardonnay in initial disclosure). See FIG. **3**.

[0210] Additionally, *Cannabis* seeds were also imbibed at 37° C. to facilitate excision of the meristem explants. With an overnight imbibition at 37° C. the radical begins to emerge from the seed which makes a natural crack in the hard seed coat. This makes isolating the *Cannabis* mature embryo/meristem explant easier. See FIG. **17**.

[0211] It is also possible to mechanically excise the *Cannabis* meristem explants from the seen. 10 g *Cannabis* seed from the Fiber variety were surface sterilized with 20%

bleach solution for 5 minutes, then rinsed with sterile distilled water for 2 minutes. Seed were then imbibed in sterile distilled water at 37 degrees C. for approximately 24 hours. Seed was then rinsed with sterile distilled water for 2 minutes and weighed (collected rehydrated weight was 18 grams). Seed was then split into two 9 gram samples and spread on sterile filter paper in petri dishes and dried in laminar flow hood. One sample was removed 24 hrs later, the other 49 hours later. The collected dry weight of each sample was 4.8 grams.

[0212] A portion of this dry hemp seed from the 49 hour dried material was used for machine excision experiments. Seed were placed through a Perten Instruments Laboratory Mill 3310 using seven different gap settings (0 to 6, smallest to largest gap) with 20 seeds per gap setting. Ground material was collected and embryonic parts were counted under a microscope. While the Perten Lab mill was used for these examples, excision of embryos and explants can be performed using and dry mill or equivalent instrumentation known in the art, for example, roller mills, hammer mills, and bladed mills or other suitable means described herein. Equivalent wet mill processing is also envisioned.

TABLE 8

Embryonic parts produced using various gap setting on the Perten Instruments Laboratory Mill 3310

Gap Setting	Embryonic Parts Produced
6	20
5	14
4	14
3	5
2	3
1	4
0	0

[0213] Further experimentation will be carried out using gap setting 6 for grinding hemp varieties. Following embryonic part production, regeneration of the embryonic material will be checked on non-selective medium. Embryonic parts generated using the gap 6 setting on Perten is shown in FIG. **18**.

[0214] Additionally, MS-based medium with or without meta-topolin may be used with meristem explants. When TDZ is used in co-culture with Agrobacterium, the use of meta-topolin during selection/regeneration may not be necessary.

TABLE 9

Hemp Meristem Regeneration Medium

Ingredients and Notes	Amount to add per liter (grams)
MS Salts complete with vitamins (PhytoTech M519)	4.43
Sucrose	30
Cleary's 3336	0.06
pH to 5.7 with 1 N KOH	
Agar (Sigma A7921)	8
autoclave	
Meta-topolin (mT) (1 mg/ml)	as needed
Carbenicillin (100 mg/ml)	2 ml
Cefotaxime (100 mg/ml)	2 ml
Timetin (150 mg/ml)	1 ml
Selection	as needed

[0215] Additional control binary constructs have also been testing including SOYTEST-2. SOYTEST-2 has a different promoter driving tdTomato to test impacts on RFP visualization (DICOTBINARY-19 uses the *Glycine max* Ubiquitin 3 XL promoter driving tdTomato, where SOYTEST-2 uses *Pinus radiata* Super Ubiquitin promoter driving tdTomato). See FIG. **19**.

[0216] We have obtained positive GUS transients in *Cannabis* meristem explants (3WS variety) using SOYTEST-2 in both the Ar18r12v and GV3101 strains of *Agrobacterium* (see FIG. **20**), demonstrating transfection of *Cannabis* meristems using disarmed strains of both *Agrobacterium rhizogenes* (Ar18r12v) and *Agrobacterium tumefaciens* (GV3101).

[0217] We have obtained additional stable RFP expressing *Cannabis* from experiments in the Honey Gold 3WS variety. The plantlet in the center of FIG. **21** (*Cannabis* plant WP421-1) is rooting on 50 mg/L streptomycin hemp node media (after being on 50 mg/L spectinomycin hemp node media for approximately 1 month).

[0218] Plant WP421-1 was transferred to the greenhouse and imaged the day of transfer, approximately 4 weeks later (FIG. **26**), and approximately 7 weeks later (FIG. **31**). Three leaves from WP421-1 were sampled after it had been in greenhouse for 4 weeks. Two of the three leaves were stably expressing RFP (FIG. **27**), while all three were stable expressing GUS (FIGS. **27** and **28**). RFP expression was relatively weaker than when we initially sent the plant, which is likely due to tissue age. That all three randomly selected leaves are stably expressing GUS is a good indicator WP421-1 is not overly chimeric.

[0219] Additional data in FIGS. **32-34** confirms the chimerism in the WP421-1 plant. 10 leaf samples were taken from EP421-1 and divided for PCR (FIGS. **33-34**) and GUS expression (FIG. **32**) analysis. For PCR, we amplified a 156 bp fragment within the aadA expression cassette of DICOTBINARY-19 using primers designated F56 and R11 (fragments and amplicon highlighted in blue in FIG. **33**). Leaf DNA from WP421-1 was extracted using the REDExtract-N-Amp™ Plant PCR Kit (Sigma-Aldrich XNAP-1KT) following manufacturer's instructions. PCR reaction was run with following:

[0220] 1. 3 minutes at 94 C for initial denaturation

[0221] 2. 30 seconds at 94 C for denaturation

[0222] 3. 30 seconds at 55 C for annealing

[0223] 4. 1 minute at 72 C for primer extension

[0224] 5. Cycle steps 2-4 34 more times (35 total cycles)

[0225] 6. 10 minutes at 72 C for final primer extension

[0226] PCR products were run on 1.5% agarose gel in SB buffer. All 10 leaf samples gave the expected 156 bp product, confirming minimal chimerism in this event

[0227] We have also blasted DNA into *Cannabis* meristem explants using PDS-1000 Helium gun with a plasmid designated DICOTBOMB-13. For particle bombardment experiments, gold-DNA "bead prep" was prepared by first washing 50 mg 0.6 um gold microcarriers (BioRad part #1652262) in 1 ml 100% ethanol and sonicating for 1 min 45 kHz. Gold was pelleted by centrifugation at 5000 rpm in microfuge (~2300×g) and ethanol removed. Gold was then resuspended in 1 ml 100% ethanol and stored at −20 C until use. To precipitate DNA onto beads, the 50 mg gold/l ml ethanol stock was sonicated for 1 min 45 kHz. 42 ul of this stock was transferred to an Eppendorf tube, then pelleted by centrifugation at 2500 rpm for 10 seconds, after which

ethanol was removed. 500 uL sterile water was added and mixture sonicated 1 min 45 kHz. Gold was again pelleted by centrifugation at 2500 rpm for 10 seconds and water removed. 25 ul sterile water was then added, followed by sonication for 1 min 45 kHz. 2.6 ug DICOTBOMB-13 DNA was added, then sterile water to bring volume up to 245 ul. 250 ul cold 2.5 M $CaCl_2$ was added, followed by 50 ul 0.1 M spermidine. Solution was mixed by low speed vortexing. Tube was incubated on ice for approximately 1 hour with gentle inversions every 5-10 minutes. DNA/gold was pelleted at 1000 rpm (~100×g) for 2 min and supernatant removed. Pellet was then washed with 1 ml 100% EtOH w/ pipette tip, then pelleted again at 1000 rpm (~100×g) for 2 min and supernatant removed 36 ul 100% EtOH was added to tube and gold completely resuspended with low-speed vortexing. Bead prep was stored at −20 C until used, with 5 ul used per bombardment. This corresponds to 360 ng DNA per blast; 290 ug gold per blast (1.2 ng DNA per ug gold).

[0228] *Cannabis* meristem explants were excised from seed and precultured on EJW1 media overnight at 28 C 16/8 photoperiod, arranged on 12% xanthan gum targeting plates (with 60 mg/L Cleary's 3336 fungicide), blasted at 6 cm from the launch assembly using 5 uL bead prep per target and a range of rupture disks (650 psi-1550 psi), then allowed to rest on EJW1 media overnight. Transients were taken the next day. GUS transient expression in *Cannabis* meristem explants bombarded with DICOTBOMB-13 is shown in FIG. **23**.

TABLE 10

Preculture Medium EJW1

Ingredients and Notes	Amount to add per liter (grams)
MS salts no vitamins	4.3
Sucrose	30
2,4-D (1 mg/ml stock)	0.2 ml
MES	2
Cleary's 3336	.03
pH	5.6
Agarose	4
Autoclave	
Carbenicillin (100 mg/ml)	.25
TDZ (1 mg/ml stock)	1 ml

Example 2

[0229] The embodiments described herein demonstrate *Cannabis* floral dip experiments.

[0230] We used strain Ar18r12v based on positive GUS transients in meristem explants, harboring DICOTBINARY-22, which has the aadA1a protein targeted to both plastid and mitochondria in the plants. *Agrobacterium* cultures were resuspended in 5% sucrose with 0.05% silwet L-77 as a wetting agent. One of the cultures was induced with 100 uM acetosyringone and one was not. These cultures were applied directly to female flowers (some flowers received only 5% sucrose+0.05% silwet L-77 "blank"). Experiment is summarized in Table 11.

TABLE 11

Description and summary of experiments with Cannabis floral dip

Experiment ID	Comments AS	Co-Culture Duration (Days)	Observations and Comments
Hrmp 4/17-1	Agro washed once with none sterile water; spun 10 min, resuspended in 5% sucrose; Silwet L-77 added to 0.05%	Agro applied directly to flowers; 1d dark in high humidity LEDA; then moved to GH7 with 3 males	5 female plants; 3 hermaphrodites (red/white twist tie below flower for inoculated, white for blank)
Hemp 4/17-2	Agro washed once with 100 uM AS sterile water; spun 10 min, resuspended in 5% sucrose; Silwet L-77 added to 0.05%	Agro applied directly to flowers; 1d dark in high humidity LEDA; then moved to GH7 with 3 males	5 female plants; 3 hermaphrodites (green twist tie below flower for inoculated, white for blank)

[0231] We noted no obvious ill effects of the inoculum application to the flowers one-day post-application. See FIG. **5**. Female flowers were then pollinated with male pollen from donor plants by dusting the plants with pollen; as well as using a paint brush to apply pollen earlier.

Example 3

[0232] The embodiments described herein demonstrate *Cannabis* node, internode, leaf, and petiole transformation experiments.

[0233] We inoculated node, internode, leaf, and petiole explants of *Cannabis* variety Elektra x Chardonnay. We used aseptically grown plantlets from sanitized and imbibed seed plated on non-selective B5 media for approximately 6 weeks. Explants were sonicated for 20 seconds at ~45 kHz in the presence of Ar18r12v/DICOTBINARY-19. Nodal explants were co-cultured on 2.5 ml WCIC INO media with 50 mg/L nystatin, 10 mg/L TBZ, and 0.5 mg/L meta-topolin (mT). Internode, leaf, and petiole explants were co-cultured on 2.5 ml WCIC INO media with 50 mg/L nystatin, 10 mg/L TBZ, 1 mg/L meta-topolin (mT), 1 mg/L napthylacetic acid (NAA), and 0.2 mg/L GA3. After 4 days of co-culture at 23 C 16/8 photoperiod, GUS transient expression was observed in all explant types. See FIG. **6**.

[0234] After co-culture, nodal explants were transferred to 100 mg/L spectinomycin hemp node media (Table 7) supplemented with 500 mg/L activated charcoal. Leaf, petiole, and internode explants were transferred to 100 mg/L spectinomycin hemp internode media, which is a modification of potato ZIG media (Cearley J A, Bolyard M G: Regeneration of *Solanum tuberosum* cv. Katandin from leaf explants in

vitro. Am Potato J 74: 125-129 (1997)). A summary of these experiments is provided in Table 13.

TABLE 12

WCIC Hemp Internode Media (modified from Cearley 1997)

Ingredients and Notes	Amount to add per liter (grams)
MS Salts complete with vitamins (PhytoTech M519)	4.43
Sucrose	20
Cleary's 3336	0.06
pH to 5.7 with 1 N KOH	
Gelrite (or Phytagel), then autoclave	2
Meta-topolin (mT) (1 mg/ml)	1 ml
Napthylacetic acid (NAA) (1 mg/ml)	1 ml
GA3 (FS) Sigma Prod G7645 (1 mg/ml)	0.2 ml
Carbenicillin (200 mg/ml)	1.25 ml
Cefotaxime (100 mg/ml)	2 ml
Selection	as needed

pollen from male plants can be stored. *Cannabis* pollen was harvested in by shaking branches of male plants onto a creased sheet of blue paper (high visibility of yellow on blue). Pollen was poured through a #80 sieve into a 50 mL conical tube. A small, visible amount of pollen was added to 7 1.5 mL microfuge tubes comprising the following treatments:

[0237] 1. 25% glycerol (w/v) PGM, inverted several times to mix and stored at −20 C.

[0238] 2. 25% glycerol (w/v) PGM, inverted several times to mix and stored at 4 C

[0239] 3. Untreated, fresh pollen, stored at 4 C

[0240] 4. Untreated pollen, stored at −20 C

[0241] 5. Pollen placed in 1.5 mL microfuge tube, placed in sweater box with MgNO3 solution. Moved to −20 C on 5/3 at 11 am.

[0242] 6. 25% w/g glycerol PGM, 1 hour incubation at RT, followed by storage at −80 C

[0243] 7. One hour untreated at room temperature in 50 mL tube.

TABLE 13

Description and summary of experiments with Cannabis nodes, leaves, petioles, and internodes.

Experiment ID	Comments	# embryos to Selection	Notes	# explants to second media	2nd media
Hemp 5/2-1	Nodes from hemp seed sanitized and imbibed; germinated on B5 3/22/19; harvested in INO; inoculated and sonicated 20s 45 kHz; co-cultured in plantcons with filter paper + 2.5 ml INO with 50 ppm nystatin +10 ppm TBZ + .5 ppm meta-topolin (mT); 23 C. 16/8 photoperiod	11	100 ppm spec hemp node media; 28 C. 16/8/photoperiod	NA	NA
Hemp 5/2-2	Leaves from hemp seed sanitized and imbibed; germinated on B5 3/22/19; harvested in INO; inoculated and sonicated 20s 45 kHz; co-cultured in plantcons with filter paper + 2.5 ml INO with 50 ppm nystatin + 10 ppm TBZ + 1 ppm meta-topolin (mT) + 1 ppm NAA + 0.2 ppm GA3; 23 C. 16/8 photoperiod	68	100 ppm spec hemp internode media; 28 C. 16/8/photoperiod	18	non selective hemp node media; 28 C. 16/8/photoperiod
Hemp 5/2-2	Petioles from hemp seed sanitized and imbibed; germinated on B5 3/22/19; harvested in INO; inoculated and sonicated 20s 45 kHz; co-cultured in plantcons with filter paper + 2.5 ml INO with 50 ppm nystatin + 10 ppm TBZ + 1 ppm meta-topolin (mT) + 1 ppm NAA + 0.2 ppm GA3; 23 C. 16/8 photoperiod	68	100 ppm spec hemp internode media; 28 C. 16/8/photoperiod	3	non selective hemp node media; 28 C. 16/8/photoperiod
Hemp 5/2-2	Internodes from hemp seed sanitized and imbibed; germinated on B5 3/22/19; harvested in INO; inoculated and sonicated 20s 45 kHz; co-cultured in plantcons with filter paper + 2.5 ml INO with 50 ppm nystatin + 10 ppm TBZ + 1 ppm meta-topolin (mT) + 1 ppm NAA + 0.2 ppm GA3; 23 C. 16/8 photoperiod	68	100 ppm spec hemp internode media; 28 C. 16/8/photoperiod	3	non selective hemp node media; 28 C. 16/8/photoperiod

Example 4

[0235] *Cannabis* meristem explants were excised, dried, and stored at −20 C. *Cannabis* meristem explants of variety 3WS were excised from seed and then dried on the surface of filter paper in a laminar flow hood for 26 hours. Dried *Cannabis* meristem explants were then stored at −20 C for 3 days. Explants were then rehydrated in 20% PEG4000 with 60 mg/L Captan and 30 mg/L Bravo fungicides, rinsed, and plated on Hemp Node media without activated charcoal (Table 7).

Example 5

[0236] This embodiment describes the transformation of *Cannabis* pollen, in particular the advantages provided when

[0244] The same day pollen was harvested, pollen from tubes #6,7 were placed onto solid PGM after one hour of incubation at room temperature. Plates were then wrapped in parafilm and placed in dark room and examined under microscope for germination in the form of pollen tube expansion. Germination of tubes was visible on both. Tube emerged more quickly from pollen from tube #6, which may be due to the liquid PGM matrix. Germination continue onto the next day, 22 hours after plating. See FIG. **24**.

[0245] To test for overnight storage, we assayed pollen for germination the next day. Pollen from tubes 1,4 and 6 were placed on ice to thaw. After half an hour, a small amount of pollen from each was added to a PGM plate partition. 50 uL of pollen was taken from 1 & 6. Tube 6 was noticeably more opaque than tube 1. Tube germination was visible only in

treatment #1. Multiple, branched tube-like structures were visible in treatment #4 at T2 (overnight storage) which may have been aberrant germination or the first indications of fungal hyphae. Following 24H of incubation, tube germination was visible in the −20° C. stored pollen that was stored in 25% (w/v) glycerol PGM. No survival was observed in either −80° C. treatment, which perhaps indicates that a slower rate of freezing is important for retaining viability. See FIG. **35**.

TABLE 14

Pollen Germination Medium - Salts II Solution (PGM2 Salts)
Pollen Germination Medium Salts II Solution (PGM2 Salts)

Stock (100X) Reagent	Volume: 10 mL CAS	g/10 mL	Original Units	100 mL stock grams added
Boric Acid (H3BO3)	0043-35-3	0.05	0.005%	0.5
CaCl2*2H2O	10035-04-8	1.47	10 mM	14.7
Potassium Phosphate, monobasic (KH2PO4)	7778-77-0	0.00680	0.05 mM	0.068
ddH2O (dissolve salts) dissolve by stirring and/or sonication		Add 8 mL		Add 80 mL
ddH2O		Fill to 10 mL w/ graduated cylinder		Fill to 100 mL w/ graduated cylinder

TABLE 15

2X PGM (Pollen Germination Medium)
2X Pollen Germination Medium

Volume	1 L	
	amount	units
PGM Salts	10	mL
Sucrose	100	g
PEG 4000	600	g
ddH2O	Fill to 1 L	
Heat to 70 C. for 10 minutes on stir plate.		
Filter sterilize.		
Store at 4 C.		

TABLE 16

Solid Pollen Germination Medium
Solid Pollen Germination Medium

Volume	1 L	
	amount	units
2X PGM	500	mL
0.6% Noble Agar	500	mL

TABLE 17

25% glycerol PGM
25% glycerol PGM

Volume	1 L	
	amount	units
2X PGM	500	mL
50% (w/y) glycerol	500	mL

Example 6

[0246] *Cannabis* value added explants (VAEs) were generated by hand excising meristem tissue from seeds surface sanitized in 20% Clorox for 5 min, rinsed, and imbibed for ~20 h in BGM. *Cannabis* VAEs of variety 3WS were excised from seed, then dried on the surface of a filter paper in a laminar flow hood for 26 hours. Dried *Cannabis* meristem explants were then stored at −20 C for 3 days. Explants were then rehydrated in 20% PEG4000 with 60 mg/L Captan and 30 mg/L Bravo fungicides, rinsed, and plated on Hemp Node media without activated charcoal. FIG. **29** shows dried *Cannabis* VAEs after 5 weeks plated on non-selective medium. FIG. **30** shows machine excised *Cannabis* meristem explants on non-selective medium for 2 weeks.

[0247] *Cannabis* VAEs may also be primed with WCIC INO or other medium prior to drying. Examples of priming and drying conditions are outlined below. These examples are for soybean transformations but are applicable to *Cannabis* VAE priming and drying and the same or similar conditions may be used with *Cannabis* explants.

TABLE 18

Priming and Drying of Explants (Soybean genotype W28, strain GV3101)

VAE Batch/Priming	Co-culture	Ex-plants	Shoots har-vested	T0 plants to GH	TF
Fresh explants giving rise to S92 series	1 ppm TDZ	75	6	3	4.0%
Fresh explants giving rise to S92 series	no TDZ	71	3	3	4.2%
S92A (std dry)	1 ppm TDZ	75	8	4	5.3%
S92B (3 hr prime in INO, then dry)	1 ppm TDZ	50	10	10	20.0%
S92C (3 hr prime in INO with 1 ppm TDZ, then dry)	1 ppm TDZ	75	9	6	8.0%
S92D (3 hr prime in INO with 10 ppm TDZ, then dry)	1 ppm TDZ	50	0	0	0.0%
S92E (3 hr prime in INO with 50 ppm TDZ, then dry)	1 ppm TDZ	63	0	0	0.0%

TABLE 18-continued

Priming and Drying of Explants (Soybean genotype W28, strain GV3101)

VAE Batch/Priming	Co-culture	Ex-plants	Shoots har-vested	T0 plants to GH	TF
S92E (3 hr prime in INO with 100 ppm TDZ, then dry)	1 ppm TDZ	50	0	0	0.0%

Example 7

[0248] This example demonstrates additional embodiments of the transformation methods and transgenic *Cannabis* plants described herein.

[0249] T1 data/POC of germline transformation of *Cannabis* using meristem explants: A leaf sample of *Cannabis* T0 event WP421-1 (plant "Candice") was taken for long-term storage at −80 for further genetic analysis, and at this time we took sections of the petiole as well for GUS expression analysis. FIG. **36** shows GUS expression in the vascular tissue of WP421-1, which is an indicator of germline status for the transgene.

[0250] WP421-1 was moved to short days in GH15 approximately 9 weeks after plant handoff to greenhouse. 10 cuttings were taken 2 days later. Some cuttings had roots approximately 2 weeks after cuttings were taken. First flowers (female) observed 5 days after moving plant to short days. WP421-1 was move into GH9 2 weeks after being put in short-day to be exposed to pollen from the 3WS 2-5 auto-flowering male. FIG. **37** shows WP421-1 adjacent to the male pollen donor wild-type 3WS plant.

[0251] 2.5 weeks after pollination with male 3WS plant, immature T1 seed of WP421-1 was planted. We noted RFP+ expression (tdTomato) in one of the seedlings 3.5 weeks after this (in plantlet "Carly"), confirming germline transmission of transgene. (FIG. **40**)

[0252] We followed this observation up with additional RFP expression (tdTomato) observations (eliminating background in a null segregant and in a wild-type leaf), GUS expression, and an aadA1a PCR that produced the expected 156 bp amplicon. (FIGS. **41** and **42**). Approximately 5250 T1 seed were harvested from WP421-1 approximately 2 months after pollination was initiated (FIG. **43**). We germinated T1 seed of WP421-1 on germination paper and planted a flat of T1 seed to examine more plants for RFP expression (tdTomato) and segregation. RFP expression (tdTomato) was apparent along with null segregants (FIG. **44**)

[0253] Of the 48 T1 WP421-1 seed planted in flats, 44 germinated and were designated WP421-1@3 through WP421-1@46. 22 of these 44 expressed RFP (tdTomato) and GUS, giving the expected 1:1 segregation ratio for this cross. (FIG. **45**)

[0254] Additional *Cannabis* transformation experiments using meristem explants: Additional experiments with *Cannabis* meristem explants inoculated with Ar18r12v/DICOT-BINARY-19 using 75 mg/L spectinomycin selection have yielded plantlets chimeric for GUS as well as greening plantlets that are GUS negative. These chimeric plantlets did not root on the subsequent 50 mg/L streptomycin media and were instead transferred to selection-free BRM (FIG. **48**). One chimeric GUS+ plant (center photo in FIG. **48**) from this set rooted on selection-free BRM and was sent to the greenhouse as the T0 plant WP421-2, but we could not detect positive GUS or RFP expression or transgene integration by PCR in subsequent tests of WP421-2, possibly indicating negative sectors of the plant outcompeted transgenic sector (FIG. **49**).

[0255] We have regenerated a transgenic *Cannabis* plantlet from particle-mediated transformation that is stably expressing GUS in all it leaves. *Cannabis* explants prepared from seed germinated at 37 C overnight of variety 3WS were precultured on EJW1 overnight and blasted on carboxymethylcellulose media using DICOTBOMB-13 (at 1.2 ng DNA/ug gold; 0.6 um gold; 1 cm gap, 6 cm distance, and 1350 psi).

[0256] Explants were rested on EJW1 overnight, then transferred to 100 mg/L spectinomycin hemp node media without activated charcoal for 1 month. Explants were then transferred to 50 mg/L streptomycin hemp regeneration media with 1 mg/L meta-topolin (mT). Leaves were sampled from greening explant and incubated in X-gluc at 37 C. Stable GUS expression was present in every leaf, demonstrating POC of particle-mediated transformation of *Cannabis* meristem explants (FIG. **51**).

Example 8

[0257] Transgenic T0 *Cannabis* Plant Generation Using Particle-Mediated Transformation of *Cannabis* Meristem Explants

[0258] The regenerating transgenic *Cannabis* plantlet from particle-mediated transformation stably expressing GUS in all it leaves from last report has rooted and been sent to GH as T0 plant WP-001181-1. This T0 plant was derived from *Cannabis* meristem explants prepared from seed germinated at 37 C overnight of variety 3WS. Meristem explants were precultured on EJW1 overnight and blasted on carboxymethylcellulose media using DICOTBOMB-13 (at 1.2 ng DNA/ug gold; 0.6 um gold; 1 cm gap, 6 cm distance, and 1350 psi). Explants were rested on EJW1 overnight, then transferred to 100 mg/L spectinomycin hemp node media without activated charcoal for 1 month (media previously described). Explants were then transferred to 50 mg/L streptomycin hemp regeneration media with 1 mg/L meta-topolin (mT) for 6 weeks (media previously described). We then attempted to root this explant by transferring it to: (i) 4 weeks on 50 mg/L streptomycin hemp node media after cutting hypocotyl to remove necrotic tissue; (ii) 2 weeks on non-selective B5 media; (iii) 6 weeks on non-selective dicot BRM media (½ MS salts with 0.1 mg/L IAA); (iv) Explant split into two; hypocotyl cut on each piece to remove necrotic tissue; and (v); 4 weeks (plant "A") to 7 weeks (plant "B") on non-selective dicot BRM media. We re-assayed leaves for GUS and found all leaves remained GUS+. (FIG. **52**).

[0259] After the WP-001181a event had been in the greenhouse for 3 weeks, we used the previously described primer set and PCR conditions to amplify a 156 bp fragment of the aadA1a gene from 10 separate leaves. At the same time, we assayed these leaves for GUS expression (each leaf sample was divided in 2, one sample for PCR, one for GUS assay). All 10 leaves tested positive for aadA1a by PCR, and all 10 were GUS positive (FIG. **53**).

[0260] Previous examples described taking petiole sections of the *Cannabis* T0 event WP421-1 to examine GUS expression in vascular tissue, which appeared to be an early

indicator of germline status in the *Cannabis* WP421-1 T0 event, and found GUS expression to be present in vascular tissue of WP001181-1a as well (FIG. **56**). The second piece of this explant rooted approximately 3 weeks after the first, and was sent to greenhouse after finding all leaves GUS+ (FIG. **57**). The ability to split the event into two T0 plants in the meristem transformation system may offer some downstream advantages. It may be possible to feminize either the WP-001181-1a or WP-001181-1b to make subsequent flowers male (process described later). Crosses from -1a onto -1b would then yield homozygotes in the T1 progeny, which may offer timing advantages for transgenic *Cannabis* breeding programs (and advantages to attempting to make hermaphroditic plants for same purpose).

[0261] DNA complexed with gold "bead prep" was made by these steps:

[0262] Sonicate 50 mg/1 ml EtOH gold suspension for 3 min 45-55 kHz to resuspend gold.

[0263] Transfer 42 ul to a new tube. Pellet by centrifugation at 2500 rpm for 10 seconds, remove EtOH.

[0264] Add 500 uL sterile water, sonicate 3 min 45-55 kHz. Pellet by centrifugation at 2500 rpm for 10 seconds, remove water.

[0265] Add 25 ul sterile water (wash sides of tube with pipette tip). Sonicate 3 min 45-55 kHz.

[0266] Add 2.6 ug DNA

[0267] Add cold sterile water to bring volume up to 245 ul.

[0268] Add 250 ul cold 2.5 M CaCl2.

[0269] Add 50 ul 0.1 M spermidine

[0270] Mix solution by low speed vortexing. Incubate tube on ice for at least 45 min (I usually go 1.5 hrs). Invert tube every 5-10 minutes.

[0271] Once coating is done, pellet the DNA/gold at 1000 rpm (~100×g) for 2 min. Remove supernatant.

[0272] Wash pellet with 1 ml 100% EtOH w/ pipette tip. Pellet DNA/gold at 1000 rpm (~100×g) for 2 min. Remove EtOH.

[0273] Add 36 ul 100% EtOH, completely resuspend gold with low-speed vortexing.

[0274] Store at −20 C, we generally use 5 ul of this prep per bombardment.

[0275] This DNA prep gives a DNA Loading Rate of 1.2 ng DNA/ug gold (360 ng DNA per blast, 290 ug gold per blast).

[0276] CMC targeting media includes 8% low viscosity carboxymethylcellulose, 2% medium viscosity carboxymethylcellulose, and 0.4% washed agar. CMC was made by adding washed agar to water, autoclaving, pouring into blender, adding carboxymethylcellulose, blending, pouring into bottle, then re-autoclaving, then poured into plates or stored.

[0277] EJW1 media is shown above in Table 10.

TABLE 19

BRM media

Ingredients and Notes	Amount to add per liter (grams)
MS Salts no vitamins M524	2.15
myo-inositol	0.1

TABLE 19-continued

BRM media

Ingredients and Notes	Amount to add per liter (grams)
sucrose	30
pH 5.8 with KOH	
Agar, Sigma A7921	8
Autoclave	
Add after autoclaving	
Cysteine (100 mg/ml) - make stock fresh	Use at 1.0 ml per Liter (100 mg/L)
Cefotaxime (100 mg/ml)	Use at 2.0 ml per Liter (200 mg/L)
IAA (1 mg/ml)	Use at 0.1 ml per Liter (0.1 mg/L)
MS Vitamins (1000X)	Use at 1.0 ml per Liter
Selection	as needed

[0278] It should also be possible to transform Cannabis meristem explants with free DNA methods where the explants do not require targeting (i.e. nanotechnology such as cell penetrating peptides, silica carbide fibers or others; as well as use of lipid and/or cationic lipid compounds).

[0279] Transient transformation of storable *Cannabis* meristem explants excised from seed using automation: We have demonstrated transient expression of GUS in meristem explants of the Fiber Hemp variety using meristem explants excised from seed using automation (described in comments to application sent in July 2019) with H1-H5 fractions pooled. These explants had been stored at −20 C for x weeks before rehydration in INO+60 mg/L Cleary's and inoculation with Ar18r12v/DICOTBINARY-19. Presence of GUS also indicates cells remained viable during this ~8 month storage time. (FIG. **58**).

[0280] Cannabis seeds can also be crushed to extract mature embryos using a metal rolling pin on a glass plate, with an adjustable gap made using shims (FIG. **59**). *Cannabis* seed of the Abacus variety was sanitized and imbibed overnight at 23 C. Seed was then either crushed under the rolling pin, with crushed material allowed to dry in a laminar flow hood for 72 hours; or seed was dried first for 72 hours in laminar flow hood and then crushed. Crushed material was stored at −20 C for 2 months, then rehydrated in INO media with 60 mg/L Cleary's fungicide. Explants were inoculated with Ar18r12v/DICOTBINARY-19 and co-cultured as previously described. We noticed transient GUS expression in meristem explants, again indicating cells were capable of surviving storage as well as maintaining some competency for *Agrobacterium* transformation (FIG. **60**). This crushing technology and roller technology can be applied to wet or dry Cannabis seed, and can be used in conjunction with other treatments to compromise seed coat (ex. seed placed in paint shaker with a metal bead or beads).

[0281] Transient transformation of elite Abacus *Cannabis* variety using *Agrobacterium*-mediated transformation of meristem explants: We have also demonstrated transient expression of GUS in meristem explants of the elite Abacus variety using meristem explants inoculated with Ar18r12v/DICOTBINARY-19 (derived from seed imbibed overnight at 23 C) (FIG. **61**).

[0282] Transmission of transgenes into T2 generation of *Cannabis* 3WS variety (from initial T0 event WP421-1): The previously described GUS positive, RFP (tdTomato) positive, and aadA positive T1 plant WP421-1@2 and cuttings from this plant (WP421-1-08C; WP421-1-10C; WP421-1-07C; WP421-1-02C) were used to examine transmission of transgenes into the T2 generation. This T1 plant and its cuttings were pollinated with pollen from a separate

GUS positive and RFP positive feminized WP421-1 T1 plant. Feminization stresses the female plant out enough that it is making male structures that have female genetic pollen, Seed is feminized from the subsequent crosses (all female). Three main substances can be used: Colloidal Silver Solution (~120 ppm); Silver Thiosulfate/Silver Nitrate (STS); or GA3. These chemicals reduce ethylene production that ordinarily helps ripening and the production of female flowers. Temperature or other stresses can cause feminization as well. This T1 plant was feminized by the following procedure. 5 days before moving plants to short days (i.e., 12 hour light periods), all branches and leaves of the plants were sprayed to saturation with ether the STS or Colloidal Silver solution. The spraying was repeated every 5 days until major male flower formation has begun. Usually male flowers begin showing at about 16-20 days after initial spraying and spraying finished after 25-30 days. Resulting T2 seeds were harvested and germinated and imaged for RFP expression. These crosses gave rise to the expected 3:1 segregation ratio (from both parents segregating 1:1), and the 3:1 ratio should include 1 homozygote, 2 hemizygotes and 1 null at T2.

TABLE 20

RFP segregation ratios in T2 Cannabis lines derived from transformed meristem explants.

Cannabis line	Ratio
WP421-1@2	10/15 positive
WP421-1-08C	13/18 positive
WP421-1-10C	16/18 positive
WP421-1-07C	13/18 positive
WP421-1-02C	12/16 positive
Total	64/85 positives

Example 9

[0283] The reduction or elimination of THC will be accomplished by knocking out the THCA synthase gene using a CRISPR/Cas9 gene editing approach. *Cannabis* has two genes that contribute to THC production, namely THCA synthase (primary) and CBDA synthase (secondary). It is postulated that in high CBD varieties of *Cannabis*, the THCA synthase gene(s) are either inactive or highly suppressed. Since CBDA synthase has about an 84% amino acid similarity to THCA synthase, it is also possible that it also plays a role in producing the low amounts of THC seen in these varieties. The proposed CRISPR approach includes a gRNAs designed to target both the THCA synthase as well as the CBDA synthase resulting in plants with single gene knockouts as well as knockouts for both genes. Plants produced from this editing approach would be analyzed with our UPLC to determine the content of 13 different cannabinoids including THCA, CBDA, and CBG. In general, high CBD varieties of cannabis have a CBDA:THCA ratio of 20:1 to 27:1 and these compounds are tightly related to each other (i.e. as CBDA goes up so does THCA). A potential outcome of this editing approach may also be a plant that is skewed with a higher ratio of CBDA:THCA, again reducing the risk to the grower of cultivating plants producing THC as well as producing more CBDA. Another possible outcome of knocking out both THCA synthase and CBD synthase would be the accumulation of the precursor compound CBG. A plant high in CBG is also a highly valued product due to the fact that the plant would normally make very little CBG and thus is a cannabinoid in higher demand.

[0284] A big risk to farmers trying to maximize their CBD amounts in their *Cannabis* plants, is pollination from male plants in the population or form adjacent fields. Pollination of female plants substantially reduces the amount of CBD made by the plants due to the reduction of trichome producing pistils and energy going toward making seed, which is low in CBD. Huang et al. successfully expressed the Solo Dancers and Barnase genes using a fusion gene, which resulted in fully sterile male/female flowers in *Arabidopsis* and tobacco without affecting growth or development. Since *Cannabis* can be easily cloned from a "mother" plant as demonstrated herein, a female sterile plant could be of high value to the grower in eliminating the risk of pollination to the crop.

[0285] Increasing trichome numbers: Cannabinoids are mainly made and secreted in the trichomes of the cannabis plant, and more specifically the trichomes associated with female flowers (pistils) of the plant. Increasing the number of trichomes will increase the total cannabinoid production in the plant. Tian, et al. successfully overexpressed the BraLTP2, a lipid transfer protein from *Brassica napus*, resulting in a 10-fold increase of trichomes in *B. napus*. The transgenic lines also produce elevated levels of 43 different secondary metabolites, which could also prove interesting to the amount and type of cannabinoids made in a transgenic cannabis plant with overexpression of this type of gene. LTPs belong to a large multigene family with many complex physiological functions. We have identified similar genes in the cannabis genome and propose to overexpress both the *B. napus* BraLTP2 as well as some homologues from cannabis. These genes could be driven by either a constitutive or flower/pistil specific promoter to drive these potential outcomes. Transgenic plants would be visually screened for an increase in trichomes as well as tested for cannabinoid content using our UPLC.

[0286] High CGBA plants: The CsPT1 ((geranylpyrophosphate:olivetolate geranyltransferase (GOT)) gene is involved in the production of CBGA, the precursor to THCA and CBDA. By overexpressing this gene, it may be possible to increase the amount of CBGA in the plant resulting in the increase of the downstream cannabinoids CBDA ad THCA. This approach could also be used in conjunction with knocking out the THCA synthase gene and ultimately making a very high CBDA plant with little or no THCA.

[0287] Herbicide resistant plants: Like many other plants, cannabis has an EPSP Synthase gene. It is known that changes to 1-3 amino acids in this gene tend to confer glyphosate resistance to the plant. Since weed pressure in cannabis is high due to the competition of weeds before its canopy is established, this would be a good target. Currently there are no federally registered pesticides for cannabis. A gene editing is used to make the required amino acid substitutions, and produce a glyphosate resistant cannabis plant.

Example 10

[0288] Transgenic T0 *Cannabis* plant generation using particle-mediated transformation of *Cannabis* meristem explants—We tested 10 leaves of the twin particle gun event described in Example 8, WP-001181-1b "Hernanda" for aadA1a by PCR and GUS by expression and all 10 leaves

were positive. (FIGS. **72-74**). As described herein (Example 2), it is also possible to transform plastids and/or proplastids of *Cannabis* meristem explants using plastid specific promoters driving aadA (and GOI) such as the large subunit promoter of RUBISCO; or a suitable prokaryotic promoter. This would give advantages of plastid transformation (maternal inheritance with null pollen, whole operon engineering, greater protein expression, etc.) in *Cannabis* and *Cannabis* breeding.

[0289] Alternate seed conditioning without imbibition—We were able to get radical emergence from *Cannabis* seed of the Badger variety using seed sanitization followed by incubation at 37° C. without imbibition. This enables new forms of both hand and machine excision and storage (as seed coat is split but at relatively low moisture compared with imbibed seed). (FIG. **75**)

[0290] Transient transformation and Stable expression of RFP (tdTomato) in Badger variety using *Agrobacterium*-mediated transformation of meristem explants—We have also demonstrated transient expression of GUS in meristem explants of the elite Badger variety using meristem explants inoculated with Ar18r12v/DICOTBINARY-19 (derived from seed imbibed overnight at 23° C. or 37° C.) under a variety of co-culture conditions (FIGS. **76-78**).

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 61

<210> SEQ ID NO 1
<211> LENGTH: 1638
<212> TYPE: DNA
<213> ORGANISM: Cannabis sativa

<400> SEQUENCE: 1

atgaattgct cagcattttc cttttggttt gtttgcaaaa taatattttt ctttctctca 60

ttccatatcc aaatttcaat agctaatcct cgagaaaact tccttaaatg cttctcaaaa 120

catattccca acaatgtagc aaatccaaaa ctcgtataca ctcaacacga ccaattgtat 180

atgtctatcc tgaattcgac aatacaaaat cttagattca tctctgatac aaccccaaaa 240

ccactcgtta ttgtcactcc ttcaaataac tcccatatcc aagcaactat tttatgctct 300

aagaaagttg gcttgcagat tcgaactcga agcggtggcc atgatgctga gggtatgtcc 360

tacatatctc aagtcccatt tgttgtagta gacttgagaa acatgcattc gatcaaaata 420

gatgttcata gccaaactgc gtgggttgaa gccggagcta cccttggaga agtttattat 480

tggatcaatg agaagaatga gaatcttagt tttcctggtg ggtattgccc tactgttggc 540

gtaggtggac actttagtgg aggaggctat ggagcattga tgcgaaatta tggccttgcg 600

gctgataata ttattgatgc acacttagtc aatgttgatg gaaaagttct agatcgaaaa 660

tccatgggag aagatctgtt ttgggctata cgtggtggtg gaggagaaaa ctttggaatc 720

attgcagcat ggaaaatcaa actggttgat gtcccatcaa agtctactat attcagtgtt 780

aaaaagaaca tggagataca tgggcttgtc aagttattta acaaatggca aaatattgct 840

tacaagtatg acaaagattt agtactcatg actcacttca taacaaagaa tattacagat 900

aatcatggga agaataagac tacagtacat ggttacttct cttcaatttt tcatggtgga 960

gtggatagtc tagtcgactt gatgaacaag agctttcctg agttgggtat taaaaaaact 1020

gattgcaaag aatttagctg gattgataca accatcttct acagtggtgt tgtaaatttt 1080

aacactgcta attttaaaaa ggaaattttg cttgatagat cagctgggaa gaagacggct 1140

ttctcaatta agttagacta tgttaagaaa ccaattccag aaactgcaat ggtcaaaatt 1200

ttggaaaaat tatatgaaga agatgtagga gctgggatgt atgtgttgta cccttacggt 1260

ggtataatgg aggagatttc agaatcagca attccattcc ctcatcgagc tggaataatg 1320

tatgaacttt ggtacactgc ttcctgggag aagcaagaag ataatgaaaa gcatataaac 1380

tgggttcgaa gtgtttataa ttttacgact ccttatgtgt cccaaaatcc aagattggcg 1440

tatctcaatt atagggacct tgatttagga aaaactaatc atgcgagtcc taataattac 1500

-continued

acacaagcac gtatttgggg tgaaaagtat tttggtaaaa attttaacag gttagttaag 1560

gtgaaaacta aagttgatcc caataatttt tttagaaacg aacaaagtat cccacctctt 1620

ccaccgcatc atcattaa 1638

<210> SEQ ID NO 2
<211> LENGTH: 1638
<212> TYPE: DNA
<213> ORGANISM: Cannabis sativa

<400> SEQUENCE: 2

atgaattgct cagcattttc cttttggttt gtttgcaaaa taatattttt ctttctctca 60

ttccatatcc aaatttcaat agctaatcct cgagaaaact tccttaaatg cttctcaaaa 120

catattccca acaatgtagc aaatccaaaa ctcgtataca ctcaacacga ccaattgtat 180

atgtctatcc tgaattcgac aatacaaaat cttagattca tctctgatac aaccccaaaa 240

ccactcgtta ttgtcactcc ttcaaataac tcccatatcc aagcaactat tttatgctct 300

aagaaagttg gcttgcagat tcgaactcga agcggtggcc atgatgctga gggtatgtcc 360

tacatatctc aagtcccatt tgttgtagta gacttgagaa acatgcattc gatcaaaata 420

gatgttcata gccaaactgc gtgggttgaa gccggagcta cccttggaga agtttattat 480

tggatcaatg agaagaatga gaatcttagt tttcctggtg ggtattgccc tactgttggc 540

gtaggtggac actttagtgg aggaggctat ggagcattga tgcgaaatta tggccttgcg 600

gctgataata ttattgatgc acacttagtc aatgttgatg gaaaagttct agatcgaaaa 660

tccatgggag aagatctgtt ttgggctata cgtggtggtg gaggagaaaa ctttggaatc 720

attgcagcat ggaaaatcaa actggttgct gtcccatcaa agtctactat attcagtgtt 780

aaaaagaaca tggagataca tgggcttgtc aagttattta acaaatggca aaatattgct 840

tacaagtatg acaaagattt agtactcatg actcacttca taacaaagaa tattacagat 900

aatcatggga agaataagac tacagtacat ggttacttct cttcaatttt tcatggtgga 960

gtggatagtc tagtcgactt gatgaacaag agctttcgtg agttgggtat taaaaaaact 1020

gattgcaaag aatttagctg gattgataca accatcttct acagtggtgt tgtaaatttt 1080

aacactgcta attttaaaaa ggaaattttg cttgatagat cagctgggaa gaagacggct 1140

ttctcaatta agttagacta tgttaagaaa ccaattccag aaactgcaat ggtcaaaatt 1200

ttggaaaaat tatatgaaga agatgtagga gctgggatgt atgtgttgta cccttacggt 1260

ggtataatgg aggagatttc agaatcagca attccattcc ctcatcgagc tggaataatg 1320

tatgaacttt ggtacactgc ttcctgggag aagcaagaag ataatgaaaa gcatataaac 1380

tgggttcgaa gtgtttataa ttttacgact ccttatgtgt cccaaaatcc aagattggcg 1440

tatctcaatt atagggacct tgatttagga aaaactaatc atgcgagtcc taataattac 1500

acacaagcac gtatttgggg tgaaaagtat tttggtaaaa attttaacag gttagttaag 1560

gtgaaaacta aagttgatcc caataatttt tttagaaacg aacaaagtat cccacctctt 1620

mcaccgcatc atcattaa 1638

<210> SEQ ID NO 3
<211> LENGTH: 1635
<212> TYPE: DNA
<213> ORGANISM: Cannabis sativa

-continued

<400> SEQUENCE: 3

atgaattgct cagcattttc cttttggttt gtttgcaaaa taatattttt ctttctctca 60

ttccatatcc aaatttcaat agctaatcct cgagaaaact tccttaaatg cttctcaaaa 120

catattccca acaatgtagc aaatccaaaa ctcgtataca ctcaacacga ccaattgtat 180

atgtctatcc tgaattcgac aatacaaaat cttagattca tctctgatac aaccccaaaa 240

ccactcgtta ttgtcactcc ttcaaataac tcccatatcc aagcaactat tttatgctct 300

aagaaagttg gcttgcagat tcgaactcga agcggtggcc atgatgctga gggtatgtcc 360

tacatatctc aagtcccatt tgttgtagta gacttgagaa acatgcattc gatcaaaata 420

gatgttcata gccaaactgc gtgggttgaa gccggagcta cccttggaga agtttattat 480

tggatcaatg agaagaatga gaatcttagt tttcctggtg ggtattgccc tactgttggc 540

gtaggtggac actttagtgg aggaggctat ggagcattga tgcgaaatta tggccttgcg 600

gctgataata ttattgatgc acacttagtc aatgttgatg gaaaagttct agatcgaaaa 660

tccatgggag aagatctgtt ttgggctata cgtggtggtg gaggagaaaa ctttggaatc 720

attgcagcat ggaaaatcaa actggttgct gtcccatcaa agtctactat attcagtgtt 780

aaaaagaaca tggagataca tgggcttgtc aagttattta acaaatggca aaatattgct 840

tacaagtatg acaaagattt agtactcatg actcacttca taacaaagaa tattacagat 900

aatcatggga agaataagac tacagtacat ggttacttct cttcaatttt tcatggtgga 960

gtggatagtc tagtcgactt gatgaacaag agctttcctg agttgggtat taaaaaaact 1020

gattgcaaag aatttagctg gattgataca accatcttct acagtggtgt tgtaaatttt 1080

aacactgcta attttaaaaa ggaaattttg cttgatagat cagctgggaa gaagacggct 1140

ttctcaatta agttagacta tgttaagaaa ccaattccag aaactgcaat ggtcaaaatt 1200

ttggaaaaat tatatgaaga agatgtagga gctgggatgt atgtgttgta cccttacggt 1260

ggtataatgg aggagatttc agaatcagca attccattcc ctcatcgagc tggaataatg 1320

tatgaacttt ggtacactgc ttcctgggag aagcaagaag ataatgaaaa gcatataaac 1380

tgggttcgaa gtgtttataa ttttacgact ccttatgtgt cccaaaatcc aagattggcg 1440

tatctcaatt atagggacct tgatttagga aaaactaatc atgcgagtcc taataattac 1500

acacaagcac gtatttgggg tgaaaagtat tttggtaaaa attttaacag gttagttaag 1560

gtgaaaacta aagttgatcc caataatttt tttagaaacg aacaaagtat cccacctctt 1620

ccaccgcatc atcat 1635

<210> SEQ ID NO 4
<211> LENGTH: 1638
<212> TYPE: DNA
<213> ORGANISM: Cannabis sativa

<400> SEQUENCE: 4

atgaattgct cagcattttc cttttggttt gtttgcaaaa taatattttt ctttctctca 60

ttccatatcc aaatttcaat agctaatcct cgagaaaact tccttaaatg cttctcaaaa 120

catattccca acaatgtagc aaatccaaaa ctcgtataca ctcaacacga ccaattgtat 180

atgtctatcc tgaattcgac aatacaaaat cttagattca tctctgatac aaccccaaaa 240

ccactcgtta ttgtcactcc ttcaaataac tcccatatcc aagcaactat tttatgctct 300

-continued

aagaaagttg gcttgcagat tcgaactcga agcggtggcc atgatgctga gggtatgtcc 360

tacatatctc aagtcccatt tgttgtagta gacttgagaa acatgcattc gatcaaaata 420

gatgttcata gccaaactgc gtgggttgaa gccggagcta cccttggaga agtttattat 480

tggatcaatg agaagaatga gaatcttagt tttcctggtg ggtattgccc tactgttggc 540

gtaggtggac actttagtgg aggaggctat ggagcattga tgcgaaatta tggccttgcg 600

gctgataata tcattgatgc acacttagtc aatgttgatg gaaaagttct agatcgaaaa 660

tccatgggag aagatctgtt ttgggctata cgtggtggtg gaggagaaaa ctttggaatc 720

attgcagcat ggaaaatcaa actggttgct gtcccatcaa agtctactat attcagtgtt 780

aaaaagaaca tggagataca tgggcttgtc aagttattta acaaatggca aaatattgct 840

tacaagtatg acaaagattt agtactcatg actcacttca taacaaagaa tattacagat 900

aatcatggga agaataagac tacagtacat ggttacttct cttcaatttt tcatggtgga 960

gtggatagtc tagtcgactt gatgaacaag agctttcgtg agttgggtat taaaaaaact 1020

gattgcaaag aattgagctg gattgataca accatcttct acagtggtgt tgtaaattac 1080

aacactgcta attttaaaaa ggaaattttg cttgatagat cagctgggaa gaagacggct 1140

ttctcaatta agttagacta tgttaagaaa ccaattccag aaactgcaat ggtcaaaatt 1200

ttggaaaaat tatatgaaga agatgtagga gctgggatgt atgtgttgta cccttacggt 1260

ggtataatgg aggagatttc agaatcagca attccattcc ctcatcgagc tggaataatg 1320

tatgaacttt ggtacactgc ttcctgggag aagcaagaag ataatgaaaa gcatataaac 1380

tgggttcgaa gtgtttataa ttttacgact ccttatgtgt cccaaaatcc aagattggcg 1440

tatctcaatt atagggacct tgatttagga aaaactaatc atgcgagtcc taataattac 1500

acacaagcac gtatttgggg tgaaaagtat tttggtaaaa attttaacag gttagttaag 1560

gtgaaaacta aagttgatcc caataatttt tttagaaacg aacaaagtat cccacctctt 1620

ccaccgcatc atcattaa 1638

<210> SEQ ID NO 5
<211> LENGTH: 1638
<212> TYPE: DNA
<213> ORGANISM: Cannabis sativa

<400> SEQUENCE: 5

atgaattgct cagcattctc cttttggttt gtttgcaaaa taatattttt ctttctctca 60

ttcaatatcc aaatttcaat agctaatcct caagaaaact tccttaaatg cttctcggaa 120

tatattccta acaatccagc aaatccaaaa ttcatataca ctcaacacga ccaattgtat 180

atgtctgtcc tgaattcgac aatacaaaat cttagattca cctctgatac aaccccaaaa 240

ccactcgtta ttgtcactcc ttcaaatgtc tcccatatcc aggccagtat tctctgctcc 300

aagaaagttg gtttgcagat tcgaactcga agcggtggcc atgatgctga gggtttgtcc 360

tacatatctc aagtcccatt tgctatagta gacttgagaa acatgcatac ggtcaaagta 420

gatattcata gccaaactgc gtgggttgaa gccggagcta cccttggaga agtttattat 480

tggatcaatg agatgaatga gaattttagt tttcctggtg ggtattgccc tactgttggc 540

gtaggtggac actttagtgg aggaggctat ggagcattga tgcgaaatta tggccttgcg 600

gctgataata tcattgatgc acacttagtc aatgttgatg gaaaagttct agatcgaaaa 660

-continued

tccatgggag aagatctatt ttgggctata cgtggtggag gaggagaaaa ctttggaatc 720

attgcagcat ggaaaatcaa acttgttgtt gtcccatcaa aggctactat attcagtgtt 780

aaaaagaaca tggagataca tgggcttgtc aagttattta acaaatggca aaatattgct 840

tacaagtatg acaaagattt aatgctcacg actcacttca gaactaggaa tattacagat 900

aatcatggga agaataagac tacagtacat ggttacttct cttccatttt tcttggtgga 960

gtggatagtc tagttgactt gatgaacaag agctttcctg agttgggtat taaaaaaact 1020

gattgcaaag aattgagctg gattgataca accatcttct acagtggtgt tgtaaattac 1080

aacactgcta attttaaaaa ggaaattttg cttgatagat cagctgggaa gaagacggct 1140

ttctcaatta agttagacta tgttaagaaa ctaatacctg aaactgcaat ggtcaaaatt 1200

ttggaaaaat tatatgaaga agaggtagga gttgggatgt atgtgttgta cccttacggt 1260

ggtataatgg atgagatttc agaatcagca attccattcc ctcatcgagc tggaataatg 1320

tatgaacttt ggtacactgc tacctgggag aagcaagaag ataacgaaaa gcatataaac 1380

tgggttcgaa gtgtttataa tttcacaact ccttatgtgt cccaaaatcc aagattggcg 1440

tatctcaatt atagggacct tgatttagga aaaactaatc ctgagagtcc taataattac 1500

acacaagcac gtatttgggg tgaaaagtat tttggtaaaa attttaacag gttagttaag 1560

gtgaaaacca aagctgatcc caataatttt tttagaaacg aacaaagtat cccacctctt 1620

ccaccgcgtc atcattaa 1638

<210> SEQ ID NO 6
<211> LENGTH: 545
<212> TYPE: PRT
<213> ORGANISM: Cannabis sativa

<400> SEQUENCE: 6

Met Asn Cys Ser Ala Phe Ser Phe Trp Phe Val Cys Lys Ile Ile Phe
1 5 10 15

Phe Phe Leu Ser Phe His Ile Gln Ile Ser Ile Ala Asn Pro Arg Glu
20 25 30

Asn Phe Leu Lys Cys Phe Ser Lys His Ile Pro Asn Asn Val Ala Asn
35 40 45

Pro Lys Leu Val Tyr Thr Gln His Asp Gln Leu Tyr Met Ser Ile Leu
50 55 60

Asn Ser Thr Ile Gln Asn Leu Arg Phe Ile Ser Asp Thr Thr Pro Lys
65 70 75 80

Pro Leu Val Ile Val Thr Pro Ser Asn Asn Ser His Ile Gln Ala Thr
85 90 95

Ile Leu Cys Ser Lys Lys Val Gly Leu Gln Ile Arg Thr Arg Ser Gly
100 105 110

Gly His Asp Ala Glu Gly Met Ser Tyr Ile Ser Gln Val Pro Phe Val
115 120 125

Val Val Asp Leu Arg Asn Met His Ser Ile Lys Ile Asp Val His Ser
130 135 140

Gln Thr Ala Trp Val Glu Ala Gly Ala Thr Leu Gly Glu Val Tyr Tyr
145 150 155 160

Trp Ile Asn Glu Lys Asn Glu Asn Leu Ser Phe Pro Gly Gly Tyr Cys
165 170 175

Pro Thr Val Gly Val Gly Gly His Phe Ser Gly Gly Gly Tyr Gly Ala

-continued

```
            180                 185                 190

Leu Met Arg Asn Tyr Gly Leu Ala Ala Asp Asn Ile Ile Asp Ala His
        195                 200                 205

Leu Val Asn Val Asp Gly Lys Val Leu Asp Arg Lys Ser Met Gly Glu
    210                 215                 220

Asp Leu Phe Trp Ala Ile Arg Gly Gly Gly Gly Glu Asn Phe Gly Ile
225                 230                 235                 240

Ile Ala Ala Trp Lys Ile Lys Leu Val Asp Val Pro Ser Lys Ser Thr
                245                 250                 255

Ile Phe Ser Val Lys Lys Asn Met Glu Ile His Gly Leu Val Lys Leu
            260                 265                 270

Phe Asn Lys Trp Gln Asn Ile Ala Tyr Lys Tyr Asp Lys Asp Leu Val
        275                 280                 285

Leu Met Thr His Phe Ile Thr Lys Asn Ile Thr Asp Asn His Gly Lys
    290                 295                 300

Asn Lys Thr Thr Val His Gly Tyr Phe Ser Ser Ile Phe His Gly Gly
305                 310                 315                 320

Val Asp Ser Leu Val Asp Leu Met Asn Lys Ser Phe Pro Glu Leu Gly
                325                 330                 335

Ile Lys Lys Thr Asp Cys Lys Glu Phe Ser Trp Ile Asp Thr Thr Ile
            340                 345                 350

Phe Tyr Ser Gly Val Val Asn Phe Asn Thr Ala Asn Phe Lys Lys Glu
        355                 360                 365

Ile Leu Leu Asp Arg Ser Ala Gly Lys Lys Thr Ala Phe Ser Ile Lys
    370                 375                 380

Leu Asp Tyr Val Lys Lys Pro Ile Pro Glu Thr Ala Met Val Lys Ile
385                 390                 395                 400

Leu Glu Lys Leu Tyr Glu Glu Asp Val Gly Ala Gly Met Tyr Val Leu
                405                 410                 415

Tyr Pro Tyr Gly Gly Ile Met Glu Glu Ile Ser Glu Ser Ala Ile Pro
            420                 425                 430

Phe Pro His Arg Ala Gly Ile Met Tyr Glu Leu Trp Tyr Thr Ala Ser
        435                 440                 445

Trp Glu Lys Gln Glu Asp Asn Glu Lys His Ile Asn Trp Val Arg Ser
    450                 455                 460

Val Tyr Asn Phe Thr Thr Pro Tyr Val Ser Gln Asn Pro Arg Leu Ala
465                 470                 475                 480

Tyr Leu Asn Tyr Arg Asp Leu Asp Leu Gly Lys Thr Asn His Ala Ser
                485                 490                 495

Pro Asn Asn Tyr Thr Gln Ala Arg Ile Trp Gly Glu Lys Tyr Phe Gly
            500                 505                 510

Lys Asn Phe Asn Arg Leu Val Lys Val Lys Thr Lys Val Asp Pro Asn
        515                 520                 525

Asn Phe Phe Arg Asn Glu Gln Ser Ile Pro Pro Leu Pro Pro His His
    530                 535                 540

His
545
```

<210> SEQ ID NO 7
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- guide RNA

<400> SEQUENCE: 7

tgcagcatgg aaaatcaaac 20

<210> SEQ ID NO 8
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- guide RNA

<400> SEQUENCE: 8

cccttacggt ggtataatgg 20

<210> SEQ ID NO 9
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- guide RNA

<400> SEQUENCE: 9

tagctattga aatttggata 20

<210> SEQ ID NO 10
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- guide RNA

<400> SEQUENCE: 10

tagagcataa aatagttgct 20

<210> SEQ ID NO 11
<211> LENGTH: 1635
<212> TYPE: DNA
<213> ORGANISM: Cannabis sativa

<400> SEQUENCE: 11

atgaagtgct caacattctc cttttggttt gtttgcaaga taatattttt ctttttctca 60

ttcaatatcc aaacttccat tgctaatcct cgagaaaact tccttaaatg cttctcgcaa 120

tatattccca ataatgcaac aaatctaaaa ctcgtataca ctcaaaacaa cccattgtat 180

atgtctgtcc taaattcgac aatacacaat cttagattca gctctgacac aaccccaaaa 240

ccacttgtta tcgtcactcc ttcacatgtc tctcatatcc aaggcactat tctatgctcc 300

aagaaagttg gcttgcagat tcgaactcga agtggtggtc atgattctga gggcatgtcc 360

tacatatctc aagtcccatt tgttatagta gacttgagaa acatgcgttc aatcaaaata 420

gatgttcata gccaaactgc atgggttgaa gccggagcta cccttggaga agtttattat 480

tgggttaatg agaaaaatga gagtcttagt ttggctgctg ggtattgccc tactgtttgc 540

gcaggtggac actttggtgg aggaggctat ggaccattga tgagaagcta tggcctcgcg 600

gctgataata tcattgatgc acacttagtc aacgttcatg gaaaagtgct agatcgaaaa 660

tctatggggg aagatctctt ttgggcttta cgtggtggtg gagcagaaag cttcggaatc 720

attgtagcat ggaaaattag actggttgct gtcccaaagt ctactatgtt tagtgttaaa 780

-continued

aagatcatgg agatacatga gcttgtcaag ttagttaaca aatggcaaaa tattgcttac 840

aagtatgaca aagatttatt actcatgact cacttcataa ctaggaacat tacagataat 900

caagggaaga ataagacagc aatacacact tacttctctt cagttttcct tggtggagtg 960

gatagtctag tcgacttgat gaacaagagt tttcctgagt tgggtattaa aaaaacggat 1020

tgcagacaat tgagctggat tgatactatc atcttctata gtggtgttgt aaattacgac 1080

actgataatt ttaacaagga aattttgctt gatagatccg ctgggcagaa cggtgctttc 1140

aagattaagt tagactacgt taagaaacca attccagaat ctgtatttgt ccaaattttg 1200

gaaaaattat atgaagaaga tataggagct gggatgtatg cgttgtaccc ttacggtggt 1260

ataatggatg agatttctga atcagcaatt ccattccctc atcgagctgg aatcttgtat 1320

gagttatggt acatatgtag ctgggagaag caagaagata acgaaaagca tctaaactgg 1380

attagaaata tttataactt catgactcct tatgtgtccc aaaatccaag attggcatat 1440

ctcaattata gagaccttga tataggaata aatgatccca agaatccaaa taattacaca 1500

caagcacgta tttggggtga gaagtatttt ggtaaaaatt ttgacaggct agtaaaagtg 1560

aaaaccctgg ttgatcccaa taatttttttt agaaacgaac aaagcatccc acctcttcca 1620

cggcatcgtc attaa 1635

<210> SEQ ID NO 12
<211> LENGTH: 544
<212> TYPE: PRT
<213> ORGANISM: Cannabis sativa

<400> SEQUENCE: 12

Met Lys Cys Ser Thr Phe Ser Phe Trp Phe Val Cys Lys Ile Ile Phe
1 5 10 15

Phe Phe Phe Ser Phe Asn Ile Gln Thr Ser Ile Ala Asn Pro Arg Glu
20 25 30

Asn Phe Leu Lys Cys Phe Ser Gln Tyr Ile Pro Asn Asn Ala Thr Asn
35 40 45

Leu Lys Leu Val Tyr Thr Gln Asn Asn Pro Leu Tyr Met Ser Val Leu
50 55 60

Asn Ser Thr Ile His Asn Leu Arg Phe Ser Ser Asp Thr Thr Pro Lys
65 70 75 80

Pro Leu Val Ile Val Thr Pro Ser His Val Ser His Ile Gln Gly Thr
85 90 95

Ile Leu Cys Ser Lys Lys Val Gly Leu Gln Ile Arg Thr Arg Ser Gly
100 105 110

Gly His Asp Ser Glu Gly Met Ser Tyr Ile Ser Gln Val Pro Phe Val
115 120 125

Ile Val Asp Leu Arg Asn Met Arg Ser Ile Lys Ile Asp Val His Ser
130 135 140

Gln Thr Ala Trp Val Glu Ala Gly Ala Thr Leu Gly Glu Val Tyr Tyr
145 150 155 160

Trp Val Asn Glu Lys Asn Glu Ser Leu Ser Leu Ala Ala Gly Tyr Cys
165 170 175

Pro Thr Val Cys Ala Gly Gly His Phe Gly Gly Gly Gly Tyr Gly Pro
180 185 190

Leu Met Arg Ser Tyr Gly Leu Ala Ala Asp Asn Ile Ile Asp Ala His

-continued

```
        195                 200                 205

Leu Val Asn Val His Gly Lys Val Leu Asp Arg Lys Ser Met Gly Glu
    210                 215                 220

Asp Leu Phe Trp Ala Leu Arg Gly Gly Gly Ala Glu Ser Phe Gly Ile
225                 230                 235                 240

Ile Val Ala Trp Lys Ile Arg Leu Val Ala Val Pro Lys Ser Thr Met
                245                 250                 255

Phe Ser Val Lys Lys Ile Met Glu Ile His Glu Leu Val Lys Leu Val
            260                 265                 270

Asn Lys Trp Gln Asn Ile Ala Tyr Lys Tyr Asp Lys Asp Leu Leu Leu
        275                 280                 285

Met Thr His Phe Ile Thr Arg Asn Ile Thr Asp Asn Gln Gly Lys Asn
    290                 295                 300

Lys Thr Ala Ile His Thr Tyr Phe Ser Ser Val Phe Leu Gly Gly Val
305                 310                 315                 320

Asp Ser Leu Val Asp Leu Met Asn Lys Ser Phe Pro Glu Leu Gly Ile
                325                 330                 335

Lys Lys Thr Asp Cys Arg Gln Leu Ser Trp Ile Asp Thr Ile Ile Phe
            340                 345                 350

Tyr Ser Gly Val Val Asn Tyr Asp Thr Asp Asn Phe Asn Lys Glu Ile
        355                 360                 365

Leu Leu Asp Arg Ser Ala Gly Gln Asn Gly Ala Phe Lys Ile Lys Leu
    370                 375                 380

Asp Tyr Val Lys Lys Pro Ile Pro Glu Ser Val Phe Val Gln Ile Leu
385                 390                 395                 400

Glu Lys Leu Tyr Glu Glu Asp Ile Gly Ala Gly Met Tyr Ala Leu Tyr
                405                 410                 415

Pro Tyr Gly Gly Ile Met Asp Glu Ile Ser Glu Ser Ala Ile Pro Phe
            420                 425                 430

Pro His Arg Ala Gly Ile Leu Tyr Glu Leu Trp Tyr Ile Cys Ser Trp
        435                 440                 445

Glu Lys Gln Glu Asp Asn Glu Lys His Leu Asn Trp Ile Arg Asn Ile
    450                 455                 460

Tyr Asn Phe Met Thr Pro Tyr Val Ser Gln Asn Pro Arg Leu Ala Tyr
465                 470                 475                 480

Leu Asn Tyr Arg Asp Leu Asp Ile Gly Ile Asn Asp Pro Lys Asn Pro
                485                 490                 495

Asn Asn Tyr Thr Gln Ala Arg Ile Trp Gly Glu Lys Tyr Phe Gly Lys
            500                 505                 510

Asn Phe Asp Arg Leu Val Lys Val Lys Thr Leu Val Asp Pro Asn Asn
        515                 520                 525

Phe Phe Arg Asn Glu Gln Ser Ile Pro Pro Leu Pro Arg His Arg His
    530                 535                 540


<210> SEQ ID NO 13
<211> LENGTH: 1635
<212> TYPE: DNA
<213> ORGANISM: Cannabis sativa

<400> SEQUENCE: 13

atgaagtgct caacattctc cttttggttt gtttgcaaga taatattttt ctttttctca     60

ttcaatatcc aaacttccat tgctaatcct cgagaaaact tccttaaatg cttctcgcaa    120
```

-continued

tatattccca ataatgcaac aaatctaaaa ctcgtataca ctcaaaacaa cccattgtat 180

atgtctgtcc taaattcgac aatacacaat cttagattca cctctgacac aaccccaaaa 240

ccacttgtta tcgtcactcc ttcacatgtc tctcatatcc aaggcactat tctatgctcc 300

aagaaagttg gcttgcagat tcgaactcga agtggtggtc atgattctga gggcatgtcc 360

tacatatctc aagtcccatt tgttatagta gacttgagaa acatgcgttc aatcaaaata 420

gatgttcata gccaaactgc atgggttgaa gccggagcta cccttggaga agtttattat 480

tgggttaatg agaaaaatga gaatcttagt ttggcggctg ggtattgccc tactgtttgc 540

gcaggtggac actttggtgg aggaggctat ggaccattga tgagaaacta tggcctcgcg 600

gctgataata tcattgatgc acacttagtc aacgttcatg gaaaagtgct agatcgaaaa 660

tctatggggg aagatctctt ttgggcttta cgtggtggtg gagcagaaag cttcggaatc 720

attgtagcat ggaaaattag actggttgct gtcccaaagt ctactatgtt tagtgttaaa 780

aagatcatgg agatacatga gcttgtcaag ttagttaaca aatggcaaaa tattgcttac 840

aagtatgaca aagatttatt actcatgact cacttcataa ctaggaacat tacagataat 900

caagggaaga ataagacagc aatacacact tacttctctt cagttttcct tggtggagtg 960

gatagtctag tcgacttgat gaacaagagt tttcctgagt tgggtattaa aaaaacggat 1020

tgcagacaat tgagctggat tgatactatc atcttctata gtggtgttgt aaattacgac 1080

actgataatt ttaacaagga aattttgctt gatagatccg ctgggcagaa cggtgctttc 1140

aagattaagt tagactacgt taagaaacca attccagaat ctgtatttgt ccaaattttg 1200

gaaaaattat atgaagaaga tataggagct gggatgtatg cgttgtaccc ttacggtggt 1260

ataatggatg agatttcaga atcagcaatt ccattccctc atcgagctgg aatcttgtat 1320

gagttatggt acatatgtag ttgggagaag caagaagata acgaaaagca tctaaactgg 1380

attagaaata tttataactt catgactcct tatgtgtcca aaaatccaag attggcatat 1440

ctcaattata gagaccttga tataggaata aatgatccca agaatccaaa taattacaca 1500

caagcacgta tttggggtga gaagtatttt ggtaaaaatt ttgacaggct agtaaaagtg 1560

aaaaccctgg ttgatcccaa taacttttt agaaacgaac aaagcatccc acctcttcca 1620

cggcatcgtc attaa 1635

<210> SEQ ID NO 14
<211> LENGTH: 544
<212> TYPE: PRT
<213> ORGANISM: Cannabis sativa

<400> SEQUENCE: 14

Met Lys Cys Ser Thr Phe Ser Phe Trp Phe Val Cys Lys Ile Ile Phe
1 5 10 15

Phe Phe Phe Ser Phe Asn Ile Gln Thr Ser Ile Ala Asn Pro Arg Glu
20 25 30

Asn Phe Leu Lys Cys Phe Ser Gln Tyr Ile Pro Asn Asn Ala Thr Asn
35 40 45

Leu Lys Leu Val Tyr Thr Gln Asn Asn Pro Leu Tyr Met Ser Val Leu
50 55 60

Asn Ser Thr Ile His Asn Leu Arg Phe Thr Ser Asp Thr Thr Pro Lys
65 70 75 80

-continued

```
Pro Leu Val Ile Val Thr Pro Ser His Val Ser His Ile Gln Gly Thr
                85                  90                  95

Ile Leu Cys Ser Lys Lys Val Gly Leu Gln Ile Arg Thr Arg Ser Gly
            100                 105                 110

Gly His Asp Ser Glu Gly Met Ser Tyr Ile Ser Gln Val Pro Phe Val
        115                 120                 125

Ile Val Asp Leu Arg Asn Met Arg Ser Ile Lys Ile Asp Val His Ser
    130                 135                 140

Gln Thr Ala Trp Val Glu Ala Gly Ala Thr Leu Gly Glu Val Tyr Tyr
145                 150                 155                 160

Trp Val Asn Glu Lys Asn Glu Asn Leu Ser Leu Ala Ala Gly Tyr Cys
                165                 170                 175

Pro Thr Val Cys Ala Gly Gly His Phe Gly Gly Gly Gly Tyr Gly Pro
            180                 185                 190

Leu Met Arg Asn Tyr Gly Leu Ala Ala Asp Asn Ile Ile Asp Ala His
        195                 200                 205

Leu Val Asn Val His Gly Lys Val Leu Asp Arg Lys Ser Met Gly Glu
    210                 215                 220

Asp Leu Phe Trp Ala Leu Arg Gly Gly Gly Ala Glu Ser Phe Gly Ile
225                 230                 235                 240

Ile Val Ala Trp Lys Ile Arg Leu Val Ala Val Pro Lys Ser Thr Met
                245                 250                 255

Phe Ser Val Lys Lys Ile Met Glu Ile His Glu Leu Val Lys Leu Val
            260                 265                 270

Asn Lys Trp Gln Asn Ile Ala Tyr Lys Tyr Asp Lys Asp Leu Leu Leu
        275                 280                 285

Met Thr His Phe Ile Thr Arg Asn Ile Thr Asp Asn Gln Gly Lys Asn
    290                 295                 300

Lys Thr Ala Ile His Thr Tyr Phe Ser Ser Val Phe Leu Gly Gly Val
305                 310                 315                 320

Asp Ser Leu Val Asp Leu Met Asn Lys Ser Phe Pro Glu Leu Gly Ile
                325                 330                 335

Lys Lys Thr Asp Cys Arg Gln Leu Ser Trp Ile Asp Thr Ile Ile Phe
            340                 345                 350

Tyr Ser Gly Val Val Asn Tyr Asp Thr Asp Asn Phe Asn Lys Glu Ile
        355                 360                 365

Leu Leu Asp Arg Ser Ala Gly Gln Asn Gly Ala Phe Lys Ile Lys Leu
    370                 375                 380

Asp Tyr Val Lys Lys Pro Ile Pro Glu Ser Val Phe Val Gln Ile Leu
385                 390                 395                 400

Glu Lys Leu Tyr Glu Glu Asp Ile Gly Ala Gly Met Tyr Ala Leu Tyr
                405                 410                 415

Pro Tyr Gly Gly Ile Met Asp Glu Ile Ser Glu Ser Ala Ile Pro Phe
            420                 425                 430

Pro His Arg Ala Gly Ile Leu Tyr Glu Leu Trp Tyr Ile Cys Ser Trp
        435                 440                 445

Glu Lys Gln Glu Asp Asn Glu Lys His Leu Asn Trp Ile Arg Asn Ile
    450                 455                 460

Tyr Asn Phe Met Thr Pro Tyr Val Ser Lys Asn Pro Arg Leu Ala Tyr
465                 470                 475                 480

Leu Asn Tyr Arg Asp Leu Asp Ile Gly Ile Asn Asp Pro Lys Asn Pro
```

-continued

```
               485                 490                 495

Asn Asn Tyr Thr Gln Ala Arg Ile Trp Gly Glu Lys Tyr Phe Gly Lys
            500                 505                 510

Asn Phe Asp Arg Leu Val Lys Val Lys Thr Leu Val Asp Pro Asn Asn
        515                 520                 525

Phe Phe Arg Asn Glu Gln Ser Ile Pro Pro Leu Pro Arg His Arg His
    530                 535                 540


<210> SEQ ID NO 15
<211> LENGTH: 1635
<212> TYPE: DNA
<213> ORGANISM: Cannabis sativa
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (333)..(441)
<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 15

atgaagtact caacattctc cttttggttt gtttgcaaga taatattttt ctttttctca     60

ttcaatatcc aaacttccat tgctaatcct cgagaaaact tccttaaatg cttctcgcaa    120

tatattccca ataatgcaac aaatctaaaa ctcgtataca ctcaaaacaa cccattgtat    180

atgtctgtcc taaattcgac aatacacaat cttagattca gctctgacac aaccccaaaa    240

ccacttgtta tcgtcactcc ttcacatgtc tctcatatcc aaggcactat tctatgctcc    300

aagaaagttg gcttgcagat tcgaactcga agnnnnnnnn nnnnnnnnnn nnnnnnnnnn    360

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn    420

nnnnnnnnnn nnnnnnnnnn ntgggttgaa gccggagcta cccttggaga agtttattat    480

tgggttaatg agaaaaatga gagtcttagt ttggctgctg ggtattgccc tactgtttgc    540

gcaggtggac actttggtgg aggaggctat ggaccattga tgagaagcta tggcctcgcg    600

gctgataata tcattgatgc acacttagtc aacgttcatg gaaaagtgct agatcgaaaa    660

tctatggggg aagatctctt ttgggcttta cgtggtggtg gagcagaaag cttcggaatc    720

attgtagcat ggaaaattag actggttgct gtcccaaagt ctactatgtt tagtgttaaa    780

aagatcatgg agatacatga gcttgtcaag ttagttaaca aatggcaaaa tattgcttac    840

aagtatgaca aagatttatt actcatgact cacttcataa ctaggaacat tacagataat    900

caagggaaga ataagacagc aatacacact tacttctctt cagttttcct tggtggagtg    960

gatagtctag tcgacttgat gaacaagagt tttcctgagt tgggtattaa aaaaacggat   1020

tgcagacaat tgagctggat tgatactatc atcttctata gtggtgttgt aaattacgac   1080

actgataatt ttaacaagga aattttgctt gatagatccg ctgggcagaa cggtgctttc   1140

aagattaagt tagactacgt taagaaacca attccagaat ctgtatttgt ccaaattttg   1200

gaaaaattat atgaagaaga tataggagct gggatgtatg cgttgtaccc ttacggtggt   1260

ataatggatg agatttctga atcagcaatt ccattccctc atcgagctgg aatcttgtat   1320

gagttatggt acatatgtag ctgggagaag caagaagata acgaaaagca tctaaactgg   1380

attagaaata tttataactt catgactcct tatgtgtccc aaaatccaag attggcatat   1440

ctcaattata gagaccttga tataggaata aatgatccca agaatccaaa taattacaca   1500

caagcacgta tttggggtga gaagtatttt ggtaaaaatt ttgacaggct agtaaaagtg   1560

aaaaccctgg ttgatcccaa taatttttttt agaaacgaac aaagcatccc acctcttcca   1620
```

-continued

cggcatcatc attaa 1635

<210> SEQ ID NO 16
<211> LENGTH: 544
<212> TYPE: PRT
<213> ORGANISM: Cannabis sativa
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (111)..(147)
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid

<400> SEQUENCE: 16

Met Lys Tyr Ser Thr Phe Ser Phe Trp Phe Val Cys Lys Ile Ile Phe
1 5 10 15

Phe Phe Phe Ser Phe Asn Ile Gln Thr Ser Ile Ala Asn Pro Arg Glu
20 25 30

Asn Phe Leu Lys Cys Phe Ser Gln Tyr Ile Pro Asn Asn Ala Thr Asn
35 40 45

Leu Lys Leu Val Tyr Thr Gln Asn Asn Pro Leu Tyr Met Ser Val Leu
50 55 60

Asn Ser Thr Ile His Asn Leu Arg Phe Ser Ser Asp Thr Thr Pro Lys
65 70 75 80

Pro Leu Val Ile Val Thr Pro Ser His Val Ser His Ile Gln Gly Thr
85 90 95

Ile Leu Cys Ser Lys Lys Val Gly Leu Gln Ile Arg Thr Arg Xaa Xaa
100 105 110

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
115 120 125

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
130 135 140

Xaa Xaa Xaa Trp Val Glu Ala Gly Ala Thr Leu Gly Glu Val Tyr Tyr
145 150 155 160

Trp Val Asn Glu Lys Asn Glu Ser Leu Ser Leu Ala Ala Gly Tyr Cys
165 170 175

Pro Thr Val Cys Ala Gly Gly His Phe Gly Gly Gly Gly Tyr Gly Pro
180 185 190

Leu Met Arg Ser Tyr Gly Leu Ala Ala Asp Asn Ile Ile Asp Ala His
195 200 205

Leu Val Asn Val His Gly Lys Val Leu Asp Arg Lys Ser Met Gly Glu
210 215 220

Asp Leu Phe Trp Ala Leu Arg Gly Gly Gly Ala Glu Ser Phe Gly Ile
225 230 235 240

Ile Val Ala Trp Lys Ile Arg Leu Val Ala Val Pro Lys Ser Thr Met
245 250 255

Phe Ser Val Lys Lys Ile Met Glu Ile His Glu Leu Val Lys Leu Val
260 265 270

Asn Lys Trp Gln Asn Ile Ala Tyr Lys Tyr Asp Lys Asp Leu Leu Leu
275 280 285

Met Thr His Phe Ile Thr Arg Asn Ile Thr Asp Asn Gln Gly Lys Asn
290 295 300

Lys Thr Ala Ile His Thr Tyr Phe Ser Ser Val Phe Leu Gly Gly Val
305 310 315 320

Asp Ser Leu Val Asp Leu Met Asn Lys Ser Phe Pro Glu Leu Gly Ile

-continued

```
               325                 330                 335

Lys Lys Thr Asp Cys Arg Gln Leu Ser Trp Ile Asp Thr Ile Ile Phe
            340                 345                 350

Tyr Ser Gly Val Val Asn Tyr Asp Thr Asp Asn Phe Asn Lys Glu Ile
        355                 360                 365

Leu Leu Asp Arg Ser Ala Gly Gln Asn Gly Ala Phe Lys Ile Lys Leu
    370                 375                 380

Asp Tyr Val Lys Lys Pro Ile Pro Glu Ser Val Phe Val Gln Ile Leu
385                 390                 395                 400

Glu Lys Leu Tyr Glu Glu Asp Ile Gly Ala Gly Met Tyr Ala Leu Tyr
                405                 410                 415

Pro Tyr Gly Gly Ile Met Asp Glu Ile Ser Glu Ser Ala Ile Pro Phe
            420                 425                 430

Pro His Arg Ala Gly Ile Leu Tyr Glu Leu Trp Tyr Ile Cys Ser Trp
        435                 440                 445

Glu Lys Gln Glu Asp Asn Glu Lys His Leu Asn Trp Ile Arg Asn Ile
    450                 455                 460

Tyr Asn Phe Met Thr Pro Tyr Val Ser Gln Asn Pro Arg Leu Ala Tyr
465                 470                 475                 480

Leu Asn Tyr Arg Asp Leu Asp Ile Gly Ile Asn Asp Pro Lys Asn Pro
                485                 490                 495

Asn Asn Tyr Thr Gln Ala Arg Ile Trp Gly Glu Lys Tyr Phe Gly Lys
            500                 505                 510

Asn Phe Asp Arg Leu Val Lys Val Lys Thr Leu Val Asp Pro Asn Asn
        515                 520                 525

Phe Phe Arg Asn Glu Gln Ser Ile Pro Pro Leu Pro Arg His His His
    530                 535                 540


<210> SEQ ID NO 17
<211> LENGTH: 1634
<212> TYPE: DNA
<213> ORGANISM: Cannabis sativa

<400> SEQUENCE: 17

atgaagtgct caacattccc cttttggttt gtttgcaaga taatattttt ctttctctca     60

ttcaatatcc aaacttcaat tgctaatcct cgagaaaact tccttaaatg cttctcgcaa    120

tatattccca ccaatgtaac aaatctaaaa cttacaccca aaacaaccaa ttgtatatgc    180

ctgtccaaaa ttcaacaata cacaatctta gattcacctc taacacaacc ccaaaactac    240

ttgttatcgt cactccttca tatgtctctc atatccaagg cactattcta tgtccaagaa    300

aattggtttg caaattcgaa ctcgaagcgg tggtcatgat tctgaagaca tgtcctacat    360

atctcaagtc ccatttgtta tagtagactt gagaaacatg cattcaatca acatagatgt    420

tcatagccaa atcgcaaggg ttgaagccgg agctaccctt ggagaagttt attattgggt    480

taatgagaaa aatgagaatc ttagtttggc tgctgggtat tgccctactg ttagcgcagc    540

tggacacttt ggtggaggag gatatggacc attgatgcaa aattatggcc tcgcggctga    600

taatatcgtt gatgcacact tagtcaacgt tgatgcaaaa gtgctagatc gaaaatctat    660

gggggaagat ctcttttggg ctatacgtgg tggtggagga gaaagcttcg gaatcattgt    720

agcatggaaa attagactgg ttgctgtccc aacaaagtct actatgttta gtgttaaaaa    780

gatcatggag atacatgagc ttgtcaagtg agttaacaaa tggcaaaata ttgcttacaa    840
```

-continued

gtatgacaaa gatttattac tcatgactca cttcataact aggaatatta caaataatca 900

tgggaagaat aagacaacaa tacacactta cttctcttca gttttccttg gtggagtgga 960

tagtctagtc gacttgatga ataagagttt tcctgagttg ggtattaaaa aaacagattg 1020

caaacaattg agctagattg atattatcat cttttatagc ggtgttgtaa attacggcac 1080

tgataatttt aataaggaaa ttttgcttga tagatcagct gggcagaacg gttctttaaa 1140

gattaagtta gactacgtta agaaaccaat tccagaatct gcgtttgtca aaattttgga 1200

aaaattatat gaagaagatg aaggagttgg gatgtatgcg ttgtaccctt acggtggtat 1260

aatggatgag atttcagaat cagcaattcc attccctcat tgagctggaa tcatgtatga 1320

attatggtac atatgtagct gggagaagca cgaagataac gaaaaagcat ctaaactgga 1380

ttcgaaatgt ttatagcttc attactcctt atgtgtccta aaatccaaga ttggcatatc 1440

tcaattatag agaccttgat actggaataa atgatcccaa gagtccaaat aattacacac 1500

aagaaagtat ttggggtgag aagtattttg gtaaaaattt tgacagggta gtaaaagtga 1560

aaaccctggt tgatcccaat aatttttttta gaaatgaaca aagcatccca cctcttccac 1620

ggcatcgtca ttaa 1634

<210> SEQ ID NO 18
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- guide RNA

<400> SEQUENCE: 18

gctagatcga aaatctatgg 20

<210> SEQ ID NO 19
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- guide RNA

<400> SEQUENCE: 19

aaagcatccc acctcttcca 20

<210> SEQ ID NO 20
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- guide RNA

<400> SEQUENCE: 20

tttaggacag acatatacaa 20

<210> SEQ ID NO 21
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- guide RNA

<400> SEQUENCE: 21

gaaagcaccg ttctgcccag 20

-continued

<210> SEQ ID NO 22
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- guide RNA

<400> SEQUENCE: 22

catttaagga agttttctcg 20

<210> SEQ ID NO 23
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- guide RNA

<400> SEQUENCE: 23

aaatgggact tgagatatgt 20

<210> SEQ ID NO 24
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- guide RNA

<400> SEQUENCE: 24

cccttggaga agtttattat 20

<210> SEQ ID NO 25
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- guide RNA

<400> SEQUENCE: 25

gtacccttac ggtggtataa 20

<210> SEQ ID NO 26
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- guide RNA

<400> SEQUENCE: 26

attccagctc gatgagggaa 20

<210> SEQ ID NO 27
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- guide RNA

<400> SEQUENCE: 27

tacacacaag cacgtatttg 20

<210> SEQ ID NO 28
<211> LENGTH: 109

-continued

<212> TYPE: PRT
<213> ORGANISM: Brassica napus

<400> SEQUENCE: 28

Met Ala Thr Gly Ser Arg Val Leu Ile Gly Leu Ala Met Ile Leu Ile
1 5 10 15

Ile Ser Gly Glu Leu Leu Val Pro Gly Gln Gly Thr Cys Gln Gly Asp
20 25 30

Ile Glu Gly Leu Met Arg Glu Cys Ala Val Tyr Val Gln Arg Pro Gly
35 40 45

Pro Lys Val Asn Pro Ser Ala Ala Cys Cys Lys Val Val Lys Arg Ser
50 55 60

Asp Ile Pro Cys Ala Cys Gly Arg Ile Thr Pro Ser Val Gln Lys Met
65 70 75 80

Ile Asp Met Asn Lys Val Val Leu Val Thr Ser Phe Cys Gly Arg Pro
85 90 95

Leu Ala His Gly Thr Lys Cys Gly Ser Tyr Ile Val Pro
100 105

<210> SEQ ID NO 29
<211> LENGTH: 330
<212> TYPE: DNA
<213> ORGANISM: Brassica napus

<400> SEQUENCE: 29

atggcgacag gttctcgtgt tctgatcggt ctagcaatga tcctcataat ctcaggagaa 60

ctgctagttc cagggcaagg aacgtgccaa ggagacatag agggtctgat gagagaatgt 120

gcggtctacg tccagcgtcc aggcccaaag gtaaacccat ccgcagcgtg ttgcaaagtc 180

gtcaagagat cagacatccc ctgcgcatgt ggccgtatca caccctcggt tcaaaaaatg 240

atagacatga ataaggttgt tcttgtcact tccttttgtg ggaggcctct cgctcatggt 300

accaagtgtg gaagctacat tgtgccatga 330

<210> SEQ ID NO 30
<211> LENGTH: 395
<212> TYPE: PRT
<213> ORGANISM: Cannabis sativa

<400> SEQUENCE: 30

Met Gly Leu Ser Ser Val Cys Thr Phe Ser Phe Gln Thr Asn Tyr His
1 5 10 15

Thr Leu Leu Asn Pro His Asn Asn Asn Pro Lys Thr Ser Leu Leu Cys
20 25 30

Tyr Arg His Pro Lys Thr Pro Ile Lys Tyr Ser Tyr Asn Asn Phe Pro
35 40 45

Ser Lys His Cys Ser Thr Lys Ser Phe His Leu Gln Asn Lys Cys Ser
50 55 60

Glu Ser Leu Ser Ile Ala Lys Asn Ser Ile Arg Ala Ala Thr Thr Asn
65 70 75 80

Gln Thr Glu Pro Pro Glu Ser Asp Asn His Ser Val Ala Thr Lys Ile
85 90 95

Leu Asn Phe Gly Lys Ala Cys Trp Lys Leu Gln Arg Pro Tyr Thr Ile
100 105 110

Ile Ala Phe Thr Ser Cys Ala Cys Gly Leu Phe Gly Lys Glu Leu Leu

-continued

```
        115                 120                 125

His Asn Thr Asn Leu Ile Ser Trp Ser Leu Met Phe Lys Ala Phe Phe
    130                 135                 140

Phe Leu Val Ala Val Leu Cys Ile Ala Ser Phe Thr Thr Thr Ile Asn
145                 150                 155                 160

Gln Ile Tyr Asp Leu His Ile Asp Arg Ile Asn Lys Pro Asp Leu Pro
                165                 170                 175

Leu Ala Ser Gly Glu Ile Ser Val Asn Thr Ala Trp Ile Met Ser Ile
            180                 185                 190

Ile Val Ala Leu Phe Gly Leu Ile Ile Thr Ile Lys Met Lys Gly Gly
        195                 200                 205

Pro Leu Tyr Ile Phe Gly Tyr Cys Phe Gly Ile Phe Gly Gly Ile Val
    210                 215                 220

Tyr Ser Val Pro Pro Phe Arg Trp Lys Gln Asn Pro Ser Thr Ala Phe
225                 230                 235                 240

Leu Leu Asn Phe Leu Ala His Ile Ile Thr Asn Phe Thr Phe Tyr Tyr
                245                 250                 255

Ala Ser Arg Ala Ala Leu Gly Leu Pro Phe Glu Leu Arg Pro Ser Phe
            260                 265                 270

Thr Phe Leu Leu Ala Phe Met Lys Ser Met Gly Ser Ala Leu Ala Leu
        275                 280                 285

Ile Lys Asp Ala Ser Asp Val Glu Gly Asp Thr Lys Phe Gly Ile Ser
    290                 295                 300

Thr Leu Ala Ser Lys Tyr Gly Ser Arg Asn Leu Thr Leu Phe Cys Ser
305                 310                 315                 320

Gly Ile Val Leu Leu Ser Tyr Val Ala Ala Ile Leu Ala Gly Ile Ile
                325                 330                 335

Trp Pro Gln Ala Phe Asn Ser Asn Val Met Leu Leu Ser His Ala Ile
            340                 345                 350

Leu Ala Phe Trp Leu Ile Leu Gln Thr Arg Asp Phe Ala Leu Thr Asn
        355                 360                 365

Tyr Asp Pro Glu Ala Gly Arg Arg Phe Tyr Glu Phe Met Trp Lys Leu
    370                 375                 380

Tyr Tyr Ala Glu Tyr Leu Val Tyr Val Phe Ile
385                 390                 395


<210> SEQ ID NO 31
<211> LENGTH: 1188
<212> TYPE: DNA
<213> ORGANISM: Cannabis sativa

<400> SEQUENCE: 31

atgggactct catcagtttg tacctttca tttcaaacta attaccatac tttattaaat     60

cctcacaata ataatcccaa aacctcatta ttatgttatc gacaccccaa aacaccaatt    120

aaatactctt acaataattt tccctctaaa cattgctcca ccaagagttt tcatctacaa    180

aacaaatgct cagaatcatt atcaatcgca aaaaattcca ttagggcagc tactacaaat    240

caaactgagc ctccagaatc tgataatcat tcagtagcaa ctaaaatttt aaactttggg    300

aaggcatgtt ggaaacttca aagaccatat acaatcatag catttacttc atgcgcttgt    360

ggattgtttg ggaaagagtt gttgcataac acaaatttaa taagttggtc tctgatgttc    420

aaggcattct ttttttggt ggctgtatta tgcattgctt cttttacaac taccatcaat    480
```

-continued

cagatttacg atcttcacat tgacagaata aacaagcctg atctaccact agcttcaggg 540

gaaatatcag taaacacagc ttggattatg agcataattg tggcactgtt tggattgata 600

ataactataa aaatgaaggg tggaccactc tatatatttg gctactgttt tggtattttt 660

ggtgggattg tctattctgt tccaccattt agatggaagc aaaatccttc cactgcattt 720

cttctcaatt tcctggccca tattattaca aatttcacat tttattatgc cagcagagca 780

gctcttggcc taccatttga gttgaggcct tcttttactt tcctgctagc atttatgaaa 840

tcaatgggtt cagctttggc tttaatcaaa gatgcttcag acgttgaagg cgacactaaa 900

tttggcatat caaccttggc aagtaaatat ggttccagaa acttgacatt attttgttct 960

ggaattgttc tcctatccta tgtggctgct atacttgctg ggattatctg gccccaggct 1020

ttcaacagta acgtaatgtt actttctcat gcaatcttag cattttggtt aatcctccag 1080

actcgagatt ttgcgttaac aaattacgac ccggaagcag gcagaagatt ttacgagttc 1140

atgtggaagc tttattatgc tgaatattta gtatatgttt tcatataa 1188

<210> SEQ ID NO 32
<211> LENGTH: 370
<212> TYPE: PRT
<213> ORGANISM: Cannabis sativa

<400> SEQUENCE: 32

Met Gly Ser Thr Gly Ile Glu Thr Gln Met Thr Pro Thr Gln Ile Ser
1 5 10 15

Asp Glu Glu Ala Asn Leu Phe Ala Met Gln Leu Ala Ser Ala Ser Val
20 25 30

Leu Pro Met Val Leu Lys Ala Ala Leu Glu Leu Asp Leu Leu Glu Ile
35 40 45

Ile Ala Lys Ala Gly Pro Gly Ala Phe Leu Ser Pro Ser Asp Ile Ala
50 55 60

Gln Gln Leu Pro Thr Gln Asn Pro Asp Ala Pro Val Met Leu Asp Arg
65 70 75 80

Met Leu Arg Leu Leu Ala Ser Tyr Asn Val Val Thr Tyr Ser Leu Arg
85 90 95

Glu Arg Glu Thr Ala Glu Glu Glu Gly Lys Val Glu Arg Leu Tyr Gly
100 105 110

Leu Ala Pro Val Ser Lys Tyr Leu Thr Lys Asn Glu Asp Gly Val Ser
115 120 125

Ile Ala Pro Leu Cys Leu Met Asn Gln Asp Lys Val Leu Met Glu Ser
130 135 140

Trp Tyr His Leu Lys Asp Ala Val Leu Asp Gly Gly Ile Pro Phe Asn
145 150 155 160

Lys Ala Tyr Gly Met Thr Ala Phe Glu Tyr His Gly Thr Asp Gln Arg
165 170 175

Phe Asn Lys Ile Phe Asn Arg Gly Met Ser Asp His Ser Thr Ile Thr
180 185 190

Met Lys Lys Ile Leu Glu Thr Tyr Lys Gly Phe Glu Gly Leu Asn Ser
195 200 205

Ile Val Asp Val Gly Gly Gly Thr Gly Ala Val Val Asn Met Ile Val
210 215 220

Ser Lys Tyr Pro Thr Ile Lys Gly Ile Asn Phe Asp Leu Pro His Val

-continued

```
225                 230                 235                 240

Ile Glu Asp Ala Pro Pro Leu Thr Gly Val Glu His Val Gly Gly Asp
                245                 250                 255

Met Phe Val Ser Val Pro Lys Gly Asp Ala Ile Phe Met Lys Trp Ile
            260                 265                 270

Cys His Asp Trp Ser Asp Glu His Cys Leu Lys Phe Leu Lys Asn Cys
        275                 280                 285

His Ala Ala Leu Pro Glu His Gly Lys Val Ile Val Ala Glu Cys Ile
    290                 295                 300

Leu Pro Val Ala Pro Asp Ser Ser Leu Ala Thr Lys Ser Thr Val His
305                 310                 315                 320

Ile Asp Val Ile Met Leu Ala His Asn Pro Gly Gly Lys Glu Arg Thr
                325                 330                 335

Glu Lys Glu Phe Glu Ala Leu Ala Lys Gly Ala Gly Phe Lys Gly Phe
            340                 345                 350

Lys Val His Cys Asn Ala Phe Asn Thr His Ile Met Glu Phe Leu Lys
        355                 360                 365

Thr Ile
    370


<210> SEQ ID NO 33
<211> LENGTH: 1113
<212> TYPE: DNA
<213> ORGANISM: Cannabis sativa

<400> SEQUENCE: 33

atgggttcaa caggaataga gacccaaatg accccaaccc aaatatccga cgaagaagcc     60

aacctcttcg ccatgcaatt agccagtgcc tcagtcttac ccatggttct caaagcagct    120

ttagagctcg acctcttgga gatcatagcc aaggccggtc caggcgcgtt tctctcacct    180

tccgacatag ctcaacagct tccgactcag aacccagacg ccccggtgat gctggaccgg    240

atgctgagac tgttggctag ctacaacgtg gtgacgtact cgctgcgtga gcgtgagacg    300

gcggaagagg aagggaaggt ggagaggctt tatgggttgg ctccggtgag taaatatctg    360

acgaagaatg aagatggagt ctccattgct cctctttgtc tcatgaacca ggataaggtt    420

cttatggaga gttggtatca cttaaaagat gcagtacttg atggaggaat acctttcaac    480

aaggcatatg gaatgacagc atttgaatat catggaaccg atcaaaggtt caataaaatc    540

tttaatagag gaatgtccga ccactcgact attaccatga aaaaaatcct cgaaacttac    600

aagggtttcg agggtcttaa ctcgattgtt gatgttggtg gtggtactgg agctgttgtt    660

aacatgatcg tctctaagta ccctactatt aagggtatta acttcgattt gcctcatgtc    720

atcgaagatg cacctccatt gaccggtgta gagcatgttg gaggagacat gtttgtaagt    780

gtaccaaaag gagatgcaat tttcatgaag tggatttgcc atgattggag cgatgaacac    840

tgcttgaaat tcttgaagaa ctgccacgct gcactgcccg aacacggaaa agtgatcgtg    900

gcggagtgca ttcttccggt ggcaccggac tcgagccttg ccacaaagag tacggtccac    960

attgatgtga tcatgttggc ccataaccct ggtggcaaag agagaacaga gaaagagttt   1020

gaggcattgg ctaagggagc tggctttaaa ggcttcaaag tccattgcaa tgctttcaat   1080

acccatatca tggaatttct caagaccatt taa                                1113
```

-continued

<210> SEQ ID NO 34
<211> LENGTH: 400
<212> TYPE: PRT
<213> ORGANISM: Cannabis sativa

<400> SEQUENCE: 34

Met Val Phe Ser Ser Val Cys Ser Phe Pro Ser Ser Leu Gly Thr Asn
1 5 10 15

Phe Lys Leu Val Pro Arg Ser Asn Phe Lys Ala Ser Ser Ser His Tyr
20 25 30

His Glu Ile Asn Asn Phe Ile Asn Asn Lys Pro Ile Lys Phe Ser Tyr
35 40 45

Phe Ser Ser Arg Leu Tyr Cys Ser Ala Lys Pro Ile Val His Arg Glu
50 55 60

Asn Lys Phe Thr Lys Ser Phe Ser Leu Ser His Leu Gln Arg Lys Ser
65 70 75 80

Ser Ile Lys Ala His Gly Glu Ile Glu Ala Asp Gly Ser Asn Gly Thr
85 90 95

Ser Glu Phe Asn Val Met Lys Ser Gly Asn Ala Ile Trp Arg Phe Val
100 105 110

Arg Pro Tyr Ala Ala Lys Gly Val Leu Phe Asn Ser Ala Ala Met Phe
115 120 125

Ala Lys Glu Leu Val Gly Asn Leu Asn Leu Phe Ser Trp Pro Leu Met
130 135 140

Phe Lys Ile Leu Ser Phe Thr Leu Val Ile Leu Cys Ile Phe Val Ser
145 150 155 160

Thr Ser Gly Ile Asn Gln Ile Tyr Asp Leu Asp Ile Asp Arg Leu Asn
165 170 175

Lys Pro Asn Leu Pro Val Ala Ser Gly Glu Ile Ser Val Glu Leu Ala
180 185 190

Trp Leu Leu Thr Ile Val Cys Thr Ile Ser Gly Leu Thr Leu Thr Ile
195 200 205

Ile Thr Asn Ser Gly Pro Phe Phe Pro Phe Leu Tyr Ser Ala Ser Ile
210 215 220

Phe Phe Gly Phe Leu Tyr Ser Ala Pro Pro Phe Arg Trp Lys Lys Asn
225 230 235 240

Pro Phe Thr Ala Cys Phe Cys Asn Val Met Leu Tyr Val Gly Thr Ser
245 250 255

Val Gly Val Tyr Tyr Ala Cys Lys Ala Ser Leu Gly Leu Pro Ala Asn
260 265 270

Trp Ser Pro Ala Phe Cys Leu Leu Phe Trp Phe Ile Ser Leu Leu Ser
275 280 285

Ile Pro Ile Ser Ile Ala Lys Asp Leu Ser Asp Ile Glu Gly Asp Arg
290 295 300

Lys Phe Gly Ile Ile Thr Phe Ser Thr Lys Phe Gly Ala Lys Pro Ile
305 310 315 320

Ala Tyr Ile Cys His Gly Leu Met Leu Leu Asn Tyr Val Ser Val Met
325 330 335

Ala Ala Ala Ile Ile Trp Pro Gln Phe Phe Asn Ser Ser Val Ile Leu
340 345 350

Leu Ser His Ala Phe Met Ala Ile Trp Val Leu Tyr Gln Ala Trp Ile
355 360 365

-continued

```
Leu Glu Lys Ser Asn Tyr Ala Thr Glu Thr Cys Gln Lys Tyr Tyr Ile
    370                 375                 380

Phe Leu Trp Ile Ile Phe Ser Leu Glu His Ala Phe Tyr Leu Phe Met
385                 390                 395                 400


<210> SEQ ID NO 35
<211> LENGTH: 1203
<212> TYPE: DNA
<213> ORGANISM: Cannabis sativa

<400> SEQUENCE: 35

atggtgttct catcagtttg tagttttcca tcctcccttg gaactaattt taaattagtt     60

cctcgtagta attttaaggc atcatcttct cattatcatg aaataaataa ttttattaat    120

aataaaccaa ttaaattctc atatttttct tcaagactat attgctctgc caaaccaatt    180

gtacacagag aaaacaaatt cacaaaatca ttttcactca gccacctcca aaggaaaagc    240

tccataaagg cacatggtga aattgaagct gatgggagta atggcacatc tgaatttaat    300

gtaatgaaaa gtggaaacgc aatttggaga tttgtaaggc catatgcagc caagggagta    360

ttgtttaact ctgctgctat gtttgcaaaa gagttggtgg ggaacctaaa tctatttagt    420

tggcctttga tgtttaagat actctctttt acattggtta ttttatgcat ttttgtaagt    480

acaagtggca tcaatcaaat ttatgatctc gacatcgaca ggttaaacaa acctaatttg    540

ccagtagcat caggagaaat ttcagttgaa ttggcatggt tgttgactat agtttgtaca    600

ataagtggcc tcacattaac aattataacg aactcagggc cattcttccc ttttctctac    660

tctgctagta tctttttttgg ctttctctat tctgctcctc cattcagatg gaagaagaat    720

ccttttacag catgtttctg taatgttatg ttgtatgttg gcacaagcgt tggtgtctat    780

tatgcttgta aggctagtct cgggcttcca gccaactgga gccctgcttt ttgtttgctc    840

ttttggttta tttcattgtt gagtataccc atctccattg caaaagatct ttcagacata    900

gaaggtgacc gcaagtttgg aatcataacc ttctcaacta aatttggagc aaaacccata    960

gcatatattt gtcatggact catgcttctg aattacgtga gtgttatggc tgcagctatt   1020

atttggccac agtttttcaa cagtagcgta atattgcttt ctcatgcatt catggcaatt   1080

tgggtattat atcaggcttg gatattggag aaatcaaatt acgccacgga gacgtgccaa   1140

aaatactata tattcctttg gataattttt tctcttgaac atgccttcta tttgttcatg   1200

tag                                                                 1203


<210> SEQ ID NO 36
<211> LENGTH: 523
<212> TYPE: PRT
<213> ORGANISM: Cannabis sativa

<400> SEQUENCE: 36

Met Ala Gln Val Ser Lys Ile Cys Ser Asn Gly Ala Gln Thr Ile Leu
1               5                   10                  15

Thr Leu Pro Asn Ile Ser Lys Ser His Thr Pro Arg Ser Leu Asn Ser
            20                  25                  30

Val Ser Leu Arg Ser Pro Phe Leu Gly Ser Ser Asn Ser Leu Ser Leu
        35                  40                  45

Lys Ile Gly Thr Glu Phe Gly Gly Cys Ser Thr Val Gly Lys Ala Met
    50                  55                  60
```

-continued

```
Ala Gly Pro Val Met Ala Ser Ala Val Thr Ala Glu Lys Pro Ser Lys
65                  70                  75                  80

Val Pro Glu Ile Val Leu Gln Pro Ile Lys Asp Ile Ser Gly Thr Val
                85                  90                  95

Lys Leu Pro Gly Ser Lys Ser Leu Ser Asn Arg Ile Leu Leu Leu Ala
            100                 105                 110

Ala Leu Ser Glu Gly Thr Thr Val Val Asp Asn Leu Leu Asp Ser Asp
        115                 120                 125

Asp Ile His Tyr Met Leu Gly Ala Leu Glu Thr Leu Gly Leu Arg Val
    130                 135                 140

Glu Ala Asp Lys Glu Ser Lys Arg Ala Ile Val Glu Gly Cys Ala Gly
145                 150                 155                 160

Gln Phe Pro Ala Gly Lys Glu Ser Val Asp Glu Val Gln Leu Phe Leu
                165                 170                 175

Gly Asn Ala Gly Thr Ala Met Arg Pro Leu Thr Ala Ala Val Thr Val
            180                 185                 190

Ala Gly Gly Asn Ala Ser Tyr Val Leu Asp Gly Val Pro Arg Met Arg
        195                 200                 205

Glu Arg Pro Ile Gly Asp Leu Val Thr Gly Leu Lys Gln Leu Gly Ala
    210                 215                 220

Asp Val Asp Cys Phe His Gly Thr Asp Cys Pro Pro Val Arg Val Leu
225                 230                 235                 240

Gly Lys Gly Gly Leu Pro Gly Gly Lys Val Lys Leu Ser Gly Ser Ile
                245                 250                 255

Ser Ser Gln Tyr Leu Thr Ala Leu Leu Met Ala Ala Pro Leu Ala Leu
            260                 265                 270

Gly Asp Val Glu Ile Glu Ile Ile Asp Lys Leu Ile Ser Val Pro Tyr
        275                 280                 285

Val Asp Met Thr Leu Lys Leu Met Ala Arg Phe Gly Val Thr Val Glu
    290                 295                 300

His Ser Asp Ser Trp Asp Arg Phe Leu Val Lys Gly Gly Gln Lys Tyr
305                 310                 315                 320

Lys Ser Pro Gly Asn Ala Tyr Val Glu Gly Asp Ala Ser Ser Ala Ser
                325                 330                 335

Tyr Phe Leu Ala Gly Ala Ala Val Thr Gly Gly Thr Val Thr Val Glu
            340                 345                 350

Gly Cys Gly Thr Ser Ser Leu Gln Gly Asp Val Lys Phe Ala Glu Val
        355                 360                 365

Leu Glu Lys Met Gly Ala Lys Val Ser Trp Thr Glu Asn Ser Val Thr
    370                 375                 380

Val Thr Gly Pro Pro Arg Asp Ser Val Lys Ser Lys His Leu Lys Ala
385                 390                 395                 400

Ile Asp Val Asn Met Asn Lys Met Pro Asp Val Ala Met Thr Leu Ala
                405                 410                 415

Val Val Ala Leu Phe Ala Asp Gly Pro Thr Ala Ile Arg Asp Val Ala
            420                 425                 430

Ser Trp Arg Val Lys Glu Thr Glu Arg Met Ile Ala Ile Cys Thr Glu
        435                 440                 445

Leu Arg Lys Leu Gly Ala Thr Val Glu Glu Gly Pro Asp Tyr Cys Val
    450                 455                 460

Ile Thr Pro Pro Glu Lys Leu Asn Ile Thr Ala Ile Asp Thr Tyr Asp
```

-continued

```
465                 470                 475                 480

Asp His Arg Met Ala Met Ala Phe Ser Leu Ala Ala Cys Ser Asp Val
                485                 490                 495

Pro Val Thr Ile Lys Asp Pro Gly Cys Thr Arg Lys Thr Phe Pro Asp
            500                 505                 510

Tyr Phe Glu Val Leu Glu Arg Phe Thr Lys His
        515                 520


<210> SEQ ID NO 37
<211> LENGTH: 523
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- engineered protein

<400> SEQUENCE: 37

Met Ala Gln Val Ser Lys Ile Cys Ser Asn Gly Ala Gln Thr Ile Leu
1               5                   10                  15

Thr Leu Pro Asn Ile Ser Lys Ser His Thr Pro Arg Ser Leu Asn Ser
            20                  25                  30

Val Ser Leu Arg Ser Pro Phe Leu Gly Ser Ser Asn Ser Leu Ser Leu
        35                  40                  45

Lys Ile Gly Thr Glu Phe Gly Gly Cys Ser Thr Val Gly Lys Ala Met
    50                  55                  60

Ala Gly Pro Val Met Ala Ser Ala Val Thr Ala Glu Lys Pro Ser Lys
65                  70                  75                  80

Val Pro Glu Ile Val Leu Gln Pro Ile Lys Asp Ile Ser Gly Thr Val
                85                  90                  95

Lys Leu Pro Gly Ser Lys Ser Leu Ser Asn Arg Ile Leu Leu Leu Ala
            100                 105                 110

Ala Leu Ser Glu Gly Thr Thr Val Val Asp Asn Leu Leu Asp Ser Asp
        115                 120                 125

Asp Ile His Tyr Met Leu Gly Ala Leu Glu Thr Leu Gly Leu Arg Val
    130                 135                 140

Glu Ala Asp Lys Glu Ser Lys Arg Ala Ile Val Glu Gly Cys Ala Gly
145                 150                 155                 160

Gln Phe Pro Ala Gly Lys Glu Ser Val Asp Glu Val Gln Leu Phe Leu
                165                 170                 175

Gly Asn Ala Gly Ile Ala Met Arg Ser Leu Thr Ala Ala Val Thr Val
            180                 185                 190

Ala Gly Gly Asn Ala Ser Tyr Val Leu Asp Gly Val Pro Arg Met Arg
        195                 200                 205

Glu Arg Pro Ile Gly Asp Leu Val Thr Gly Leu Lys Gln Leu Gly Ala
    210                 215                 220

Asp Val Asp Cys Phe His Gly Thr Asp Cys Pro Pro Val Arg Val Leu
225                 230                 235                 240

Gly Lys Gly Gly Leu Pro Gly Gly Lys Val Lys Leu Ser Gly Ser Ile
                245                 250                 255

Ser Ser Gln Tyr Leu Thr Ala Leu Leu Met Ala Ala Pro Leu Ala Leu
            260                 265                 270

Gly Asp Val Glu Ile Glu Ile Ile Asp Lys Leu Ile Ser Val Pro Tyr
        275                 280                 285

Val Asp Met Thr Leu Lys Leu Met Ala Arg Phe Gly Val Thr Val Glu
```

-continued

```
    290                 295                 300

His Ser Asp Ser Trp Asp Arg Phe Leu Val Lys Gly Gly Gln Lys Tyr
305                 310                 315                 320

Lys Ser Pro Gly Asn Ala Tyr Val Glu Gly Asp Ala Ser Ser Ala Ser
                325                 330                 335

Tyr Phe Leu Ala Gly Ala Ala Val Thr Gly Gly Thr Val Thr Val Glu
            340                 345                 350

Gly Cys Gly Thr Ser Ser Leu Gln Gly Asp Val Lys Phe Ala Glu Val
        355                 360                 365

Leu Glu Lys Met Gly Ala Lys Val Ser Trp Thr Glu Asn Ser Val Thr
    370                 375                 380

Val Thr Gly Pro Pro Arg Asp Ser Val Lys Ser Lys His Leu Lys Ala
385                 390                 395                 400

Ile Asp Val Asn Met Asn Lys Met Pro Asp Val Ala Met Thr Leu Ala
                405                 410                 415

Val Val Ala Leu Phe Ala Asp Gly Pro Thr Ala Ile Arg Asp Val Ala
            420                 425                 430

Ser Trp Arg Val Lys Glu Thr Glu Arg Met Ile Ala Ile Cys Thr Glu
        435                 440                 445

Leu Arg Lys Leu Gly Ala Thr Val Glu Glu Gly Leu Asp Tyr Cys Val
    450                 455                 460

Ile Thr Pro Pro Glu Lys Leu Asn Ile Thr Ala Ile Asp Thr Tyr Asp
465                 470                 475                 480

Asp His Arg Met Ala Met Ala Phe Ser Leu Ala Ala Cys Ser Asp Val
                485                 490                 495

Pro Val Thr Ile Lys Asp Pro Gly Cys Thr Arg Lys Thr Phe Pro Asp
            500                 505                 510

Tyr Phe Glu Val Leu Glu Arg Phe Thr Lys His
        515                 520


<210> SEQ ID NO 38
<211> LENGTH: 1572
<212> TYPE: DNA
<213> ORGANISM: Cannabis sativa

<400> SEQUENCE: 38

atggcccaag tgagcaaaat ctgtagcaat ggagctcaaa ctatccttac tctcccaaat     60

atatctaagt ctcatacacc aagatcccta aattcagttt cgttgagatc accgtttttg    120

ggttcatcta actctttgag tttgaagatt ggaactgaat ttgggggttg ttctacggtt    180

ggtaaagcta tggctggtcc agtcatggct tcagctgtca cagcggagaa gccttcaaag    240

gtaccggaga ttgtgttgca gcccattaaa gatatctctg gcactgtcaa gttgccgggt    300

tccaagtcac tatcgaatcg gattctactc ctggctgctc tttctgaggg gacaactgtt    360

gtggacaact tgttagatag tgatgacatt cactacatgc ttggtgcctt ggaaaccctt    420

ggtcttcgtg ttgaagcaga caaggaaagc aaacgagcaa ttgtggaagg ttgtgcgggt    480

cagtttcctg caggtaaaga atctgttgac gaagttcaac ttttccttgg aaatgctgga    540

acagcaatgc gtccactcac agctgcggtg actgttgctg gtggaaatgc tagctacgta    600

cttgatggtg ttcctcgaat gagagaaaga ccaattggag atttggtgac tggtcttaag    660

cagcttggtg cagatgttga ttgttttcat ggtacggatt gtccccctgt tcgtgtgctt    720
```

-continued

ggaaaaggag gccttcctgg gggcaaggtg aaactttctg gatcaattag cagtcaatat 780

ttgacagcct tgcttatggc agctcccttg gctcttggag atgttgaaat cgagataatt 840

gataaattga tctcggttcc ctatgttgat atgactttga agttgatggc acgttttggg 900

gttactgttg aacacagtga tagctgggat cgatttttag ttaaaggagg tcaaaagtac 960

aaatctcctg gaaacgctta tgttgaaggt gatgcttcaa gtgctagtta cttcctagct 1020

ggtgctgcag tcactggtgg tacagtcacc gtagaaggtt gtgggactag tagtttacag 1080

ggagacgtaa aatttgctga agttcttgag aaaatgggtg ctaaagttag ctggacagag 1140

aacagtgtca cggtcactgg accaccacga gattctgtaa aaagtaaaca cttgaaagcc 1200

attgatgtca acatgaacaa aatgcctgat gttgccatga ctcttgctgt agttgctctt 1260

tttgctgatg gccccactgc tataagagat gtggcaagtt ggagagtcaa ggagacagag 1320

agaatgattg ccatctgcac tgaactcaga aagcttggag caacagttga ggaaggaccc 1380

gattactgcg tgatcactcc accagagaaa ctaaatatca cagcaataga cacatacgac 1440

gaccacagga tggctatggc gttctctctt gcagcttgtt cagatgtgcc agttaccatt 1500

aaggatcctg gttgcacccg aaaaactttc ccagattact ttgaagtcct tgagagattt 1560

acaaagcact ga 1572

<210> SEQ ID NO 39
<211> LENGTH: 1572
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- engineered gene

<400> SEQUENCE: 39

atggcccaag tgagcaaaat ctgtagcaat ggagctcaaa ctatccttac tctcccaaat 60

atatctaagt ctcatacacc aagatcccta aattcagttt cgttgagatc accgtttttg 120

ggttcatcta actctttgag tttgaagatt ggaactgaat ttgggggttg ttctacggtt 180

ggtaaagcta tggctggtcc agtcatggct tcagctgtca cagcggagaa gccttcaaag 240

gtaccggaga ttgtgttgca gcccattaaa gatatctctg gcactgtcaa gttgccgggt 300

tccaagtcac tatcgaatcg gattctactc ctggctgctc tttctgaggg gacaactgtt 360

gtggacaact tgttagatag tgatgacatt cactacatgc ttggtgcctt ggaaaccctt 420

ggtcttcgtg ttgaagcaga caaggaaagc aaacgagcaa ttgtggaagg ttgtgcgggt 480

cagtttcctg caggtaaaga atctgttgac gaagttcaac ttttccttgg aaatgctgga 540

atagcaatgc gttcactcac agctgcggtg actgttgctg gtggaaatgc tagctacgta 600

cttgatggtg ttcctcgaat gagagaaaga ccaattggag atttggtgac tggtcttaag 660

cagcttggtg cagatgttga ttgttttcat ggtacggatt gtccccctgt tcgtgtgctt 720

ggaaaaggag gccttcctgg gggcaaggtg aaactttctg gatcaattag cagtcaatat 780

ttgacagcct tgcttatggc agctcccttg gctcttggag atgttgaaat cgagataatt 840

gataaattga tctcggttcc ctatgttgat atgactttga agttgatggc acgttttggg 900

gttactgttg aacacagtga tagctgggat cgatttttag ttaaaggagg tcaaaagtac 960

aaatctcctg gaaacgctta tgttgaaggt gatgcttcaa gtgctagtta cttcctagct 1020

ggtgctgcag tcactggtgg tacagtcacc gtagaaggtt gtgggactag tagtttacag 1080

-continued

ggagacgtaa aatttgctga agttcttgag aaaatgggtg ctaaagttag ctggacagag 1140

aacagtgtca cggtcactgg accaccacga gattctgtaa aaagtaaaca cttgaaagcc 1200

attgatgtca acatgaacaa aatgcctgat gttgccatga ctcttgctgt agttgctctt 1260

tttgctgatg gccccactgc tataagagat gtggcaagtt ggagagtcaa ggagacagag 1320

agaatgattg ccatctgcac tgaactcaga aagcttggag caacagttga ggaaggactt 1380

gattactgcg tgatcactcc accagagaaa ctaaatatca cagcaataga cacatacgac 1440

gaccacagga tggctatggc gttctctctt gcagcttgtt cagatgtgcc agttaccatt 1500

aaggatcctg gttgcacccg aaaaactttc ccagattact ttgaagtcct tgagagattt 1560

acaaagcact ga 1572

<210> SEQ ID NO 40
<211> LENGTH: 4196
<212> TYPE: DNA
<213> ORGANISM: Cannabis sativa

<400> SEQUENCE: 40

ggttggtaag ccctcctacc ctctttgaaa attgaaagag agtcaatgtc gacctacagc 60

agcagcatcc attaacgtta ccattgccac caaaaatcca acctttattt gtatagagag 120

aatcagagaa ggtttgggtt tcagagagag agagaagaag aacaaaaaaa tggcccaagt 180

gagcaaaatc tgtagcaatg gagctcaaac tatccttact ctcccaaata tatctaagtc 240

tcatacacca agatccctaa attcagtttc gttgagatca ccgtttttgg gttcatctaa 300

ctctttgagt ttgaagattg gaactgaatt tgggggttgt tctacggttg gtaaagctat 360

ggctggtcca gtcatggctt cagctgtcac agcggagaag ccttcaaagg taccggagat 420

tgtgttgcag cccattaaag atatctctgg cactgtcaag ttgccgggtt ccaagtcact 480

atcgaatcgg attctactcc tggctgctct ttctgaggta tatttcattt tttttaaaac 540

gtcaaacatg tatttttgtc gaggaagttt tctgtatata caaagataag agagtaaaaa 600

tatggaacat caataccaaa atgaaccaaa actaggctaa gctatcaaat catgtcatgg 660

tatgccatac tctactttcc tatctcaagc tccacagcta taaaatacta tatcgtaatt 720

attttgtcaa ctgctttcat attccttgta atttccctca ttcccactaa aactagttcc 780

aatggattgt gtggctggaa actgtagtta gttacattag ctagatctga accatgatca 840

gcatcgactg cccaactggt aaaccatgta attgcatgga attcttcctt tgttatccac 900

aaatttgaaa agtatttttg aggtatacaa agattgtgct ttttatgagc aattttcttt 960

tagttttatg ttaagagttt gtagcgatgg gatgtttttt ttctagaaaa tggacagtaa 1020

agcttagcat ttttacttta ttggtgtaaa tgaatagtgt tcattgaagc tgaactcatg 1080

cccttaattg ggaggaaaat tgagagaaat ggagtaaagt aatatgatat tttggttaaa 1140

ttcgtaagaa tatgatggaa ataaaaaatg caactcaact gggttactga agttatattt 1200

ctggtctcag ttgtgctttt acaactttag tctagagctc cacgctgcgg agagattcgg 1260

agtccttaca gtttatttttg ataatgattt atgagaattt cataactcta cgcttttgtt 1320

acattatata tgaggtgttt cgttggtgca ttgtctcacc tgaactccct aaattttaga 1380

atgtgggatt tagaatgaag ttatactatt agtgtttgag tcatctagaa tttgtagctg 1440

ctcattctcc atatactctt tctctatttc ctccccatat tttggcgcta ctacttatct 1500

-continued

ttacagttca tgttattttc atgtacttga gttttttgcc ctataaaata ttttgagcgg 1560

tgggaagtaa ctgtttttttt tgttataatt atccagggga caactgttgt ggacaacttg 1620

ttagatagtg atgacattca ctacatgctt ggtgccttgg aaaccccttgg tcttcgtgtt 1680

gaagcagaca aggaaagcaa acgagcaatt gtggaaggtt gtgcgggtca gtttcctgca 1740

ggtaaagaat ctgttgacga agttcaactt ttccttggaa atgctggaac agcaatgcgt 1800

ccactcacag ctgcggtgac tgttgctggt ggaaatgcta ggtttgtctt cattgcaatt 1860

gcttttgaat ataaagtact tctaatgcag tgaatttatg ctcttgtttt tcttactggc 1920

cgagtagctc ttacatttta ggtaaagaaa gtcacttttg ctaacaacat caccatttat 1980

acttccctct ttactttgat gtggttatgc tagaaattac atgttggaaa tgaactagca 2040

catatcataa attattttgt atgctgttat tacattttct cagtaacctc ttaacttcta 2100

tatctcagct acgtacttga tggtgttcct cgaatgagag aaagaccaat tggagatttg 2160

gtgactggtc ttaagcagct tggtgcagat gttgattgtt ttcatggtac ggattgtccc 2220

cctgttcgtg tgcttggaaa aggaggcctt cctgggggca aggtgaggct tgcattgctt 2280

cttcttattc tttttggcca taaaacatca ttgtaatagt ggttttatgt tatgaaatcc 2340

attgactggt ttatttttag gttgttgttt tgcttttaaa taaaaacaat attgtcaaat 2400

gatgcataag tagtgattac atctacatca tttaatttat tatcttaaat gatgacaaac 2460

ttcatcattt tgactcagaa ttatgtaata ttacccctttg caggtgaaac tttctggatc 2520

aattagcagt caatatttga cagccttgct tatggcagct cccttggctc ttggagatgt 2580

tgaaatcgag ataattgata aattgatctc ggttccctat gttgatatga ctttgaagtt 2640

gatggcacgt tttggggtta ctgttgaaca cagtgatagc tgggatcgat ttttagttaa 2700

aggaggtcaa aagtacaagt aggtttcttc tgaatatagt tgatagtatt gttacattac 2760

atctggttat gtcaaagagt aataaattga aaaataaaaa tctgtcagat ctcctggaaa 2820

cgcttatgtt gaaggtgatg cttcaagtgc tagttacttc ctagctggtg ctgcagtcac 2880

tggtggtaca gtcaccgtag aaggttgtgg gactagtagt ttacaggtat tttgcttaga 2940

ccttgaaatc tcttattctt gtacttgtgt ttacatagaa tctaagatta agtgtattta 3000

catacattaa ctggtgttta ataaagggag acgtaaaatt tgctgaagtt cttgagaaaa 3060

tgggtgctaa agttagctgg acagagaaca gtgtcacggt cactggacca ccacgagatt 3120

ctgtaaaaag taaacacttg aaagccattg atgtcaacat gaacaaaatg cctgatgttg 3180

ccatgactct tgctgtagtt gctcttttttg ctgatggccc cactgctata agagatggta 3240

tgtttttcct taaatttgtg agatggtaaa atggggcagt cggtttgggt tggggtagat 3300

tatcggttct cgtctgccat aataaaaaat aatctgctca tttgcaataa atttcacaga 3360

cacaaaaatg aaaaccaata aaatattatt ttgtttagag gattaaatac tcatttcttg 3420

cctttcctaa ttcccagtgg caagttggag agtcaaggag acagagagaa tgattgccat 3480

ctgcactgaa ctcagaaagg ttagttttta tgctgtttta tgtacttgtt atgtcatgcg 3540

ccttggaatg taatggctga tagctatctg ttcttatggg aacaaacatt tcagcttgga 3600

gcaacagttg aggaaggacc cgattactgc gtgatcactc caccagagaa actaaatatc 3660

acagcaatag acacatacga cgaccacagg atggctatgg cgttctctct tgcagcttgt 3720

tcagatgtgc cagttaccat taaggatcct ggttgcaccc gaaaaacttt cccagattac 3780

-continued

tttgaagtcc ttgagagatt tacaaagcac tgaatgagta tttattaact ggatagagaa 3840

caatagcatc ggctactgtc attacaacta aagcagttgg gaggcaggca atccttttca 3900

attatcatgt gtttgatttt ggtcgactgt attgcaagtt gagcttctca ttattattaa 3960

gactgtaatc gtagttattt gttgtaactt ctgcaaaccc ttcatgttat tttttcaccc 4020

ttctaataag ccagtggggc aaattctata tctgctatat gagcttgagt gtagagagaa 4080

cttttgtcaa tgtataggtt tctagcagaa gcaccatccc taatatgctt tattataaga 4140

gttgctgtga tcgtgtagtg ttatttttatt gaaagtaacc gacgcatctc atatta 4196

<210> SEQ ID NO 41
<211> LENGTH: 46
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- prime editing guide RNA

<400> SEQUENCE: 41

tgaagacttt gcacaacttt tccttggaaa tgcgtttaag tcttct 46

<210> SEQ ID NO 42
<211> LENGTH: 46
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- prime editing guide RNA

<400> SEQUENCE: 42

agaagactta aacgcatttc caaggaaaag ttgtgcaaag tcttca 46

<210> SEQ ID NO 43
<211> LENGTH: 64
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- engineered gene

<400> SEQUENCE: 43

acctgctata gtgctgagtg aacgcattgc tattccagca tttccaagga aacatatagc 60

aggt 64

<210> SEQ ID NO 44
<211> LENGTH: 46
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- prime editing guide RNA

<400> SEQUENCE: 44

tgaagacttt gcacttggag caacagttga ggagtttaag tcttct 46

<210> SEQ ID NO 45
<211> LENGTH: 46
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- prime editing guide RNA

<400> SEQUENCE: 45

agaagactta aactcctcaa ctgttgctcc aagtgcaaag tcttca 46

-continued

<210> SEQ ID NO 46
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- engineered gene

<400> SEQUENCE: 46

acctgctata gtgccacgca gtaatcaagt ccttcctcaa ctgttgaaca tatagcaggt 60

<210> SEQ ID NO 47
<211> LENGTH: 349
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- engineered gene

<400> SEQUENCE: 47

ggtctcaaat ggcgacaggt tctcgtgttc tgatcggtct agcaatgatc ctcataatct 60

caggagaact gctagttcca gggcaaggaa cgtgccaagg agacatagag ggtctgatga 120

gagaatgtgc ggtctacgtc cagcgtccag gcccaaaggt aaacccatcc gcagcgtgtt 180

gcaaagtcgt caagagatca gacatcccct gcgcatgtgg ccgtatcaca ccctcggttc 240

aaaaaatgat agacatgaat aaggttgttc ttgtcacttc cttttgtggg aggcctctcg 300

ctcatggtac caagtgtgga agctacattg tgccatgagc ttagagacc 349

<210> SEQ ID NO 48
<211> LENGTH: 348
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- engineered gene

<400> SEQUENCE: 48

ggtctcaaat ggcgacaggt tctcgtgttc tgatcggtct agcaatgatc ctcataatct 60

caggagaact gctagttcca gggcaaggaa cgtgccaagg agacatagag ggtctgatga 120

gagaatgtgc ggtctacgtc cagcgtccag gcccaaaggt aaacccatcc gcagcgtgtt 180

gcaaagtcgt caagagatca gacatcccct gcgcatgtgg ccgtatcaca ccctcggttc 240

aaaaaatgat agacatgaat aaggttgttc ttgtcacttc cttttgtggg aggcctctcg 300

ctcatggtac caagtgtgga agctacattg tgccaagttc gagagacc 348

<210> SEQ ID NO 49
<211> LENGTH: 1207
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- engineered gene

<400> SEQUENCE: 49

ggtctcaaat gggactctca tcagtttgta ccttttcatt tcaaactaat taccatactt 60

tattaaatcc tcacaataat aatcccaaaa cctcattatt atgttatcga caccccaaaa 120

caccaattaa atactcttac aataattttc cctctaaaca ttgctccacc aagagttttc 180

atctacaaaa caaatgctca gaatcattat caatcgcaaa aaattccatt agggcagcta 240

ctacaaatca aactgagcct ccagaatctg ataatcattc agtagcaact aaaatttaa 300

-continued

actttgggaa ggcatgttgg aaacttcaaa gaccatatac aatcatagca tttacttcat 360

gcgcttgtgg attgtttggg aaagagttgt tgcataacac aaatttaata agttggtcac 420

tgatgttcaa ggcattcttt tttttggtgg ctgtattatg cattgcttct tttacaacta 480

ccatcaatca gatttacgat cttcacattg acagaataaa caagcctgat ctaccactag 540

cttcagggga aatatcagta aacacagctt ggattatgag cataattgtg gcactgtttg 600

gattgataat aactataaaa atgaagggtg gaccactcta tatatttggc tactgttttg 660

gtatttttgg tgggattgtc tattctgttc caccatttag atggaagcaa aatccttcca 720

ctgcatttct tctcaatttc ctggcccata ttattacaaa tttcacattt tattatgcca 780

gcagagcagc tcttggccta ccatttgagt tgaggccttc ttttactttc ctgctagcat 840

ttatgaaatc aatgggttca gctttggctt taatcaaaga tgcttcagac gttgaaggcg 900

acactaaatt tggcatatca accttggcaa gtaaatatgg ttccagaaac ttgacattat 960

tttgttctgg aattgttctc ctatcctatg tggctgctat acttgctggg attatctggc 1020

cccaggcttt caacagtaac gtaatgttac tttctcatgc aatcttagca ttttggttaa 1080

tcctccagac tcgagatttt gcgttaacaa attacgaccc ggaagcaggc agaagatttt 1140

acgagttcat gtggaagctt tattatgctg aatatttagt atatgttttc atataagctt 1200

agagacc 1207

<210> SEQ ID NO 50
<211> LENGTH: 1206
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- engineered gene

<400> SEQUENCE: 50

ggtctcaaat gggactctca tcagtttgta ccttttcatt tcaaactaat taccatactt 60

tattaaatcc tcacaataat aatcccaaaa cctcattatt atgttatcga caccccaaaa 120

caccaattaa atactcttac aataatttttc cctctaaaca ttgctccacc aagagttttc 180

atctacaaaa caaatgctca gaatcattat caatcgcaaa aaattccatt agggcagcta 240

ctacaaatca aactgagcct ccagaatctg ataatcattc agtagcaact aaaatttaa 300

actttgggaa ggcatgttgg aaacttcaaa gaccatatac aatcatagca tttacttcat 360

gcgcttgtgg attgtttggg aaagagttgt tgcataacac aaatttaata agttggtcac 420

tgatgttcaa ggcattcttt tttttggtgg ctgtattatg cattgcttct tttacaacta 480

ccatcaatca gatttacgat cttcacattg acagaataaa caagcctgat ctaccactag 540

cttcagggga aatatcagta aacacagctt ggattatgag cataattgtg gcactgtttg 600

gattgataat aactataaaa atgaagggtg gaccactcta tatatttggc tactgttttg 660

gtatttttgg tgggattgtc tattctgttc caccatttag atggaagcaa aatccttcca 720

ctgcatttct tctcaatttc ctggcccata ttattacaaa tttcacattt tattatgcca 780

gcagagcagc tcttggccta ccatttgagt tgaggccttc ttttactttc ctgctagcat 840

ttatgaaatc aatgggttca gctttggctt taatcaaaga tgcttcagac gttgaaggcg 900

acactaaatt tggcatatca accttggcaa gtaaatatgg ttccagaaac ttgacattat 960

tttgttctgg aattgttctc ctatcctatg tggctgctat acttgctggg attatctggc 1020

-continued

cccaggcttt caacagtaac gtaatgttac tttctcatgc aatcttagca ttttggttaa 1080

tcctccagac tcgagatttt gcgttaacaa attacgaccc ggaagcaggc agaagatttt 1140

acgagttcat gtggaagctt tattatgctg aatatttagt atatgttttc ataagttcga 1200

gagacc 1206

<210> SEQ ID NO 51
<211> LENGTH: 1132
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- engineered gene

<400> SEQUENCE: 51

ggtctcaaat gggttcaaca ggaatagaaa cccaaatgac cccaacccaa atatccgacg 60

aagaagccaa cctcttcgcc atgcaattag ccagtgcctc agtcttaccc atggttctca 120

aagcagcttt agagctcgac ctcttggaga tcatagccaa ggccggtcca ggcgcgtttc 180

tctcaccttc cgacatagct caacagcttc cgactcagaa cccagacgcc ccggtgatgc 240

tggaccggat gctgagactg ttggctagct acaacgtggt gacgtactcg ctgcgtgagc 300

gtgaaacggc ggaagaggaa gggaaggtgg agaggcttta tgggttggct ccggtgagta 360

aatatctgac gaagaatgaa gatggagtct ccattgctcc tctttgtctc atgaaccagg 420

ataaggttct tatggagagt tggtatcact taaaagatgc agtacttgat ggaggaatac 480

ctttcaacaa ggcatatgga atgacagcat ttgaatatca tggaaccgat caaaggttca 540

ataaaatctt taatagagga atgtccgacc actcgactat taccatgaaa aaaatcctcg 600

aaacttacaa gggtttcgag ggtcttaact cgattgttga tgttggtggt ggtactggag 660

ctgttgttaa catgatcgtt tctaagtacc ctactattaa gggtattaac ttcgatttgc 720

ctcatgtcat cgaagatgca cctccattga ccggtgtaga gcatgttgga ggagacatgt 780

ttgtaagtgt accaaaagga gatgcaattt tcatgaagtg gatttgccat gattggagcg 840

atgaacactg cttgaaattc ttgaagaact gccacgctgc actgcccgaa cacggaaaag 900

tgatcgtggc ggagtgcatt cttccggtgg caccggactc gagccttgcc acaaagagta 960

cggtccacat tgatgtgatc atgttggccc ataaccctgg tggcaaagag agaacagaga 1020

aagagtttga ggcattggct aagggagctg gctttaaagg cttcaaagtc cattgcaatg 1080

ctttcaatac ccatatcatg gaatttctca agaccattta agcttagaga cc 1132

<210> SEQ ID NO 52
<211> LENGTH: 1131
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- engineered gene

<400> SEQUENCE: 52

ggtctcaaat gggttcaaca ggaatagaaa cccaaatgac cccaacccaa atatccgacg 60

aagaagccaa cctcttcgcc atgcaattag ccagtgcctc agtcttaccc atggttctca 120

aagcagcttt agagctcgac ctcttggaga tcatagccaa ggccggtcca ggcgcgtttc 180

tctcaccttc cgacatagct caacagcttc cgactcagaa cccagacgcc ccggtgatgc 240

tggaccggat gctgagactg ttggctagct acaacgtggt gacgtactcg ctgcgtgagc 300

-continued

gtgaaacggc ggaagaggaa gggaaggtgg agaggcttta tgggttggct ccggtgagta 360

aatatctgac gaagaatgaa gatggagtct ccattgctcc tctttgtctc atgaaccagg 420

ataaggttct tatggagagt tggtatcact taaaagatgc agtacttgat ggaggaatac 480

ctttcaacaa ggcatatgga atgacagcat ttgaatatca tggaaccgat caaaggttca 540

ataaaatctt taatagagga atgtccgacc actcgactat taccatgaaa aaaatcctcg 600

aaacttacaa gggtttcgag ggtcttaact cgattgttga tgttggtggt ggtactggag 660

ctgttgttaa catgatcgtt tctaagtacc ctactattaa gggtattaac ttcgatttgc 720

ctcatgtcat cgaagatgca cctccattga ccggtgtaga gcatgttgga ggagacatgt 780

ttgtaagtgt accaaaagga gatgcaattt tcatgaagtg gatttgccat gattggagcg 840

atgaacactg cttgaaattc ttgaagaact gccacgctgc actgcccgaa cacggaaaag 900

tgatcgtggc ggagtgcatt cttccggtgg caccggactc gagccttgcc acaaagagta 960

cggtccacat tgatgtgatc atgttggccc ataaccctgg tggcaaagag agaacagaga 1020

aagagtttga ggcattggct aagggagctg gctttaaagg cttcaaagtc cattgcaatg 1080

ctttcaatac ccatatcatg gaatttctca agaccattag ttcgagagac c 1131

<210> SEQ ID NO 53
<211> LENGTH: 1222
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- engineered gene

<400> SEQUENCE: 53

ggtctcaaat ggtgttctca tcagtttgta gttttccatc ctcccttgga actaatttta 60

aattagttcc tcgtagtaat tttaaggcat catcttctca ttatcatgaa ataaataatt 120

ttattaataa taaaccaatt aaattctcat atttttcttc aagactatat tgctctgcca 180

aaccaattgt acacagagaa aacaaattca caaaatcatt ttcactcagc cacctccaaa 240

ggaaaagctc cataaaggca catggtgaaa ttgaagctga tgggagtaat ggcacatctg 300

aatttaatgt aatgaaaagt ggaaacgcaa tttggagatt tgtaaggcca tatgcagcca 360

agggagtatt gtttaactct gctgctatgt ttgcaaaaga gttggtgggg aacctaaatc 420

tatttagttg gcctttgatg tttaagatac tctcttttac attggttatt ttatgcattt 480

ttgtaagtac aagtggcatc aatcaaattt atgatctcga catcgacagg ttaaacaaac 540

ctaatttgcc agtagcatca ggagaaattt cagttgaatt ggcatggttg ttgactatag 600

tttgtacaat aagtggcctc acattaacaa ttataacgaa ctcagggcca ttcttccctt 660

ttctctactc tgctagtatc ttttttggct ttctctattc tgctcctcca ttcagatgga 720

agaagaatcc ttttacagca tgtttctgta atgttatgtt gtatgttggc acaagcgttg 780

gtgtctatta tgcttgtaag gctagtctcg ggcttccagc caactggagc cctgcttttt 840

gtttgctctt ttggtttatt tcattgttga gtatacccat ctccattgca aaagatcttt 900

cagacataga aggtgaccgc aagtttggaa tcataacctt ctcaactaaa tttggagcaa 960

aacccatagc atatatttgt catggactca tgcttctgaa ttacgtgagt gttatggctg 1020

cagctattat ttggccacag tttttcaaca gtagcgtaat attgctttct catgcattca 1080

tggcaatttg ggtattatat caggcttgga tattggagaa atcaaattac gccacggaaa 1140

-continued

cgtgccaaaa atactatata ttcctttgga taatttttc tcttgaacat gccttctatt 1200

tgttcatgta ggcttagaga cc 1222

<210> SEQ ID NO 54
<211> LENGTH: 1221
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- engineered gene

<400> SEQUENCE: 54

ggtctcaaat ggtgttctca tcagtttgta gttttccatc ctcccttgga actaatttta 60

aattagttcc tcgtagtaat tttaaggcat catcttctca ttatcatgaa ataaataatt 120

ttattaataa taaaccaatt aaattctcat atttttcttc aagactatat tgctctgcca 180

aaccaattgt acacagagaa aacaaattca caaaatcatt ttcactcagc cacctccaaa 240

ggaaaagctc cataaaggca catggtgaaa ttgaagctga tgggagtaat ggcacatctg 300

aatttaatgt aatgaaaagt ggaaacgcaa tttggagatt tgtaaggcca tatgcagcca 360

agggagtatt gtttaactct gctgctatgt ttgcaaaaga gttggtgggg aacctaaatc 420

tatttagttg gcctttgatg tttaagatac tctcttttac attggttatt ttatgcattt 480

ttgtaagtac aagtggcatc aatcaaattt atgatctcga catcgacagg ttaaacaaac 540

ctaatttgcc agtagcatca ggagaaattt cagttgaatt ggcatggttg ttgactatag 600

tttgtacaat aagtggcctc acattaacaa ttataacgaa ctcagggcca ttcttccctt 660

ttctctactc tgctagtatc ttttttggct ttctctattc tgctcctcca ttcagatgga 720

agaagaatcc ttttacagca tgtttctgta atgttatgtt gtatgttggc acaagcgttg 780

gtgtctatta tgcttgtaag gctagtctcg ggcttccagc caactggagc cctgcttttt 840

gtttgctctt ttggtttatt tcattgttga gtatacccat ctccattgca aaagatcttt 900

cagacataga aggtgaccgc aagtttggaa tcataacctt ctcaactaaa tttggagcaa 960

aacccatagc atatatttgt catggactca tgcttctgaa ttacgtgagt gttatggctg 1020

cagctattat ttggccacag tttttcaaca gtagcgtaat attgctttct catgcattca 1080

tggcaatttg ggtattatat caggcttgga tattggagaa atcaaattac gccacggaaa 1140

cgtgccaaaa atactatata ttcctttgga taatttttc tcttgaacat gccttctatt 1200

tgttcatgag ttcgagagac c 1221

<210> SEQ ID NO 55
<211> LENGTH: 61
<212> TYPE: DNA
<213> ORGANISM: Cannabis sativa

<400> SEQUENCE: 55

ttgacgaagt tcaacttttc cttggaaatg ctggaacagc aatgcgtcca ctcacagctg 60

c 61

<210> SEQ ID NO 56
<211> LENGTH: 57
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- engineered gene
<220> FEATURE:

-continued

<221> NAME/KEY: misc_feature
<222> LOCATION: (21)..(21)
<223> OTHER INFORMATION: N represents a scaffold sequence

<400> SEQUENCE: 56

caacttttcc ttggaaatgc ntgagtgaac gcattgctat tccagcattt ccaagga 57

<210> SEQ ID NO 57
<211> LENGTH: 56
<212> TYPE: DNA
<213> ORGANISM: Cannabis sativa

<400> SEQUENCE: 57

cttggagcaa cagttgagga aggacccgat tactgcgtga tcactccacc agagaa 56

<210> SEQ ID NO 58
<211> LENGTH: 53
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic- engineered gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (21)..(21)
<223> OTHER INFORMATION: N represents a scaffold sequence

<400> SEQUENCE: 58

cttggagcaa cagttgagga ncacgcagta atcaagtcct tcctcaactg ttg 53

<210> SEQ ID NO 59
<211> LENGTH: 1638
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: In silico- consensus sequence

<400> SEQUENCE: 59

atgaattgct cagcattttc cttttggttt gtttgcaaaa taatattttt ctttctctca 60

ttccatatcc aaatttcaat agctaatcct cgagaaaact tccttaaatg cttctcaaaa 120

catattccca acaatgtagc aaatccaaaa ctcgtataca ctcaacacga ccaattgtat 180

atgtctatcc tgaattcgac aatacaaaat cttagattca tctctgatac aaccccaaaa 240

ccactcgtta ttgtcactcc ttcaaataac tcccatatcc aagcaactat tttatgctct 300

aagaaagttg gcttgcagat tcgaactcga agcggtggcc atgatgctga gggtatgtcc 360

tacatatctc aagtcccatt tgttgtagta gacttgagaa acatgcattc gatcaaaata 420

gatgttcata gccaaactgc gtgggttgaa gccggagcta cccttggaga agtttattat 480

tggatcaatg agaagaatga gaatcttagt tttcctggtg ggtattgccc tactgttggc 540

gtaggtggac actttagtgg aggaggctat ggagcattga tgcgaaatta tggccttgcg 600

gctgataata ttattgatgc acacttagtc aatgttgatg gaaaagttct agatcgaaaa 660

tccatgggag aagatctgtt ttgggctata cgtggtggtg gaggagaaaa ctttggaatc 720

attgcagcat ggaaaatcaa actggttgct gtcccatcaa agtctactat attcagtgtt 780

aaaaagaaca tggagataca tgggcttgtc aagttattta acaaatggca aaatattgct 840

tacaagtatg acaaagattt agtactcatg actcacttca taacaaagaa tattacagat 900

aatcatggga agaataagac tacagtacat ggttacttct cttcaatttt tcatggtgga 960

-continued

gtggatagtc tagtcgactt gatgaacaag agctttcctg agttgggtat taaaaaaact 1020

gattgcaaag aatttagctg gattgataca accatcttct acagtggtgt tgtaaatttt 1080

aacactgcta attttaaaaa ggaaattttg cttgatagat cagctgggaa gaagacggct 1140

ttctcaatta agttagacta tgttaagaaa ccaattccag aaactgcaat ggtcaaaatt 1200

ttggaaaaat tatatgaaga agatgtagga gctgggatgt atgtgttgta cccttacggt 1260

ggtataatgg aggagatttc agaatcagca attccattcc ctcatcgagc tggaataatg 1320

tatgaacttt ggtacactgc ttcctgggag aagcaagaag ataatgaaaa gcatataaac 1380

tgggttcgaa gtgtttataa ttttacgact ccttatgtgt cccaaaatcc aagattggcg 1440

tatctcaatt atagggacct tgatttagga aaaactaatc atgcgagtcc taataattac 1500

acacaagcac gtatttgggg tgaaaagtat tttggtaaaa attttaacag gttagttaag 1560

gtgaaaacta aagttgatcc caataatttt tttagaaacg aacaaagtat cccacctctt 1620

ccaccgcatc atcattaa 1638

<210> SEQ ID NO 60
<211> LENGTH: 1737
<212> TYPE: DNA
<213> ORGANISM: Arabidopsis thaliana

<400> SEQUENCE: 60

atgaaggaga tcgcgatgag gaattcaaag cgcaagcctg agccgacgcc gttcgccggg 60

aagaagctcc ggtcgacgcg attacgccgg aagagagcac agatctctcc cgttcttgtt 120

caatcacctc tctggagcaa acaaatcgga gtctctgctg cttctgtcga ttcctgctcc 180

gatttgctag ctgatgacaa cgtttcctgt ggttcgagca gagtcgagaa gagctcgaat 240

ccgaagaaga ctctaattga agaggtagaa gtttctaaac ctggttataa tgtgaaggag 300

acgattggtg attcgaaatt tcgaaggatt acgaggtctt actctaagct acacaaggag 360

aaggagggag atgagatcga agtaagcgaa tcgtcttgtg ttgattcgaa ttctggtgct 420

ggattaagga gattgaatgt gaagggaaat aaaattaacg acaacgatga gatctctttc 480

tcacgatccg atgtgacctt cgccggacat gtctccaaca gccggagttt gaatttcgaa 540

tcggagaata aggagagcga cgtcgtttct gtcatatctg gagttgagta ctgttccaag 600

ttcgggagcg ttaccggagg agctgataac gaagaaattg aaatctccaa gccgagcagc 660

ttcgtggaag ctgattcctc tcttggatcg gccaaggaat tgaagccgga gcttgagata 720

gtcggatgcg tctctgatct cgcttgctct gagaaattct cggaagaggt ttcggattct 780

ctcgatgatg agtcatctga gcaacgttca gagatatatt cacagtattc cgacttcgat 840

tactcggatt acactccgtc catcttcttc gactctggca gcgaattctc tgagaaatct 900

tcctctgatt ctcctatttc acattctcgc tctctgtacc tccagttcaa ggaacagttc 960

tgtagatcca cgattcccaa cgattttgga tcttcttgcg aggaagaaat tcactctgaa 1020

ttgctaaggt ttgatgatga ggaggtggaa gagagctatc taaggctgag ggaaagagaa 1080

agaagtcatg catatatgcg ggactgtgct aaggcatact gctccaggat ggacaatact 1140

ggtctcatcc ctcgtctacg ctccatcatg gttcaatgga ttgtaaagca atgttctgac 1200

atggggcttc agcaagagac attgtttcta ggagttggtc tgttggatcg attcctgagc 1260

aaaggatcat tcaaaagcga aaggactcta atactagtcg ggattgcgag tcttactctg 1320

-continued

```
gccaccagaa ttgaagaaaa tcaaccttac aacagcatcc ggaaaaggaa cttcaccatt   1380

cagaacctaa gatatagccg gcatgaagtg gtggcaatgg agtggctggt tcaagaagtc   1440

ctcaacttca aatgcttcac acccacaatc ttcaacttct tgtggttcta cttaaaagct   1500

gctcgagcca atccagaagt tgaaaggaaa gccaaatcct tggctgttac ctcactatcc   1560

gaccaaactc aactctgttt ttggccctca actgtagcag ctgcactcgt ggttctcgcc   1620

tgcatcgaac acaacaaaat ctctgcatac caacgagtca taaaggtcca tgttagaaca   1680

acagataacg agttgcctga atgcgttaag agtctggact ggttgcttgg gcagtaa      1737


<210> SEQ ID NO 61
<211> LENGTH: 832
<212> TYPE: DNA
<213> ORGANISM: Bacillus amyloliquefaciens

<400> SEQUENCE: 61

ctggaaaacg tcacattgct tccgcatatc gggtcagcaa cggctaaaat ccgcttgaat     60

atgttcacac aagccgctca aaacatgatt gacgccgtat acggaagaac gccgaaaaac    120

cttactaagg aatttcaata agaagaaaaa tcccggttgg ttcagccggg gtttatttttt    180

cgctagataa aaagtactat ttttaaattc tttctattcc tttctttcgt tgctgataca    240

atgaaaagga atcagcttca catgatgaaa atgggaggta ttgctttgaa aaaacgatta    300

tcgtggattt ccgtttgttt actggtgctt gtctccgcgg cggggatgct gttttcaaca    360

gctgccaaaa cggaaacatc ttctcacaag gcacacacag aagcacaggt tatcaacacg    420

tttgacgggg ttgcggatta tcttcagaca tatcataagc tacctgataa ttacattaca    480

aaatcagaag cacaagccct cggctgggtg gcatcaaaag ggaaccttgc agacgtcgct    540

ccggggaaaa gcatcggcgg agacatcttc tcaaacaggg aaggcaaact cccgggcaaa    600

agcggacgaa catggcgtga agcggatatt aactatacat caggcttcag aaattcagac    660

cggattcttt actcaagcga ctggctgatt tacaaaacaa cggaccatta tcagaccttt    720

acaaaaatca gataacgaaa aaaacggctt ccctgcggag gccgtttttt tcagctttac    780

ataaagtgtg taataaattt ttcttcaaac tctgatcggt caatttcact tt            832
```

We claim:

1. A method of preparing an explant, the method comprising the steps of,

rehydrating a dry *Cannabis* seed in a hydration medium, and

excising meristematic tissue from the rehydrated *Cannabis* seed to form an explant.

2. The method of claim **1**, wherein the hydration medium comprises one or more priming agents.

3. The method of claim **1**, wherein the seed is a *Cannabis sativa* seed.

4. The method of claim **1**, additionally comprising the step of surface sterilizing the *Cannabis* seed prior to rehydration.

5. The method of claim **1**, wherein the method additionally comprises the step of drying the explant.

6. The method of claim **5**, wherein the dried explant is capable of being stored for at least 10 days.

7. The method of claim **5**, wherein the explant is dried in the presence of one or more transformation supplements.

8. The method of claim **1**, wherein the method additionally comprises the step of transforming the explant with a heterologous nucleic acid of interest.

9. The method of claim **8**, wherein the explant is transformed using *Agrobacterium* mediated transformation or particle bombardment.

10. A *Cannabis* explant generated by the method of claim **1**.

11. A dried *Cannabis* explant generated by the method of claim **5**.

12. A method of transforming *Cannabis* with a heterologous nucleic acid, the method comprising the steps of,

rehydrating a dry *Cannabis* seed in a hydration medium,

excising meristematic tissue from the rehydrated *Cannabis* seed to form a *Cannabis* explant,

incubating the *Cannabis* explant in a pretreatment medium,

inoculating the *Cannabis* explant with *Agrobacterium* spp. comprising the heterologous nucleic acid,

co-culturing the *Cannabis* explant in a co-culture medium for between about 1 day and about 6 days,

culturing the *Cannabis* explant on a selection medium to select for transformed *Cannabis* explants.

13. The method of claim **12**, additionally comprising the step of force treating the *Cannabis* explant prior to or following inoculation.

14. The method of claim **13**, wherein the force treatment is selected from the group consisting of sonication, vortexing, centrifugation, heat-shock, increase pressure, vacuum infiltration, and addition of chemicals.

15. The method of claim **12**, additionally comprising the step of surface sterilizing the *Cannabis* seed prior to rehydration.

16. The method of claim **12**, wherein the heterologous nucleic acid modulates the expression or activity of an endogenous *Cannabis* gene selected from the group consisting of tetrahydrocannabinolic acid synthase (THCA synthase), cannabidiolic acid synthase (CBDA synthase), O-methyltransferase (CsOMT21), lipid transfer protein 2 (LTP2), prenyltransferase 3 (CsPT3), and prenyltransferase 1 (CsPT1).

17. The method of claim **12**, wherein the *Cannabis* seed is a *Cannabis sativa* seed.

18. A transformed *Cannabis* explant produced by the method of claim **12**.

19. A *Cannabis* plant grown from the *Cannabis* explant of claim **18**.

20. A method of producing a transformed *Cannabis* seed, the method comprising:

contacting a female *Cannabis* flower with an *Agrobacterium* spp. culture, wherein the *Agrobacterium* comprises a heterologous nucleic acid; and

pollinating the contacted female *Cannabis* flower with male pollen from a suitable donor plant, whereby a transformed *Cannabis* seed is produced.

21. The method of claim **20**, wherein the *Agrobacterium* spp. culture comprises sucrose and a wetting agent.

22. The method of claim **20**, wherein the *Agrobacterium* comprises a vector comprising the heterologous nucleic acid.

23. A method of transforming a *Cannabis* plant, the method comprising:

growing a sanitized and imbibed *Cannabis* seed on a non-selective culture medium suitable for supporting the growth and survival of the *Cannabis* seed until a *Cannabis* explant is formed;

inoculating the *Cannabis* explant with a heterologous nucleic acid;

co-culturing the *Cannabis* explant in a co-culture medium for between about 1 day and about 6 days,

culturing the *Cannabis* explant on a selection medium to select for transformed *Cannabis* explants.

24. The method of claim **23**, wherein the explant is selected from the group consisting of a leaf explant, a node explant, an internode explant, a petiole explant, a hypocotyl explant, and a bud explant.

25. The method of claim **23**, wherein the *Cannabis* explant is inoculated using particle bombardment, high velocity microprojection, microinjection, electroporation, direct DNA uptake, cell-penetrating peptides, silica carbide fibers, nanoparticles, and bacterially-mediated transformation.

26. The method of claim **23**, wherein *Agrobacterium* spp. is used to inoculate the *Cannabis* explant.

27. The method of claim **23**, additionally comprising the step of force treating the *Cannabis* explant prior to or following inoculation.

28. The method of claim **27**, wherein the force treatment is selected from the group consisting of sonication, vortexing, centrifugation, heat-shock, increased pressure, vacuum infiltration, and addition of chemicals.

29. The method of claim **23**, wherein the heterologous nucleic acid modulates the expression or activity of an endogenous *Cannabis* gene selected from the group consisting of tetrahydrocannabinolic acid synthase (THCA synthase), cannabidiolic acid synthase (CBDA synthase), O-methyltransferase (CsOMT21), lipid transfer protein 2 (LTP2), prenyltransferase 3 (CsPT3), and prenyltransferase 1 (CsPT1).

30. The method of claim **23**, wherein the *Cannabis* seed is a *Cannabis sativa* seed.

31. The method of claim **12**, wherein the heterologous nucleic acid encodes a polypeptide at least 90% identical to SEQ ID NO:28.

32. The method of claim **23**, wherein the heterologous nucleic acid encodes a polypeptide at least 90% identical to SEQ ID NO:28.

33. The method of claim **12**, wherein the heterologous nucleic acid encodes a guide RNA that targets *Cannabis sativa* THCA synthase gene, *Cannabis sativa* CBDA synthase gene, or *Cannabis sativa* EPSP synthase gene.

34. The method of claim **23**, wherein the heterologous nucleic acid encodes a guide RNA that targets *Cannabis sativa* THCA synthase gene, *Cannabis sativa* CBDA synthase gene, or *Cannabis sativa* EPSP synthase gene.

* * * * *